Official Title of Study:  
Randomized, Open -Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus  
Platinum -Doublet Chemotherapy versus Platinum -Doublet Chemotherapy in Early Stage  
NSCLC  
(CheckMate 816: CHECKpoint pathway and nivoluMAb  clinical Trial Evaluation 816)  
 
PROTOCOL(S) CA209 -816 
 
Study ID: [REMOVED] 
  
Document Date (Date in which document was last revised): August 18 , 2021 
Page: 1
Protocol Number: CA209816
IND Number: 125,872
EUDRACT Number: 2016-003536-21
Date: 30-Sep-2016
Revised Date: 18-Aug-2021
CLINICAL PROTOCOL CA209816
Randomized, Open-Label, Phase 3 Tri al of Nivolumab plus Ipilimu mab or Nivolumab plus 
Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemother apy in Early Stage 
NSCLC
(CheckMate 816: CHECKpoint pathway and nivoluMAb clinical Trial  Evaluation 816)
Protocol Amendment 07
24-hr Emergency Telephone Number
Bristol-Myers Squibb Company
3401 Princeton Pike
Lawrenceville, NJ 08648
This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the p roposed BMS sponsored 
study. Any permitted disclosures will be made only on a confide ntial "need to know" basis 
within your organization or  to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly pro hibited unless expressly 
authorized in writing by BMS. Any supplemental information (e.g., amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document.  Any person who receives 
this document without due authorization from BMS is requested t o return it to BMS or 
promptly destroy it. All other rights reserved. References to B MS in this protocol may apply 
to partners to which BMS has transferred obligations, e.g., a C ontract Research 
Organization (CRO).
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 2DOCUMENT HISTORY
Document Date of Issue Summary of Changes
Protocol 
Amendment 0718-Aug-2021‚Ä¢To account for a potential slowdown i n EFS events accrual in lon g-term 
follow-up, the protocol was amended to:
‚àíRevise EFS modeling assumpti ons to a piecewise exponential 
distribution with lower events rate in the longer term.
‚àíInclude one additional EFS interim analysis at 90% information 
fraction  
 
Revised 
Protocol 0614-Jul-2020‚Ä¢Clarified EFS definition
‚Ä¢Removed the first of 2 interim analyses of EFS and updated alpha  
spending on the remaining interim and final analyses of EFS
‚Ä¢Clarified that the actual timing of analyses may differ from pro jected 
timing
‚Ä¢Removed text about descriptive EFS analysis
Revised 
Protocol 0518-Sep-2019‚Ä¢Modified pCR analysis population and projected timelines
‚Ä¢Updated surgical approach endpoint 
‚Ä¢Updated the censoring rule of TTDM
‚Ä¢No optional biopsy at disease progression collected in China.
‚Ä¢Updated Management Algorithms to include myocarditis
Revised 
Protocol 0425-Jun-2019‚Ä¢Added the concomitant administration of substances that are als o 
tubularly secreted (eg, probenecid) could potentially result in  delayed 
clearance of pemetrexed. 
‚Ä¢Added hypothesis testing for overall survival
‚Ä¢Clarified the pCR analysis population
‚Ä¢Added exploratory endpoint of Event Free Survival on next line of 
therapy
‚Ä¢Added instructions for BICR
‚Ä¢Updated Appendix 8 Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow Up  and 
Reporting Adverse Events
Revised 
Protocol 0321-Sep-2018‚Ä¢Enrollment in Arm A (nivolumab plus ipilimumab) was stopped
‚Ä¢Randomization of participants (1:1 ratio) into Arm C and B will
continue to for a total of 350 participants
‚Ä¢Definition of event free survival is clarified.
‚Ä¢Participants with large-cell neuroendocrine carcinoma tumor hist ology 
are excluded
‚Ä¢Additional platinum doublet chemotherapy regimen (paclitaxel/carboplatin) was added 
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 3Document Date of Issue Summary of Changes
‚Ä¢Dose modification for docetaxel was updated
‚Ä¢Time to death or distant metastases (TTDM) was added to seconda ry 
endpoints.
‚Ä¢Tumor assessments for participants who do not proceed to defini tive 
surgery was clarified
‚Ä¢Statistical analysis plan was updated
‚Ä¢Rationale, background information, and trial schematic were upda ted
‚Ä¢Pulmonary function parameters were clarified
‚Ä¢Time relationship between adjuvant radiotherapy and tumor imaging assessments was clarified
‚Ä¢Time window of Cycle 1 Day 1 end-of-infusion PK sampling for Arm  A 
and C was clarified
Administrative 
Letter 0331-Jan-2018‚Ä¢1. Page 19, Table 2-1 Screening Procedural Outline (CA209816), Pulmonary Function Test notes
‚Ä¢Previously written:
‚Ä¢Should be performed within 6 weeks prior to randomization.
‚Ä¢Changed to:
‚Ä¢Should be performed within 6 weeks prior to randomization. PFTs  
should be evaluated at screening with the following parameters:  FVC, 
FEV1, TLC, FRC, and DLco.
‚Ä¢
‚Ä¢2. Page 22, Table 2-2 Neoadjuvant Period Procedural Outline 
(CA209816), Pulmonary Function Test notes
‚Ä¢Previously written:
‚Ä¢PFTs should be re-evaluated prior to surgery only.
‚Ä¢Changed to:
‚Ä¢PFTs should be re-evaluated prior to surgery with the following  
parameters: FVC, FEV1, TLC, FRC, and DLco.
‚Ä¢3. Page 28,  Section Table 2-4 Post-Neoadjuvant Period for Participants Receiving Adjuvant Chemotherapy (CA209816), Tumor Assessments
‚Ä¢Previously written:
‚Ä¢Tumor assessments using CT, with contrast, of the chest includi ng 
adrenal glands and CT or MRI of other additional suspected/known sites of disease. The first tumor assessment should occur 12 weeks (¬±   7 days) 
after definitive surgery per RECIST  1.1 and then should occur e very 12 
weeks (¬± 7 days) per RECIST 1.1 for 2 years (104 weeks), then every 6 months (24 weeks ¬±  7 days) for  3 years, a nd every year (52 weeks ¬±  7 
days) for 5 years  or until disease recurrence or progression is confirmed 
by BICR. Use same imaging methods and machine of the same quality as was used at screening/baseline.
‚Ä¢Changed to:
‚Ä¢Tumor assessments using CT, with contrast, of the chest includi ng 
adrenal glands and CT or MRI of other additional suspected/known sites of disease. The first tumor assessment should occur 12 weeks (¬± 7 days) after definitive surgery per RECIST  1.1 and then should occur e very 12 
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 4Document Date of Issue Summary of Changes
weeks (¬± 7 days) per RECIST 1.1 for 2 years (104 weeks), then every 6 months (24 weeks ¬±  7 days) for  3 years, a nd every year (52 weeks ¬±  7 
days) for 5 years  or until disease recurrence or progression is confirmed 
by BICR. Use same imaging methods and machine of the same qualit y as 
was used at screening/baseline.
‚Ä¢Adjuvant radiotherapy is allowed on study. As radiotherapy may interfere with imaging interpretation, efforts should be made to schedule radiotherapy so tumor assessments as scheduled per protocol do not 
cross over into the radiation period.
‚Ä¢4. Page 92, Table 9.5-1 Pharmacokinetic (PK) Sample Collections for 
Nivolumab and Ipilimumab - Arm A and Arm C  Footnote d
‚Ä¢Previously written:
‚Ä¢No text
‚Ä¢Added footnote:
‚Ä¢dAs per revised protocol 02, the Cycle 1 Day 1 end-of-infusion PK 
sampling of nivolumab/ipilimumab in Arm A and of nivolumab in Arm C should be taken immediately, ie within 5 minutes prior to stopping the infusion of nivolumab and ipilimumab, respectively. PK sampling  
greater than 5 minutes before the end of infusion will be repor ted as a 
deviation.
Revised 
Protocol 0206-Jul-2017‚Ä¢Nivolumab plus platinum-doublet chemotherapy arm (Arm C) was added
‚Ä¢The sample size was increased to 642 participants with the addi tion of 
the new treatment arm.
‚Ä¢The primary objective was changed to multiple primary objective s of 
event free survival and pathological complete response; the secondary objective was changed to major pathology response.
‚Ä¢Additional rationale and background information was provided. 
‚Ä¢Pre-screening tissue requirement was increased from minimum of 10 slides to 15 slides.
‚Ä¢Contrast requirements for brain MRI scans were updated 
‚Ä¢Time window for pulmonary function test window was expanded fro m 
with 28 days of randomization to within 6 weeks of randomizatio n
‚Ä¢Synopsis was updated with exploratory objectives, endpoints, an d 
schema.
‚Ä¢Language in treatments administered was deleted and reference t o 
Investigator Brochure and Pharmacy Manual was included. 
Revised 
Protocol 0103-Mar-2017 Incorporates Amendment 02 and Administrative Letters  01 and 02
Amendment 02 03-Mar-2017‚Ä¢To adjust the dosing details of the chemotherapy regimens to include the dose approved by the local prescribing information and the stan dard of 
care infusion time for each country included in this study. 
‚Ä¢To expanded and to split the broad biomarke r objective into 3 m ore 
detailed objectives 
‚Ä¢Clarify lymph node samples at screening and at definitive surge ry 
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 5Document Date of Issue Summary of Changes
‚Ä¢Clarify requirements for PET/CT scans and broadening the window  of 
scans prior to surgery
‚Ä¢Clarify tissue sample process for calculation of the primary en dpoint
‚Ä¢Adjust Hepatitis B Virus criteria
‚Ä¢Added live vaccines and strong CYP3A4 inhibitors to the Prohibi ted 
Treatments
‚Ä¢Added caution for concomitant administration of NSAIDs with pemetrexed. 
‚Ä¢Added unacceptable methods of contraception to Appendix 6
Administrative 
Letter 0230-Nov-2017‚Ä¢Clarify the correct version of the TNM Staging System.
‚Ä¢Clarify that a minimum of 228 PD-L1+ participants will be rando mized.
‚Ä¢Clarify that physical exams, vital signs, and physical measurem ents 
should be collected prior to each dose of neoadjuvant and adjuv ant 
therapy.
‚Ä¢Clarify that the first post-ope rative tumor assessment should be 
performed 12 weeks ( ¬±7 days) after definitive surgery.
‚Ä¢Remove the phrase ‚Äúnon-protocol regimen‚Äù in regards to a non-ci splatin 
regimen as the protocol includes a non-cisplatin regimen option .
‚Ä¢Clarify that weight-bas ed dosing should be rounded up to the nearest 
milligram or per institutional standards.
‚Ä¢Clarify that the EQ-5D-3 L should be collected prior to Day 1 only in 
cycles that have multiple dosing days in each cycle.
Administrative 
Letter 0131-Oct-2017 ‚Ä¢To correct the IND number
Original 
Protocol30-Sep-2016 Not Applicable
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
OVERALL RATIONALE FOR PROTOCOL AMENDMENT 07: 
Based on historical and emerging external data, event accrual f or event-free survival (EFS) 
analysis is expected to slow down in long-term follow up after de finitive surgery for resectable 
non-small-cell lung cancer (NSCLC). Recurrence dynamics after c omplete res ection for stage I/II 
NSCLC show a constant recurrence r ate of 6-7 events per 100 perso n-years of follow-up during 
the first 4 y ears, decreasing to 2 events pe r 100 person-year thereafter.1 A similar slowdown was 
seen with stage III NSCLC. In a randomized, Phas e III trial com paring neoadjuvant 
chemoradiation and chemotherapy both followed by surgery in stag e III NSCLC, no difference 
was seen in progression-free survival (PFS, primary e ndpoint), with the PFS curves dropping 
sharply during the first year indicating init ial high h azard rates, then flattening thereafter 
suggesting a markedly decreasing and stabilizing hazard rate.2Such pattern of recurrence 
dynamics was repeatedly seen in other neoadjuvant trials conduc ted in Stage I-III NSCLC.3,4
Furthermore, preliminary data from recentl y published Phase II trials inc orporating nivolumab into 
neoadjuvant regimens suggest potentially further decreased haza rd rates for rec urrence after 
surgery by the flattened shape of Kaplan-Meier curves of EFS/PFS. For example, in the single-
arm NADIM trial of neoadjuvant nivolumab + chemotherapy followed b y surgery and adjuvant 
nivolumab for Stage IIIA NSCLC, the 24-month PFS rate was 77.1% ( 95% CI 59.9-87.7), greatly 
exceeding historic standards.5,6
To account for the aforementioned event dynamics which may prec lude the necessary EFS events 
from accruing in a reasonable timeframe or potentially never accru ing, the statistical analyses plan 
has been updated to model the assumptions based on a piecewise exponential distribution and 
incorporate a calendar-based rule in addition to the existing even t-driven approach to trigger 
analysis timing. Moreover, one additional EFS interim analysis (IA ) has been added  
 at 90% of EFS ev ents information fraction  
. No changes have been made to the target number of events for the existing 
interim and final analyses, and the overall ty pe 1 error has be en maintained. At the time of this 
amendment, EFS and overall survival (OS) remain blinded and have  not been analyzed by the 
Sponsor or investigators.
Protocol Amendment No.: 07
Date: 18-Aug-2021 6
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF PROTOCOL AMENDMENT 07
Section Number and Name Description of Change Brief Rationale
Title Page Updated title to ‚ÄúClinical Trial Physician‚Äù and 
added Clinical Scientist contact information. Updated to align with study contacts and the role name 
for Medical Monitor at BMS. 
Section 5.3, End of Study DefinitionIncluded additional interim analysis and calendar-based rule or the EFS final analysis.To account for a potential slowdown in EFS event accrual in long-term follow-up in this setting.
Section 9.2.1 , Time Period and 
Frequency for Collecting AE and SAE InformationRemoved obsolete cross-referenced sections to the Investigator Brochure (IB). To align with the updated IB. 
Section 10.1.2 , Event Free 
Survival (EFS)‚Ä¢Updated power calculation.
‚Ä¢Revised EFS assumptions for the control arm with piecewise exponential model.
‚Ä¢Added an additional interim analysis at 90% information fraction  
 
‚Ä¢Updated the timing of analyses based on a piecewise exponential model. To account for a potential 
slowdown in EFS event 
accrual in long-term follow-up in this setting.
Section 10.1.4 , Analyses 
Timing Projections
Section 10.3.3 , Interim 
Analyses‚Ä¢Revised timing projections based on 
updated EFS assumptions modeling and additional interim analysis included.
‚Ä¢Removed Table 10.1.4-1, Scheduled Analyses, Criteria, and Projected Timelines.To align with Sections 10.1.2 
and 10.1.3 updates.
Appendix 2 , Abbreviations and 
Trademarks Updated the following abbreviations:
‚Ä¢final analysis
‚Ä¢interim analysis Abbreviations were updated 
for clarity and completeness.
References
1Luo F, Huang J, Sima CS et al. Patterns of recurrence and second  primary lung cancer in early-stage lung cancer 
survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg. 2013; 145:75-81)
Protocol Amendment No.: 07
Date: 18-Aug-2021 7
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
2Thomas M, Rube C, H offknecht P et al. Effect of preoperative chemoradiation in add ition to preoperative 
chemotherapy: a randomised trial in stage III non-small-cell lu ng cancer. Lancet Oncol 2008; 9:636-48.)
3 Pless M, Stupp R, Ris HB, et al. Induction chemoradiation in st age IIIA/N2 non-s mall-cell l ung cancer: a phase 
3 randomised trial. Lancet 2015; 386:1049-56.
4Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant 
chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. Clin Oncol 2010 Jul 1; 28(19): 
3138-45
5Provencio M, Insa A, Casal-Rubio J et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-
cell lung cancer (NADIM): an open-label, multicentre, single-ar m, phase 2 trial. Lancet Oncol 2020; 21:1413-
22.
6Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolum ab or nivolumab plus ipilimumab in 
operable non-small cell lung cancer: the phase II randomized NEOSTAR trial. Nat Med 2021.27;504-14.)
Protocol Amendment No.: 07
Date: 18-Aug-2021 8
Approved 9.0 v
Approved
1.0
v
TABLE OF CONTENT6 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................. ................................................ 
OVERALL RATIONALE FOR PROTOCOL AMENDMENT 07: ............................ 
SUMMARY OF KEY CHANGES OF PROTOCOL AMENDMENT 07 ............... ... 
TABLE OF CONTENTS .............................................................................................. 
1 SYNOPSIS .................................................... ............................................................. 
2 SCHEDULE OF ACTIVITIES.................................................................................. 
3 INTRODUCTION ................................................ ..................................................... 
3.1 Study Rationale ................................................................................................. 
3.1.1 Research Hypothesis ................................................................................ 
3.2 Background ................................................ ....................................................... 
3.2.1 Indication Background ............................................................................. 
3.2.2 Nivolumab Mechanism of Action ............................................................. 
3.2.3 Ipilimumab Mechanism of Action ............................................................ 
3.2.4 Nivolumab Combined with Ipilimumab Clinical Activity ........................ 
3.2.5 Immuno-oncology Treatment Combined with Chemotherapy Clinical 
Activity ........................................................................................................ 
3.3 Benefit/Risk Assessment ................................... ............................................... 
4 OBJECTIVES AND ENDPOINTS .................................... ....................................... 
5 STUDY DESIGN....................................................................................................... 
5.1 Overall Design ............................................ ...................................................... 
5.1.1 Data Monitoring Committee and Other External Committees ................ 
5.2 Number of Participants ..................................................................................... 
5.3 End of Study Definition ................................... ................................................. 
5.4 Scientific Rationale for Study Design...................... ......................................... 
5.4.1 Rationale for Open-Label Design ............................................................ 
5.4.2 Rationale for Preoperative Systemic Therapy in NSCLC ........................ 
5.4.3 Rationale for Immuno-oncology Treatment in Neoadjuvant NSCLC ...... 
5.4.3.1 Rationale for Combination of Nivolumab and Ipilimumab (Arm A):
............................................................................................................... 
5.4.3.2 Rationale for PD-1 Inhibitor with Chemotherapy (Arm C) ............ 
5.4.4 Rationale for Pathologic Response .......................................................... 
5.4.5 Rationale for Patient Population ............................................................. 
5.4.6 Rationale for Choices of Platinum-based Chemotherapy Doublet .......... 
5.5 Justification for Dose .................................... .................................................... 
5.5.1 Rationale for Shorter Infusion Times for Nivolumab .............................. 
5.5.2 Rationale for Nivolumab 360 mg Flat Dose ............................................ 
6 STUDY POPULATION ............................................................................................ 
6.1 Inclusion Criteria .............................................................................................. 
6.2 Exclusion Criteria ............................................................................................. 
6.3 Lifestyle Restrictions ........................................................................................ 
6.4 Screen Failures ........................................... ....................................................... 
6.4.1 Retesting During Screening or Lead-In Period ....................................... 
7 TREATMENT ................................................... ........................................................ 



































Clinical Protocol
BMS-936558CA209816
nivolumab
Protocol Amendment No.: 07Date: 18-Aug-2021 9
Approved 9.0 v
Approved
1.0
v
7.1 Treatments Administered .................................................................................. 
7.2 Method of Treatment Assignment ............................ ........................................ 
7.3 Blinding............................................................................................................. 
7.4 Dosage Modification ....................................... .................................................. 
7.4.1 Dose Reductions for Platinum Doublet Chemotherapy ........................... 
7.4.1.1 Platinum Doublet Chemotherapy - Dose Reductions for 
Hematologic Toxicity ............................................................................ 
7.4.1.2 Platinum Doublet Chemotherapy - Dose Reductions for Non-
Hematologic Toxicities ......................................................................... 
7.4.2 Dose Delay ............................................................................................... 
7.4.2.1 Nivolumab Dose Delay Criteria ..................................................... 
7.4.2.2 Dose Delay Criteria for Platinum Doublet Chemotherapy ............ 
7.4.2.3 Docetaxel Dose Delay Criteria ....................................................... 
7.4.3 Treatment of Nivolumab- and Ipilimumab-related Infusion Reactions ... 
7.5 Preparation/Handling/Storage/Accountability ............... ................................... 
7.5.1 Retained Samples for Bioavailability / Bioequivalence ........................... 
7.6 Treatment Compliance ...................................... ................................................ 
7.7 Concomitant Therapy........................................ ................................................ 
7.7.1 Prohibited and/or Restricted Treatments................................................. 
7.7.2 Other Restrictions and Precautions ......................................................... 
7.7.3 Permitted Therapy ................................................................................... 
7.8 Treatment After the End of the Study ...................... ......................................... 
8 DISCONTINUATION CRITERIA ........................................................................... 
8.1 Discontinuation from Study Treatment ............................................................ 
8.1.1 Study Treatment Discontinuation Criteria ............................................... 
8.1.1.1 Nivolumab Discontinuation Criteria .............................................. 
8.1.1.2 Platinum Doublet Chemotherapy Dose Discontinuation ............... 
8.1.1.3 Docetaxel Dose Discontinuation .................................................... 
8.1.2 Criteria to Resume Treatment .................................................................. 
8.1.2.1 Criteria to Resume Nivolumab Treatment ...................................... 
8.1.2.2 Criteria to Resume Platinum Doublet Chemotherapy Dosing ....... 
8.1.2.3 Criteria to Resume Treatment with Docetaxel ................................ 
8.1.3 Post Study Follow-up ............................................................................... 
8.2 Discontinuation from the Study ............................ ............................................ 
8.3 Lost to Follow-Up ......................................... .................................................... 
9 STUDY ASSESSMENTS AND PROCEDURES ............................ ......................... 
9.1 Efficacy Assessments ........................................................................................ 
9.1.1 Imaging Assessment for the Study............................................................ 
9.1.2 Patient-reported Outcomes ...................................................................... 
9.2 Adverse Events ................................................................................................. 
9.2.1 Time Period and Frequency for Collecting AE and SAE Information .... 
9.2.2 Method of Detecting AEs and SAEs ......................................................... 
9.2.3 Follow-up of AEs and SAEs ..................................................................... 
9.2.4 Regulatory Reporting Requirements for SAEs ......................................... 
9.2.5 Pregnancy ................................................................................................ 
9.2.6 Laboratory Test Result Abnormalities ..................................................... 


































Clinical Protocol
BMS-936558CA209816
nivolumab
Protocol Amendment No.: 07Date: 18-Aug-2021 10
Approved 9.0 v
Approved
1.0
v
9.2.7 Potential Drug Induced Liver Injury (DILI) ............................................  
9.2.8 Other Safety Considerations ....................................................................  
9.2.9 Management Algorithms ..........................................................................  
9.3 Overdose .................................................. .........................................................  
9.4 Safety ................................................................................................................  
9.4.1 Clinical Safety Laboratory Assessments ..................................................  
9.4.2 Imaging Safety Assessment ......................................................................  
9.5 Pharmacokinetics ..............................................................................................  
9.6 Pharmacodynamics ...........................................................................................  
9.7 Pharmacogenomics ...........................................................................................  
9.8 Biomarkers ................................................ ........................................................  
9.8.1 Additional Research Collection ...............................................................  
9.8.1.1 Tumor Tissue Specimens .................................................................  
 
 
 
 
 
9.8.2 Safety Analyses.........................................................................................  
9.9 Health Economics OR Medical Resource Utilization and Health  Economics .  
9.10 Other Assessments ..........................................................................................  
9.10.1 Diagnostic/Pre-surgical Evaluation and Surgical Guidelines: .............  
9.10.2 Post-surgical Evaluation: ......................................................................  
10 STATISTICAL CONSIDERATIONS ................................. ...................................  
10.1 Sample Size Determination ................................ .............................................  
10.1.1 Pathologic Complete Response (pCR) ...................................................  
10.1.2 Event Free Survival (EFS) .....................................................................  
10.1.3 Power Consideration for Overall Survival (OS) ...................................  
10.1.4 Analyses Timing Projections ..................................................................  
10.2 Populations for Analyses ................................. ...............................................  
10.3 Statistical Analyses .........................................................................................  
10.3.1 Efficacy Analyses ...................................................................................  
10.3.2 Other Analyses .......................................................................................  
10.3.3 Interim Analyses .....................................................................................  
11 REFERENCES ................................................. .......................................................  
12 APPENDICES ................................................. ........................................................  
APPENDIX 1 TNM STAGING SYSTEM FOR LUNG CANCER (7TH EDITION)   
APPENDIX 2 ABBREVIATIONS AND TRADEMARKS ....................... .................  
APPENDIX 3 ECOG PERFORMANCE STATUS .....................................................  
APPENDIX 4 NIVOLUMAB MANAGEMENT ALGORITHMS .................... .........  
APPENDIX 5 RESPONSE CRITERIA (RECIST 1.1) ................................................  
APPENDIX 6 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION ...................................... ...............................  
APPENDIX 7 STUDY GOVERNANCE CONSIDERATIONS .................... .............  





























Clinical Protocol
BMS-936558CA209816
nivolumab
Protocol Amendment No.: 07Date: 18-Aug-2021 11
Approved 9.0 v
Approved
1.0
v
APPENDIX 8 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW UP AND REPORTING ADVERSE EVENTS .....................................  
APPENDIX 9 REVISED PROTOCOL SUMMARY OF CHANGE HISTORY ........  
 
Clinical Protocol
BMS-936558CA209816
nivolumab
Protocol Amendment No.: 07Date: 18-Aug-2021 12
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
1 SYNOPSIS
Protocol Title: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimu mab or 
Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Do ublet Chemotherapy in 
Early Stage NSCLC
Study Phase: 3
Rationale:
Approximately 80% of lung cancer cases are non-small cell lung cancer (NSCLC), with most 
patients presenting with late-stage disease. At initial diagnosi s, 20% of patients present with stage 
I or II disease, whereas 30% present with stage III disease and 50% with stage IV disease. With 
enhanced lung cancer screening techniques, the percentage of pa tients diagnosed during the early 
stages may increase over the duration of the trial. A standard TNM staging system is used to 
determine the staging for NSCLC ( Appendix 1 ). Patients with pathologic stage I NSCLC have a 
5-year survival of approximately 6 0%. Stage II to III NSCLC patients have a 5-year s urvival of 
approximately 25% to 40%.1Surgical resection remains the mainstay of treatment for stage I and 
II patients; however, despite potenti ally cur ative surgery, approximately 50% of stage IB and 
60-75% of stage II NSCLC patients w ill relapse and eventu ally die of their disease.2,3A rational 
approach to improve survival in these patients is to eradicate micrometastatic disease and to 
minimize the risk of relapse after adjuvant or neoadjuvant chem otherapy.
This phase 3 study, CA209816, w ill evalu ate the clinical efficacy of ni volumab plus ipilimumab
or nivolumab plus platinum doublet ch emotherapy in operable lung  cancer. Specifically, this study 
will compare event free survival (EFS) and compare the pathologi c complete response (pCR) rate
among participants with Stage IB-IIIa NSCLC treated with nivolum ab plus platinum doublet 
chemotherapy to the EFS and pCR rates in participants treated with  platinum-doublet 
chemotherapy.
Study Population:
1) Key Inclusion Criteria
a) Eastern Cooperative Group (ECOG) Performance Status 0-1
b) Participants with histologically confirmed Stage IB (‚â• 4 cm),  II, IIIA (N2) NSCLC (per 
the 7th International Association for the Study of L ung Cancer) who are considered 
resectable
c) Measurable disease according to Response Evaluatio n Criteria in Solid Tumors versi on 1.1 
(RECIST 1.1)
d) Participants must have tumor tissue sample available for PD-L1  immunohistochemical 
(IHC) testing performed by a third-party analyzing lab during the screening period:i) Either a formalin-fixed, paraffin-embedded (FFPE) tissue bloc k or unstained tumor 
tissue sections, with an associated pathology report, must be s ubmitted for biomarker 
Protocol Amendment No.: 07
Date: 18-Aug-2021 13
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
evaluation prior to randomization. The tumor tissue sample may be fresh or archival if 
obtained within 3 months prior to enrollment. 
ii) Tissue must be a core needle biopsy, excisional or incisiona l biopsy. Fine needle 
biopsies obtained by EBUS is not considered adequate for biomar ker review and 
randomization. Core needle biopsies ob tained by EBUS are acceptable for 
randomization. 
e) All suspicious mediastinal lymph nodes including those that are pathologically enlarged or 
FDG avid on PET/CT require further sampling for pathological co nfirmation if accessible 
by EBUS, thoracoscopy , or mediastinoscopy. 
2) Key Exclusion Criteria:
a) Presence of locally advanced, unresectable or metastatic diseas e. 
b) Participants with known EGFR mutations or ALK translocation. If testing is done, testing 
will be done using an FDA-approved assay and will be performed locally.
Objectives and Endpoints:
Objective Endpoint
Primary
‚Ä¢To compare the event-free survival (EFS) by 
blinded independent central review (BICR) in 
participants receiving nivolumab plus platinum 
doublet chemotherapy vs  participants receiving 
platinum doublet chemotherapy in operable stage 
IB (‚â•4 cm), II, or resectable IIIA (N2) NSCLC.‚Ä¢EFS defined as the length of time from 
randomization to any of the following events: 
any progression of disease precluding surgery, 
progression or recurrence disease (based on 
BICR assessment per RECIST 1.1) after 
surgery, or death due to any cause. Participants 
who don‚Äôt undergo s urgery for reason other 
than progression will be  considered to have an 
event at RECIST 1.1 progression (based on 
BICR) or d eath.
‚Ä¢To compare the pathologic complete response 
(pCR) rate in participants receiving nivolumab
plus platinum doublet chemotherapy vs 
participants receiving platinum doublet 
chemotherapy in operable stage IB ( ‚â•4 cm), II, or 
resectable IIIA (N2) NSCLC‚Ä¢pCR rate is defined as number of randomized 
participants with absence of residual tumor in 
lung and lymph nodes as evalu ated by blinded 
independent pathology review (BIPR), divided 
by the number of randomized participants for 
each treatment group. 
Secondary
‚Ä¢To assess the major pathologic response (MPR) 
rate by BIPR of participants receiving nivolumab
plus platinum doublet chemotherapy vs  
participants receiving platinum doublet 
chemotherapy in operable stage IB ( ‚â•4 cm), II, or 
resectable IIIA (N2) NSCLC‚Ä¢MPR rate, defined as number of randomized 
participants with ‚â§ 10% residual tumor in lung and lymph nodes as evaluated by BIPR, divided by the number of randomized participants for each treatment group. Viable tumors in situ carcinoma should not be included in MPR calculation.
Protocol Amendment No.: 07
Date: 18-Aug-2021 14
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Objective Endpoint
‚Ä¢To compare the OS of participants receiving 
nivolumab plus platinum doublet chemotherapy vs 
participants receiving platinum doublet 
chemotherapy in operable stage IB ( ‚â•4 cm), II, or 
resectable IIIA (N2) NSCLC‚Ä¢OS is defined as the time between the date of 
randomization and the date of death. OS will be 
censored on the last date a participant was 
known to be alive.
‚Ä¢To assess the time to death or distant metastases (TTDM) of participants receiving nivolumab plus platinum doublet chemotherapy vs participants receiving platinum doublet chemotherapy in 
operable stage IB ( ‚â•4 cm), II, or re sectable IIIA 
(N2) NSCLC‚Ä¢TTDM is define d as the time be tween the date 
of randomization and the first date of distant
metastasis or the date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the thorax
using BICR according to RECIST 1.1. Patients 
who have not developed distant metastasis or died at the time of analysis will be censored on the date of their last evaluable tumor assessment.
‚Ä¢Exploratory
‚Ä¢To assess clinical response rate (cRR) by BICR of participants receiving nivolumab plus platinum doublet chemotherapy vs  participants receiving platinum doublet chemotherapy in operable stage 
IB (‚â•4 cm), II, or resectable IIIA (N2) NSCLC ‚Ä¢cRR is defined as proportion of all randomized 
participants whose overall radiological 
response prior to definitive surgery is either a complete response or partial response per RECIST 1.1 criteria by BICR
‚Ä¢To assess the pCR rate, MPR rate , c RR, EFS, 
TTDM, and OS in early-stage NSCLC participants 
treated with nivolumab plus platinum doublet 
chemotherapy compared to those treated with platinum doublet chemotherapy by PDL1 status 
(PD-L1 ‚â•1% , PD-L1< 1%/not 
evaluable/indeterminate)   ‚Ä¢pCR rate, MPR rate, cRR, EFS, TTDM, and OS 
as described above
‚Ä¢To assess the feasibility of surgery and rate of peri-and post-operative complications (within 90 days 
of surgery) in participants receiving nivolumab 
plus platinum doublet chemotherapy compared to participants receiving platinum doublet ‚Ä¢Proportion of delayed or can celed surgery, 
duration of surgery, length of hospital stay, 
surgical approach, including completeness of 
the resection, incidence of AE/SAE associated with surgery, including pneumonitis, ARDS, re-admission to the Intensive Care Unit, atrial fibrillation or other supraventricular tachycardia (SVT) to 90 days post-surgery 
‚Ä¢To assess the safety and tolerability of nivolumab 
plus platinum doublet chemotherapy compared to 
platinum doublet chemotherapy in early stage NSCLC‚Ä¢Safety and tolerability will be measured by 
incidence of AE, SAE, immune-related AEs, 
deaths, and laboratory abnormalities
‚Ä¢To describe the pCR r ate, MPR rate , c RR, EFS, 
TTDM, OS, feasibility of surgery, rate of peri- and post-operative complications (within 90 days of surgery), safety and tolerability in early-stage NSCLC participants treated with nivolumab plus 
ipilimumab and by PDL1 status (PD-L1 ‚â•1% , 
PD-L1< 1%/not evaluable/indeterminate)‚Ä¢pCR rate, MPR rate, c RR, EFS, OS, TTDM, 
feasibility of surgery, rate of peri- and post-
operative complications, safety and tolerability 
Protocol Amendment No.: 07
Date: 18-Aug-2021 15
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Objective Endpoint
‚Ä¢To assess pharmacokinetics of the nivolumab plus 
ipilimumab or nivolumab plus platinum doublet 
chemotherapy in participants with early stage 
NSCLC ‚Ä¢Pharmacokinetic endpoints - See Table 9.5-1
‚Ä¢To assess the participant‚Äôs overall health status and health utility using the 3-level version of the EQ-5D-3L visual analog scale (VAS) and utility index, respectively‚Ä¢Change in EQ-5D-3L scores
‚Ä¢To assess Event Free survival on next line of therapy (EFS2) in early-stage NSCLC participants treated with nivolumab plus platinum doublet chemotherapy compared to those treated with platinum doublet‚Ä¢Event Free survival on next line of therapy (EFS2)
‚Ä¢To evaluate tumor mutation burden as a potential predictive biomarker of efficacy (such as EFS and OS) of nivolumab plus platinum doublet chemotherapy and of platinum-doublet chemotherapy, using data generated from tumor and blood (germ-line control) specimens.
‚Ä¢To explore potential predictive biomarkers of  nivolumab plus platinum doublet chemotherapy efficacy (such as EFS and OS) in peripheral blood and tumor specimens  
 
 
 
 
 ‚Ä¢Biomarker endpoints - See Section 9.8.
Protocol Amendment No.: 07
Date: 18-Aug-2021 16
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Overall Design:
This is an open-label, randomized clinical trial of up to 3 cyc les of neoadjuvant nivolumab 
(3 mg/kg every 2 weeks) and a single dose of 1 mg/kg dose of ipil imumab, up to 3 cycles of 
nivolumab (360 mg) plus platinum doublet chemotherapy every 3 w eeks, or neoadjuvant platinum 
doublet chemothe rapy (up to 3 cy cles) in participa nts with early stage (Stage IB [‚â• 4 cm], II, and 
resectable IIIA [N2]) NSCLC. 
Revised protocol 03 withholds rando mization into Arm A of neoadjuvant nivolumab plus 
ipilimumab but continues randomizing eligible participants into  either neoadjuvant nivolumab plus 
platinum doublet chemotherapy arm  or platinum doublet chemotherapy  arm. Participants already 
randomized in the original 2-arm part (neoadjuvant nivolumab pl us ipilimumab vs neoajduvant 
chemotherapy) and in the arm of neoadjuvant nivolumab plus ipil imumab in 3-arm part defined 
by revised protocol 02 will remai n in trial and continue schedu led trial procedures.
Study Schema
Eligible participants will be randomized between 2 arms in a 1:1  ratio. Participants will be stratified 
by:
‚Ä¢PD-L1 expression ( ‚â•1% or <1%/not evaluable/indeterminate)
‚Ä¢Disease stage (IB/II vs IIIA)
‚Ä¢Gender
PD-L1 status will be determined by immunohistochemical (IHC) st aining of PD-L1 protein in the 
submitted tumor sample and categorized as follows: 
‚Ä¢PD-L1 positive -  defined as ‚â• 1% tumor cell mem brane staining positive in a minimum of 
100 evaluable tumor cells
‚Ä¢PD-L1 negative ‚Äì defined as < 1% tumor cell membrane staining positive in a minimum of 
100 evaluable tumor cells
‚Ä¢PD-L1 not evaluable/indeterminate - defined as participants with i nsufficient sample quantity 
or quality to stain for PD-L1 status or those in whom PD-L1 stat us could not be determined 
Protocol Amendment No.: 07
Date: 18-Aug-2021 17
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
despite appropriate amounts of tissue sample. For the purpose o f stratification, this category 
will be grouped with PD-L1 negative participants. No more than 10% of p articipants will be 
randomized into this category.
Tumor tissue (archival  [blocks/slides ‚â§3 months old] or recent tumor biopsy) must be submitted 
to a third-party vendor for determination of PD-L1 status testi ng prior to randomization. 
PET/CT including contrast from the base of the skull to upper t highs will be performed at baseline 
(within 28 days pri or to randomization) and within 14 da ys prior to planned definitive surgery. A 
separate CT, with contrast, of the chest, abdomen, and all othe r suspected sites of disease (as well 
as the PET/CT) is required if the CT component of a PET/CT is no t of sufficient diagnostic  quality 
for RECIST 1.1 measurements. Subsequent assessments (CT, includ ing contrast, of the chest
including adrenal glands and CT or MRI of other additional suspected/known sites of disease.) 
will be performed in accordance with the Schedule of Activities . Tumor assessments must continue 
per protocol until disease recurrence/progression is confirmed by BICR per RECIST 1.1. Details 
will be outlined in the radiology manual. OS will be followed c ontinuously every 3 months via in-
person or phone contact after Post-neoadjuvant Follow-up Visit 2 or after completion of adjuvant 
therapy, when applicable. 
Following the completion of neoadjuvant treatment, all par ticipants who r emain operative
candidates will undergo definitive surgery for NSCLC. Surgery s hould be performed within 
6 weeks after completing neoadj uvant treatment for each treatment arm.
Following definitive surgery, participants in each arm may rece ive adjuvant chemotherapy with or 
without radiation per institutional standard at the discretion of the investigator. 
Number of Participants: 
Approximately 350 participants will be randomized in a 1:1 ratio  (175 participants in each arm) to 
the 2 arms (neoadjuvant nivolumab plus platinum doublet chemothe rapy and platinum doublet 
chemotherapy) from 1:1:1 randomization in revised protocol 02 a nd 1:1 randomization in revised 
protocol 03.
In addition, it is expected to have around 70 participants rando mized in the original 2-arm study
(Arm A and Arm B) and approximately another 75 participants rand omized in the arm of 
neoadjuvant nivolumab plus ipilimu mab (Arm A) when the study ha d 3 arms. 
Treatment Arms and Duration:
Arm A: Participants randomized into Ar m A received nivolumab 3 mg/kg IV over 30 minutes 
every 2 weeks for up to 3 doses (ie, 6 weeks of treatment; each cycle is 14 days). In Cycle 1 Day 1 
only, nivolumab will be followed by a single dose of ipilimumab  1 mg/kg IV over 30 minutes.
Arm B: Participants randomized to Arm B w ill receive investigator-choic e of platinum doublet 
chemotherapy regimens in 3-week cycles up to a maximum of 3 cyc les of IV chemotherapy 
(ie, 9 weeks of treatment; each cycle is 21 days). 
Protocol Amendment No.: 07
Date: 18-Aug-2021 18
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢Regimen 1:
‚àíVinorelbine 25 mg/m2or 30 mg/m2IV (per local prescribing information) push over 
10 minutes or per institutional standard, Days 1 and 8
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard Day  1, immediately 
following vinorelbine
‚Ä¢Regimen 2:
‚àíDocetaxel 60 mg/m2or 75 mg/m2IV (per local prescribing information) over 60 minutes 
or per institutional standard on Day 1
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following docetaxel
‚Ä¢Regimen 3: (squamous histology):
‚àíGemcitabine 1000 mg/m2 or 1250 mg/m2IV (per local prescribing information) over 
30 minutes or per institutional standard on Days 1 and 8
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following gemcitabine
‚Ä¢Regimen 4: (non-squam ous histology only):
‚àíPemetrexed 500 mg/m2IV over 10 minutes or per institutional standard on Day 1
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following pemetrexed
‚Ä¢Regimen 5:
‚àíPaclitaxel 175 or 200 mg/m2IV over 180 minutes or per institutional standard on Day 1
‚àíCarboplatin AUC 5 or 6 IV over 30 minutes or per institutional standard on Day 1, 
immediately foll owing paclitaxel
Arm C: Participants randomized into Arm C will receive nivolumab 360 mg  I V  +  p l a t i n u m  
doublet ch emotherapy in 3-week cycles up to a maximum of 3 cycl es of IV chemotherapy 
(ie, 9 weeks of treatment; each cycle is 21 days)
‚Ä¢Non-squamous NSCLC: nivolumab at a flat dose of 360 mg as 30-mi nute IV infusion on Day 
1, followed by pemetrexed at a dose of 500 mg/m2 IV over 10 minutes or per institutional 
standard with cisplatin at a dose of 75 mg/m¬≤ IV over 120 minut es or per institutional standard, 
of a 3-week treatment cycle, for up to 3 cycles.
‚Ä¢Squamous NSCLC: nivolumab at a flat dose of 360 mg as 30 minute I V infusion on day 1, 
followed by gemcitabine at a dose of 1000 mg/m2or 1250 mg/m2(per local prescribing 
information) IV over 30 minutes or per institutional standard w ith cisplatin at a dose of 
75 mg/m2IV over 120 minutes or per institutional standard, of a 3-week treatment cycle for 
up to 3 cycles. Gemcitabine will also be administered at a dose of 1000 mg/m2or 1250 mg/m2
Protocol Amendment No.: 07
Date: 18-Aug-2021 19
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
as a 30 minute IV infusion or per institutional standard on day 8 of each 3-week tr eatment 
cycle.
‚Ä¢Any histology: nivolumab at a f lat dose of 3 60 mg as 30-minute IV infusion on Day 1, followed 
by paclitaxel 175 or 200 mg/m2IV over 180 minutes or per institutional standard and 
carboplatin AUC 5 or 6 IV over 30 minutes or per institutional standard of a 3-week treatment 
cycle, for up to 3 cycles
Study treatment: 
Study Drug for CA209816
Medication Potency IP/Non-IP 
BMS-936558-01 Nivolumab 10 mg/mL IP
Ipilimumab Solution for Injection 5 mg/mL IP
Vinorelbine 10 mg/mL IP
Gemcitabine 38 mg/mL IP
Docetaxel 10 mg/mL IP
Pemetrexed 500 mg/vial IP
Cisplatin 1 mg/mL IP
Carboplatin 10 mg/mL IP
Paclitaxel 6 mg/mL IP
Independent Data Monitoring Committee
An independent Data Monitoring Committee (DMC) w ill be establis hed to provide oversight of 
safety and efficacy considerations, study conduct, and risk-ben efit ratio in protocol CA209816. An 
interim DMC review will occur after 15 participants are enrolled  in Arm A and after 15 participants 
are enrolled in Arm C and have completed surgery. Following rev iew, the DMC will recommend 
continuation, modification, or discontinuation of this study ba sed on reported safety data. 
Representatives of the Sponsor w ill serve only as c oordinators of the committee, without having 
full member responsibilities or privileges. In addition, the Sp onsor will independently review 
safety data in a blinded manner during the conduct of this tria l to ensure that any safety issues are 
identified and addressed. Availa ble efficacy dat a will also be r eviewed by the DMC during the 
conduct of the st udy. Details of the DMC responsibilities and p rocedures will be sp ecified in the 
DMC charter.
Protocol Amendment No.: 07
Date: 18-Aug-2021 20
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Independent Radiology/Pathology Review:
Independent pathology and radiol ogy review will be established for central review and 
confirmation of e ndpoints. Imag es and tumor/lymph node samples will be submitted  to these third-
party vendors for central review. Sites will be trained prior t o enrolling the first study participant. 
Images and pathology samples acquisition guidelines and submission process will be ou tlined in 
the study Imaging/Laboratory Manuals to be provided by the vend ors.
Tumor and lymph node collection from definitive surgical resect ion and sampling of fresh tumor 
sample in RNAlater for biomarker studies (as applicable depende nt on the size of the residual 
tumor) is mandatory on the day of surgery. RNAlater sample will  not be collected in China.
Processing the remainder of the specimen for histopathologic an alysis should be performed within 
72 hours of the procedure. Sections will be used for central pa thology review assessing pathologic
complete response (pCR) and major pathologic response (MPR). Any tumor, tumor bed or lymph 
node specimens that are reviewed  locally must be submitted for central pathology review. Gross 
examination on the entire specime n should be performed which includes all tumor, and associated 
lymph node tissue and uninvolved parenchyma. The specimen s hould be sectioned at 0.5 cm 
intervals, and blocks should be submitted for the full cross sec tion for every other 0.5 cm interval. 
For very large tumors with no gross evidence of response, a minimum of 1 slide/cm is required for assessment of pathologic respons e. When estimating viable tumor , in situ carcinoma should not be 
included. Pathology specimen collection and processing guideline s are outlined in the CA209816 
Laboratory Manual. A blinded pathology review process will be u tilized to assess for confirmation 
of endpoints.
Radiologic tumor assessments should be submitted to the third-party radiology vendor as they are 
performed on a n ongoing basis.
Tumor assessments will be sent to and reviewed by a Blinded Ind ependent Central Review (BICR) 
from a third-party radiology vendor on an on-going basis. At th e time of investigator assessed 
radiographic progression per RECIST 1.1, the site must request a BICR- for confirmation of 
progression or disease recurrence. However, BICR confirmation o f progression should not be 
requested if investigator judges the progression will not precl ude surgery. Participants should 
proceed to definitive surgery and tumor assessments post surger y should be continue per schedule 
of activities. Details of the BICR responsibilities and procedur es will be specified in the BICR 
charter.
Participants whose disease progre ssion or disease recurrence is  not confirmed by central review 
will be required to continue t umor assessments (if clinically fe asible) according to the protocol-
specified schedule, even after the initiation of subsequent ant i-cancer therapies. Subsequent tumor 
assessments must be submitted to the third party radiology vend or for subsequent review and may 
be discontinued when the invest igator and independent radiologi sts both assess the participant to 
have met RECIST 1.1 criteria for progression or disease recurrence.
Abbreviations are listed in  Appendix 2.
Protocol Amendment No.: 07
Date: 18-Aug-2021 21
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
REFERENCES
1Mountain, CA.  Regional lymph node classification for lung canc er staging. Chest. 1997: 1718-
23.
2Goldstraw P, Crowley J, Chansky K, et al for the International Association for the Study of 
Lung Cancer Internatonal Stag ing Committee. The I ASLC Lung Canc er Staging Project: 
proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of 
the TNM Classification of malignant tumours. J Thorac Onco. 200 7; 2(8):706-14.
3Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009; 136: 
260-71.
Protocol Amendment No.: 07
Date: 18-Aug-2021 22
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
2 SCHEDULE OF ACTIVITIES
Table 2-1: Screening Procedural Outline (CA209816) a
ProcedureScreening 
VisitNotes
Eligibility Assessments
Informed Consent XInformed Consent Form prior to screening for study participatio n. If a participant is re-enrolled, the 
participant must be re-consented, and eligibility should be re- confirmed. Register in Interactive Response 
Technology to obtain participant number. 
Inclusion/Exclusion Criteria XAll inclusion/exclusion criteria should be assessed at screenin g and confirmed prior to first dose. 
Participants must also meet operative criteria ( Section 9.10.1 ).
Medical History X
Tumor Tissue Samples XTumor tissue submission prior to randomization is mandatory. If a recent/archived (within 3 months) 
biopsy sample is not available at screening, a fresh biopsy will be taken. 
Sufficient tumor tissue obtained prior to randomization (block or minimum of 15 slides, obtained from 
core biopsy, punch biopsy, excisional biopsy or surgical specim en). If less than 15 slides are available, 
then the Medical Monitor should be contacted to advise on eligibility. 
For participants for whom a biopsy is not feasible, archival tu mor material must be made available. Fine 
needle aspirate of draining lymph node is not acceptable. Core needle biopsies obtained by EBUS are acceptable. PD-L1 status must be determined prior to randomizat ion.
Mediastinal lymph node sampling XAll suspicious mediastinal lymph nodes including those that are pathologically enlarged or FDG avid on 
PET/CT require further sampling for pathological confirmation if accessible by EBUS, mediastinoscopy, 
or thoracoscopy.
Screening/Baseline Tumor 
AssessmentsXPET/CT including contrast from the base of the skull to the upp er thighs, within 28 days prior to 
randomization. A separate CT with contrast of the chest, abdomen, and other suspected areas of disease (as 
well as the PET/CT) is required if the CT component of the PET/ CT is not of sufficient diagnostic quality 
for RECIST 1.1 measurements.
Participants with stage II or higher disease and those with a suspicion of brain metastasis should have a 
MRI or CT of the brain pre- and post-contrast within 28 days of randomization. 
Tumor assessments should be performed following RECIST 1.1 crit eria.
Prior Medication X
ECOG Performance Status X Within 14 days prior to randomization ( Appendix 3)
Protocol Amendment No.: 07
Date: 18-Aug-2021 23
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 2-1: Screening Procedural Outline (CA209816) a
ProcedureScreening 
VisitNotes
Safety Assessments
History and Physical Examination XIncludes assessment of symptoms, review of system (ROS), height, weight, BSA (for platinum dosing), 
and full physical exam within 14 days prior to randomization. 
Vital Signs and Oxygen Saturation XIncludes body temperature, respiratory rate, and seated blood pressure, heart rate, and oxygen saturation by pulse oximetry (at rest). Obtained at the screening visit and w ithin 72 hours prior to first dose. 
Pulmonary Function Test X Should be performed within 6 weeks prio r to randomization. Includes FVC, FEV1, TLC, FRC, and DLco.
Concomitant Medication Collection X Within 14 days of randomization.
Serious Adverse Events AssessmentX Serious Adverse Events from the time of consent
Adverse Events Assessment X
Laboratory Tests XCBC w/differential, chemistry panel including: Albumin, LDH, AS T, ALT, ALP, T. Bili, BUN or serum 
urea level, creatinine, phosphate, Ca, Mg, Na, K, Cl, glucose, amylase, lipase, TSH, T4 (free), T3 (free or total) within 14 days prior to randomization.Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), reflex HBV DNA, hepatitis C 
antibody (HCV Ab), and reflex hepatitis C RNA (HCV RNA). Within 28 days prior to randomization.
ECG XECG to be performed prior to randomization and recorded after the participant has been supine for at least 
5 minutes.
Pregnancy Test  XUrine or serum test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 14 days prior to randomization. 
Study Treatment
Randomize X
aScreening assessments should occur within 28 days of randomizat ion unless otherwise noted. 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nit rogen; Ca, calcium; CBC complete blood count; Cl, chloride; DLco, 
diffusing capacity; EBUS, endobronchial ultrasound; ECG, electrocardiogram; FEV1, forced expiratory volume in 1 second; FVC, f orced vital capacity; FRC,
functional residual capacity; FVC, forced vital capacity; HBcAb , Hepatitis B core antibody; HBsAg, Hepatitis B surface antigen ; HCV Ab, Hepatitis C 
antibody; ICF, informed consent form; LDH, lactate dehydrogenas e, K, potassium; Mg, magnesium; NA, sodium; RECIST, Response Evaluation Criteria in 
Solid Tumors; SOC, standard of care; T.Bili, total bilirubin; TLC, total lung capacity; TSH, thyroid stimulating hormone.
Protocol Amendment No.: 07
Date: 18-Aug-2021 24
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 2-2: Neoadjuvant Period Procedural Outline (CA209816)
ProcedureDuring Treatment
Visitsa,b Notes
Safety Assessments
Physical Examination X Includes assessment of signs, symptoms, and ROS prior to each dose. 
Vital Signs and Oxygen 
SaturationXIncluding BP, HR, temperature, respiratory rate, and oxygen saturation by pulse oximetry (at rest) prior to each dose. 
Physical Measurements XWeight, Body Surface Area (for cytotoxic dosing), and ECOG status. The dosing calculations for treatment arms should be based on the body weight, except for n ivolumab on Arm C, which will be 
administered using a flat dose of 360 mg. If the participant‚Äôs weight on the day of dosing differs by 
> 10% from the weight used to calculate the previous dose, the d ose must be recalculated for the dose 
of the day by using the participant‚Äôs weight of the day, and th is updated value becomes the reference 
for subsequent dosing calculations. All doses should be rounded  to the nearest milligram or as per 
institutional standard.
Serious Adverse Event 
AssessmentX
Adverse Events Assessment X
Review of Concomitant MedicationsX
Pulmonary Function Test See notes PFTs should be re-evaluated pri or to surgery only. Includes FVC, FEV1, TLC, FRC, and DLco.
Laboratory test XOn-study lo cal laboratory assessments should be done within 72 hours prior  to each dose, starting 
with Cycle 1 Day 1 (C1D1). C1D1 labs do not need to be repeated  if they were performed within 14 
days of dosing.
CBC w/differential, LFTs (ALT, AST, total bilirubin, alkaline p hosphatase), BUN or serum urea 
level, creatinine, Ca, Mg, Na, K, Cl, LDH, glucose, amylase, lipase, albumin, and phosphate.
TSH with reflexive T4 (free), T3 (free or total) for Arm A and Arm C only. Repeat every 6 weeks 
while receiving nivolumab.
Pregnancy Test  XSerum or urine (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to 
first dose and then every 4 weeks for Arm A, every 3 weeks for Arm C, and Arm B while receiving 
study treatment. An extension of up to 72 hours prior to the start of study drug may be permissible in 
situations where results cannot be obtained within the standard  24 hours window, subject to Medical 
Monitor approval.
Protocol Amendment No.: 07
Date: 18-Aug-2021 25
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 2-2: Neoadjuvant Period Procedural Outline (CA209816)
ProcedureDuring Treatment
Visitsa,b Notes
Efficacy Assessments
Tumor Assessments XPET/CT including contrast of the base of the skull through the upper thighs, within 14 days prior to 
surgery per RECIST 1.1. A separate CT with contrast of the ches t, abdomen, and all other suspected 
areas of disease (as well as the PET/CT) is required if the CT component of a PET/CT is not of 
sufficient diagnostic quality for RECIST measurements. 
Pharmacokinetic Assessments
PK samplescX Arm C only. Refer to Table 9.5-1
Biomarker Assessments
Exploratory Biomarker X
Patient-reported Outcomes Assessment
EQ-5D-3L XFor C1D1: performed after randomization PRIOR to first dose. On Day 1 of each cycle of study drug 
administration, the EQ-5D-3L will be administered PRIOR to trea tment. 
Study Treatment
IRT Drug Vial Assignments X
Dispense Study treatment XWithin 7 calendar days after randomization, the participants must receive the first dose of study medication. Participants no less than 18 days between doses for nivolumab on Arm C.
If a dose is delayed for any reason, participants should be dos ed no later than 7 days following a 
planned dose on any arm. 
If more than 7 days delay is needed for any reason, the intended dose should be skipped. If a participant receiving chemotherapy on a Day 1 and Day 8 schedule (ie, cisplatin/gemcitabine) is unable to receive Day 1 of chemotherapy but recovers in time to  receive the Day 8 dose, the Day 8 
dose of chemotherapy may be administered.
Surgery per Standard of Care See notesSurgery should be performed within 6 weeks after completing up to 3 cycles of neoadjuvant therapy 
as indicated by the institutional standard of care (SOC). 
Doses skipped during pre-operative treatment should not be repl aced.  
aEach cycle in Arm B and Arm C is 21 days.
Protocol Amendment No.: 07
Date: 18-Aug-2021 26
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
bNeoadjuvant period assessments should be performed within 72 ho urs prior to dosing, unless otherwise noted.
cArm C only
ALT, alanine aminotransferase; AST, aspartate aminotransferase;  BP, blood pressure; BUN, blood urea nit rogen; Ca, calcium; CBC complete bl ood c ount; 
Cl, chloride; DLco, diffusing capacity; EBUS, endobronchial ult rasound; ECG, electrocardiogram; ECOG, Eastern Cooperative Onco logy Group;  FEV1, 
forced expiratory volume in 1 second; FVC, forced vital capacit y; FRC, functional residual capacity; FV C, forced vital capacity; HR, h eart rate; HBcAb, 
Hepatitis B core antibody; HBsAg, Hepatitis B surface antigen; HCV Ab, Hepatitis C antibody; ICF, informed consent form; IRT, interactive response 
technology; LDH, lactate dehydrogenase, K, potassium; Mg, magnesium; NA, sodium; PFT, pulmonary function test; RECIST, Respons e Evaluation Criteria 
in Solid Tumors; SOC, standard of care; T.Bili, total bilirubin ; TLC, total lung capacity; TSH, thyroid stimulating hormone.
Protocol Amendment No.: 07
Date: 18-Aug-2021 27
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 2-3: Post-Neoadjuvant Period for Those Participants Not Re ceiving Adjuvant Therapy (CA209816)
ProcedurePost-Neoadjuvant 
Therapy 
Visits 1 and 2aSurvival 
Follow-Up 
Visits b,cNotes
Safety Assessments
Physical Examination X Includes assessment of signs and symptoms and ROS.
Vital Signs and Oxygen Saturation X Include BP, HR, temperature, and oxygen saturation by pulse oximetry (at rest).
Serious Adverse Events Assessment XAll AE/SAEs to be collected for up to 100 days after the last d ose of 
neoadjuvant therapy or 90 days after surgery, whichever is long er. 
Adverse Events Assessment XAll AE/SAEs to be collected for up to 100 days after the last d ose of 
neoadjuvant therapy or 90 days after surgery, whichever is longer. 
Review of Concomitant 
MedicationsX X Document subsequent cancer therapy
Laboratory Tests XCBC w/ differential, LFTs (ALTs, AST, total bilirubin, alkaline  phosphatase), 
BUN or serum urea level, creatinine, Ca, Mg, Na, K, Cl, LDH, glucose, 
amylase, lipase, albumin, and phosphate.TSH with reflex T4 (free) and T3 (free or total) for Arm A and Arm C only. 
Laboratory tests should be done at Post-neoadjuvant Visit 1 and  repeated at 
Post-neoadjuvant Visit 2 if study-related toxicity persists.
Pregnancy Test X Serum or urine (minimum sensitivity 25 IU/L or equivalent units of HCG)
Efficacy Assessments
Tumor Assessments ----See Notes---Tumor assessments with CT, including contrast, of the chest inc luding adrenal 
glands and CT or MRI of other additional suspected/known sites of disease. The 
first tumor assessment should occur 12 weeks (¬± 7 days) after definitive surgery 
per RECIST 1.1 and then should occur every 12 weeks ( ¬±7 days) per RECIST 
1.1 for 2 years (104 weeks), then every 6 months (24 weeks ¬±7 days) for 3 
years, and every year (52 weeks ¬±7 days) for 5 years o r until disease recurrence 
or progression is confirmed by blinded independent central revi ew (BICR). 
For participants who did not receive definitive surgery AND wit hout tumor 
progression confirmed by BICR, the first tumor assessments should be done 12 
weeks (¬± 7 days) following the tumor restaging, subsequent tumor assessments will be performed with the same frequency and methods as descri bed for those 
Protocol Amendment No.: 07
Date: 18-Aug-2021 28
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 2-3: Post-Neoadjuvant Period for Those Participants Not Re ceiving Adjuvant Therapy (CA209816)
ProcedurePost-Neoadjuvant 
Therapy 
Visits 1 and 2aSurvival 
Follow-Up 
Visits b,cNotes
having received definitive surgery; in case the planned initiat ion of subsequent 
anti-cancer therapy is within 12 weeks of restaging, every effo rt should be made 
to repeat tumor assessment prior to subsequent anti-cancer ther apy.
Use same imaging method and a machine of the same quality as was used at 
screening/baseline
Pathology and Biomarker Assessments
Tissue and biomarker assessments --See notes--Tissue collection from definitive surgical resection is mandato ry for pathologic 
response assessments and highly recommended for biomarker asses sments on 
the day of surgery. Tumor biopsy collection is optional but hig hly 
recommended from participants at disease progression.All tumor biopsy collection details will be provided in the lab  manual. 
Patient-reported Outcomes Assessment
EQ-5D-3L X XEvery 3 months after Post-neoadjuvant Visit 2 for 1 year and then once every 
6 months thereafter. May be completed as a phone call if a clinic visit is not 
otherwise required. 
Participant Survival Status
Survival Status X XEvery 3 months after Post-neoadjuvant Follow-Up Visit 2. May be 
accomplished by visit, phone contact, or email to assess subseq uent anti-cancer 
therapy
aPost-neoadjuvant Visit 1within 30 days from the last dose of ne oadjuvant therapy ¬±7 days and prior to surgery (this may lead to shortened interval between last 
dose of neoadjuvant treatment and post-neoadjuvant visit 1). If  Post-neoadjuvant Visit 1 falls within 7 days of the scheduled surgery d ate, then the 
Post-neoadjuvant Visit 1 visit may coincide with the surgery ad mission. All Neoadjuvant Visit 1 assessment procedures should b e completed prior to surgery. 
Post-adjuvant Visit 2 = 70 days ( ¬±7 days) from Post-neoadjuvant Visit 1. Post-neoadjuvant visits may coincide with the date  of post-surgical follow-up. Timing 
of Post-neoadjuvant Visits 1 and 2 are based on the pre-surgica l neoadjuvant treatment timelines.
bSurvival Follow-up Visits begin 3 months after Post-neoadjuvant  Visit 2. Visits should occur every 3 months ( ¬±7 days).
cFor those participants who have progression confirmed by BICR, participants will continue to be followed for survival status e very 3 months by visit, phone 
contact, or email.
Protocol Amendment No.: 07
Date: 18-Aug-2021 29
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
ALT, alanine aminotransferase; AST, aspartate aminotransferase;  BUN, blood urea nit rogen; Ca, calcium; CBC complete blood count; Cl, chloride; DLco, 
diffusing capacity; EBUS, endobronchial ultrasound; ECG, electrocardiogram; FEV1, forced expiratory volume in 1 second; FVC, f orced vital capacity; FRC, 
functional residual capacity; FVC, forced vital capacity; HBcAb , Hepatitis B core antibody; HBsAg, Hepatitis B surface antigen; HCV Ab, Hepatitis C 
antibody; ICF, informed consent form; LDH, lactate dehydrogenas e, K, potassium; Mg, magnesium; NA, sodium; RECIST, Response Ev aluation Criteria in 
Solid Tumors; SOC, standard of care; T.Bili, total bilirubin; TLC, total lung capacity; TSH, thyroid stimulating hormone.
Protocol Amendment No.: 07
Date: 18-Aug-2021 30
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 2-4: Post-Neoadjuvant Period for Participants Receiving Ad juvant Chemotherapy (CA209816)
ProcedureDuring Adjuvant 
Treatment VisitaPost Neoadjuvant 
Therapy 
Visits 1 and 2bSurvival 
Follow-Up 
Visitsc,dNotes
Safety Assessments
Physical 
MeasurementsXWeight, BSA (for cytotoxic dosing), and ECOG status prior to each dose. The dosing calculations for the platinum doublet 
chemotherapy arm should be based on the body weight. If the participant‚Äôs weight on the day of dosing differs by > 10% from  
the weight used to calculate the previous dose, the dose must be recalculated for the dose of the day using the participant‚Äôs we ight 
of the day, and this updated value becomes the reference for subsequent dosing calculations. All doses should be rounded to the nearest milligram or per institutional standard.
Physical Examination X XIncludes assessment of signs, symptoms, and ROS prior to each dose.
Vital Signs and 
Oxygen SaturationXXInclude BP, HR, temperature, and oxygen saturation by pulse oximetry (at rest) prior to each dose
Serious Adverse Events AssessmentXXAll AEs/SAEs to be collected for up to 30 days after the last dose of adjuvant therapy. 
Adverse Event AssessmentsXXAll AEs/SAEs to be collected for up to 30 days after the last dose of adjuvant therapy 
Review Concomitant MedicationX X X Document subsequent cancer therapy.
Laboratory test X XOn-study local laboratory assessments should be done within 72 hours prior to each dose and at Post-neoadjuvant Visit 1. To 
be repeated at Post-neoadjuvant Visit 2 if study-related toxicit y 
persists.  CBC w/ differential, albumin, LFTs (ALT, AST, total bilirubin, alkaline, phosphatase), BUN or serum urea level, creatinine, Ca , 
Mg, Na, K, Cl, LDH, glucose, amylase, lipase, phosphate.
TSH with reflex T4 (free) and T3 (free or total) for Arm A and 
Arm C only. To be conducted only at Post-neoadjuvant Therapy 
Protocol Amendment No.: 07
Date: 18-Aug-2021 31
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 2-4: Post-Neoadjuvant Period for Participants Receiving Ad juvant Chemotherapy (CA209816)
ProcedureDuring Adjuvant 
Treatment VisitaPost Neoadjuvant 
Therapy 
Visits 1 and 2bSurvival 
Follow-Up 
Visitsc,dNotes
Visit 1 and repeated at Post- Neoadjuvant Therapy Visit 2 if 
study-related toxicity persists.
Pregnancy test X XSerum or urine (minimum sensitivity 25 IU/L or equivalent units  
of HCG) within 24 hours prior to first dose and then every 4 
weeks while receiving study treatment. 
An extension of up to 72 hours prior to the start of study drug  
may be permissible in situations where results cannot be obtain ed 
within the standard 24 hours window, subject to Medical Monitor  
approval.
Efficacy Assessments
Tumor Assessments ---See Notes---Tumor assessments using CT, with contrast, of the chest 
including adrenal glands and CT or MRI of other additional suspected/known sites of disease. 
The first tumor assessment should occur 12 weeks (¬± 7d a y s )  
after definitive surgery per RECIST 1.1 and then should occur 
every 12 weeks ( ¬±7 days) per RECIST 1.1 for 2 years (104 
weeks), then every 6 months (24 weeks ¬±7 days) for 3 years, and 
every year (52 weeks ¬±7 days) for 5 years or until disease 
recurrence or progression is confirmed by BICR. 
Use same imaging methods and machine of the same quality as 
was used at screening/baseline. 
Biomarker Assessment
Exploratory Biomarker ---See Notes---Tumor biopsy collection is optional but highly recommended 
from participants at disease progression. 
All tumor biopsy collection details will be provided in the lab  
manual.
Protocol Amendment No.: 07
Date: 18-Aug-2021 32
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 2-4: Post-Neoadjuvant Period for Participants Receiving Ad juvant Chemotherapy (CA209816)
ProcedureDuring Adjuvant 
Treatment VisitaPost Neoadjuvant 
Therapy 
Visits 1 and 2bSurvival 
Follow-Up 
Visitsc,dNotes
Patient-reported Outcomes Assessment
EQ-5D-3L X X XEvery 3 months after Post-neoadjuvant Visit 2 for 1 year and 
then once every 6 months thereafter. May be completed as a 
phone call if a clinical visit is not otherwise specified. 
Participant Survival Status
Survival Status X X XEvery 3 months after Post-neoadjuvant Follow-Up Visit 2. May 
be accomplished by visit, phone contact, or email to assess 
subsequent anti-cancer therapy
Study Treatment
Administer Adjuvant 
Chemotherapy ¬±PORTXPost-operative radiation therapy (PORT) should be administered 
according to standard of care.
aEach cycle is 21 days. Assessments should be performed within 7 2 hours prior to dosing of adjuvant therapy. 
bPost-neoadjuvant Visit 1 within 30 days from the last dose of n eoadjuvant therapy ¬±7 days and prior to s urgery (this may lead to shortened interval between 
last dose of neoadjuvant treatment and post-neoadjuvant visit 1 ).  If Post-neoadjuvant Visit 1 falls within 7 days of the sche duled surgery d ate, then the 
Post-neoadjuvant Visit may coincide with the surgery admission.  All Post-neoadjuvant Visit 1 assessment procedures should be c ompleted prior to surgery. 
Post-neoadjuvant Visit 2 = 70 days ( ¬±7 days ) from Post-neoadjuvant Visit 1. Post-neoadjuvant Visit 2 may c oincide with the date of post-surgical follow-up. 
Timing of Post-neoadjuvant Visits 1 and 2 are based on the pre-surgical neoadjuvant therapy timelines.
cSurvival Follow-up Visits begin 3 months after Post-neoadjuvant  Visit 2 or after completion of adjuvant therapy, whichever occu rs later. Visits should occur 
every 3 months ( ¬±7 days).
dFor those participants who have progression confirmed, participants will continued to be followed for survival status every 3 months by visit, phone contact, or 
email.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; BUN, blood urea nitrogen; Ca, calcium; CBC  complete blood count; Cl, 
chloride; HR, heart rate; ECOG, Eastern Cooperative Oncology Gr oup; DLco, diffusing capacity; EBUS, endobronchial ultrasound; ECG, electrocardiogram; 
FEV1, forced expiratory volume in 1 second; FVC, forced vital c apacity; FRC, functional resi dual capacity; FV C, forced vital c apacity; HBcAb, Hepat itis B 
core antibody; HBsAg, Hepatitis B surface antigen; HCV Ab, Hepa titis C antibody; ICF , informed consent form; LDH, lactate dehydrogenase, K, potassium; 
Mg, magnesium; NA, sodium; RECI ST, Response Evaluation Criteria in Solid Tumors; SOC, standard of care; T.Bili, total bilirubi n; PORT post-operative 
radiation therapyTLC, total lung capacity; TSH, thyroid stimulating hormone
Protocol Amendment No.: 07
Date: 18-Aug-2021 33
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
3 INTRODUCTION
Nivolumab (BMS-936558) is a fully human, IgG4 (kappa) isotype m Ab that binds PD-1 on 
activated immune cells and dis rupts engagement of the receptor with its ligands PD-L1 
(B7 H1/CD274) and PD-L2 (B7-DC/CD273), thereby abrogating inhibi tory signals and 
augmenting the host antitumor response. In early clinical trial s, nivolumab has demonstrated 
activity in several tum or types, including melanoma, renal cell carcinoma (RCC), and non-small 
cell lung cancer (NSCLC).
CTLA-4, an activation-induced T-cell surface molecule, is a mem ber of the CD28:B7 
immunoglobu lin superfamily that competes with CD28 for B7. The proposed mechanism of action 
for ipilimumab is interference of the interaction of CTLA-4 wit h B7 molecules on APCs, with 
subsequent blockade of the inhibitory modulatio n of T- cell activation promoted by the CTLA 4/B7 
interaction.Nivolumab is in clinical development for the treatment of patie nts with NSCLC, RCC, melanoma, 
squamous cell carcinoma of the head and neck (SCCHN) and other tumors (eg, glioblastoma 
multiforme, mesothelioma, small cell lung cancer, gastric). The  combination of nivolumab and 
ipilimumab is in clinical development for the treatment of NSCL C, RCC, and other tumors. 
Opdivo¬Æ is approved in the United States (US), European Union, and other countries for the 
treatment of patients with unresectable or metastatic melanoma,  advanced NSCLC with
progression on or after platinum-based chemotherapy, advanced R CC whose disease progressed 
on an antiangiogenic therapy ( US only), classical Hodgkin lymph oma that has relapsed or 
progressed after a utologous hemat opoietic stem cell tran splantation and post-transplantation 
brentuximab vedotin treatment (US only), head and neck carcinom a (US only), and bladder cancer 
(US only). Opdivo is also approved in combination with Ye rvoy
¬Æin unresectable and metastatic 
melanoma. 3.1 Study Rationale
Approximately 80% of lung cancer cases are NSCLC, with most pat ients presenting with late-stage 
disease. Of patients with NSCLC, 20% present with stage I or II  disease, whereas 30% present 
with stage III disease and 50% with stage IV disease. With enha nced lung cancer screening 
techniques, the percentage of those diagnosed during the early stages may increase over the 
duration of the trial. A  standard TNM staging system is used to determine the staging for NSCLC 
(Appendix 1 ). Patients with pathologic stage I NSCLC have a 5-year surviva l of approximately 
60%. Stage II to III NSCLC patients have a 5-year survival of a pproximately 25% to 40%.
1
Surgical resection remains the mainstay of treatment for stage I and II patients; however, despite 
potential curative surgery, a pproximately 50% of stage IB and 6 0-75% of stage I-II NSCLC 
patients will relapse and eventually die of their disease.2,3A rational approach to improve survival 
in these patients is to eradicate micrometastatic disease and t o minimize the risk of relapse with 
adjuvant or neoadjuvant chemotherapy. Many adjuvant studies hav e been performed, and these 
trials are summarized in Table 3.1-1 . Although there are some conflicting results, the overall 
evidence from these studies suggests that adjuvant platinum dou blet chemotherapy is beneficial 
for good Performance Status patients with stage ‚â•I disease. The benefit to stage IB patients is less 
Protocol Amendment No.: 07
Date: 18-Aug-2021 34
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
clear and may depend on the size of the pr imary tumor and other risk factors. The LACE 
meta-analysis of modern adjuvant and neoadjuvant trials, all of  which used cisplatin-based 
chemotherapy, suggested a 5% absolute survival advantage at 5 y ears from adjuvant chemotherapy 
with the benefit being greatest for stage II and IIIA patients.  A 2010 meta-analysis including both 
older and more recent trials confirmed the survival benefit sho wn in the LACE meta-analysis and 
also suggested a benefit of adjuvant chemotherapy for stage IB disease.4
Table 3.1-1: Select Adjuvant NSCLC Studies
Trial Stage Treatment # of Pts 5 Yr OS HR P Value
ECOG 1505 I-IIICis-doublet
Cis-double+Bev749
75272 mo mOS 
in both arms0.99 0.9
ALPI I - IIISurg
MVP60360145%50%0.96 0.59
IALT I ‚Äì IIISurg
Cis-based93593240%
44.5%0.86 <0.03
ANITA IB - IIIASurg
Cis-Vin43340743%51%0.80 0.017
BLT I - IIIASurg
Cis-based189
19258%60%1.02 0.90
NCIC/JBR10 IB ‚Äì IISurg
Cis-Vin240
24254%69%0.69 0.03
CALGB IBSurg
Carb-pac17117357%59%0.80 0.10
ALPI I - IIISurg
MVP60360145%50%0.96 0.59
ALPI, Adjuvant Lung Cancer Project Italy; OS, overall survival; HR, hazard ratio; ECOG, Eastern Cooperative 
Oncology Group, IALT, International Adjuvant Lung Cancer Trial; ANITA, Adjuvant Navelbine International 
Trialist Association; BLT, Big Lung Trial; NCI-C, National Canc er Institute-Canada; CALGB, Cancer and 
Leukemia Group B; MVP, mitomycin, vindesine, cisplatin; Cis-Vin, cisplatin-vinorelbine; Carb-pac, carboplatin-paclitaxel.
The early-stage (IB-III) NSCLC represents a population o f high unmet need with a 5-year s urvival 
rate of 25-50%.2,3,5The current available standard of  care (SOC) only provides a 5%  absol u te 
improvement in 5-year overall survival (OS).6,7,8,9The SOC comprises adjuvant or neoadjuvant 
platinum doublet chemotherapy for patients with operable stage IB-IIIA NSCLC or 
chemoradiation for patients with unresectable stage IIIA/B NSCL C. Follow-up of adjuvant trials 
are long and may require decades before a new treatment is intr oduced into clinical pr actice. 
Preoperative or neoadjuvant chemotherapy has been assessed in a  number of trials for patients with 
operable NSCLC. A meta-analysis based on 7 trials involving 988  patients suggested that 
neoadjuvant chemotherapy improved OS when given preoperatively in a similar magnitude to 
Protocol Amendment No.: 07
Date: 18-Aug-2021 35
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
those observed with adjuvant chemotherapy.10Neoadjuvant therapy offers the possibility for the 
identification of s urrogate clinical and biol ogical ma rkers that may c orrelate with res ponse to 
therapy and a potential long-term outcome. Studies that address  the role of preoperative 
chemotherapy have found chemotherapy compliance to be favorable  in the preoperative 
setting.6,7,8Randomized trials are currently on-going to explore the potenti al benefit of nivolumab 
in the adjuvant and locally adva nced unresectable NSCLC setting . In addition, the safety and 
efficacy profile of neoadjuvant nivolumab monotherapy or in com bination (nivolumab plus 
ipilimumab or nivolumab plus chemotherapy) are being evaluated in ongoing trials.   
The phase 3 study, CA209816, will evaluate the clinical efficac y and will establish the safety of 
nivolumab plus ipilimumab, especially nivolumab plus platinum d oublet chemotherapy, in 
resectable lung cancer. Specifically, this study will compare EFS and pCR rate among participants 
treated with neoadjuvant nivolumab plus platinum doublet chemot herapy vs participants treated 
with platinum doublet chemotherapy, and will describe pCR r ate and EFS for those treated with 
neoadjuvant nivolumab plus ipilimumab in Stage Ib-IIIa NSCLC.
3.1.1 Research Hypothesis
In participants with stage IB ( ‚â•4 cm), II or IIIA (N2) NSCLC considered resectable by the local  
multidisciplinary team, administration of neoadjuvant nivolumab  plus platinum doublet 
chemotherapy (up to 3 cycles) has superior efficacy to neoadjuv ant platinum doublet 
chemotherapy (up to 3 cycles).
3.2 Background
3.2.1 Indication Background
Approval of nivolumab in advanced NSCLC was based on 2 phase 3 trials (CheckMate 017 and 
CheckMate 057) which demonstrated survival benefit over docetax el across histologies. The 
approval in squamous NSCLC was based on the results of CA209017 , a randomized trial of 
nivolumab versus docetaxel. The median OS for patients in the n ivolumab arm was 9.2 months 
versus 6 months for those in the docetaxel arm (HR = 0.59). Im provement in survival was observed 
for nivolumab regardless of PD-L1 expression, though there was a trend toward better efficacy for 
those with PD-L1 expressing tumors. A single-arm trial (CA20906 3) of 117 patients with 
metastatic squamous NSCLC with progression after platinum-based chemotherapy and at least 
1 additional systemic regimen showed a 15% objective response ra te (ORR); 59% of participants 
with an ORR had response durations of 6 months or longer.11
The approval of nivolumab for the treatment of non-squamous NSCLC is based on a second phase 3 study, CA209057, which met its primary endpoint of superior OS of nivolumab versus docetaxel 
in patients with previously treated non-squamous NSCLC at a pre planned interim analysis (IA). 
Patients in the nivolumab arm had a 27% reduction in risk of de ath (HR = 0.73; P = 0.0015). 
Interaction P values, reported for PD-L1 e xpression subgroups by each of the predefined 
expression levels, suggested a clinically important signal of a  predictive association. Nivolumab 
also significantly improved ORR vs docetaxel (P=0.0246), with O RR as high as 36% in patients 
with PD-L1 expressing tumors. OS approximately doubled with niv olumab vs docetaxel at 1%, 
Protocol Amendment No.: 07
Date: 18-Aug-2021 36
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
5% and 10% PD-L1 expression level. In contrast, no statistically significant difference in OS was 
seen between nivolumab and docetaxel when PD-L1 was not expresse d in the tumor, although 
these patients also experienced durable responses, and the safe ty profile was more favorable for 
nivolumab vs docetaxel.12
Although the first-line CA209026 trial did not demonstrate that  single agent nivolumab provided 
superior efficacy over platinum doublet chemotherapy, the effic acy of nivolumab was similar to 
that of chemotherapy in this first line patien t population. In the ongoing st udy CA209012, 
77 patients were treated with nivolumab 3 mg/kg Q2W + ipilimumab  1 mg/kg Q12W or Q6W.
Overall response rates wer e observed in 43% of all treated pati ents and in 57% and 92% of patients 
with ‚â•1% and ‚â•50% tumor PD-L1 e xpression, respectively. Six investigator-assessed CRs (8%) 
and 3 pathologic responses wer e observed.  The median duration of response (DOR) was not 
reached in the overall p opulation or s ubpopulations. Duration of response ranged from 1.4+ to 
27.9+ months.13Recent 2-year OS data in CA 209012 showed survival data in all treated patients 
and by PD-L1 expression. All treated patients (n = 77) showed a  1 years OS of 76% and 2 year OS 
of 49%. When analyzed by PD-L1 expression, patients with ‚â•1% PD-L1 (n = 47) had a 1 years 
OS of 87% and 2 year OS of 58%, which increased to 100% and 62% , respectively for ‚â•50% 
PD-L1 patients. Nivolumab plus ipilimumab remained tolerable, a s most treatment-related AEs 
were manageable and no new safety concerns were identified in f ollow-up.14
The ongoing phase 3 CheckMate 227 study enrolled patients with stage IV or recurrent NSCLC 
that was not previously treated. Those with a level of tumor PD -L1 expression of at least 1% were 
randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab 
monotherapy, or chemotherapy;  those with a tumor PD-L1 e xpression level of less than 1% were 
randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus 
chemotherapy, or chemotherapy. Tumor mutational burden was determined by the FoundationOne CDx assay. Recently, in the pre-specified analysis of patients with high tumor mutational b urden 
at a prospective cutoff of ‚â•10 mutations/MB, progression-free survival was significantly lo nger 
in the group treated by nivolumab  plus ipilimumab compared to c hemotherapy, demonstrating a 
median PFS of 7 .2 months vs 5.5 months, respectively (HR 0.58; 97.5% CI 0.41, 0.81) (Nivolumab 
plus ipilimumab in lung cancer wit h a high tumor mutational bur den.
15The treatment effect was 
consistent in a pre-specified multi-variate analysis when adjus ted for PD-L1 expression, histology, 
and other clinical factors. The ORR was also significantly grea ter for the nivolumab plus 
ipilimumab group (45.3% vs 26.9%; tr eatment difference 18.4%; 9 5% CI (7.6, 28.8), and the 
responses appeared durable with 68% of responses ongoing after 1 year and the DOR not reached (95% CI 12.2, NR) compared to 5.4 months (95% CI 4.2,6.9) for chemotherapy. In patients with TMB <10 mut/Mb, ORR was 24.6% in  nivolumab plus ipilimumab arm and 25.9% in 
chemotherapy arm, HR for PFS being 1.07 (95% CI: 0.84, 1.35). I n all ra ndomized patients 
(irrespective of TMB or PD-L1 status), 1-year PFS was also high er with nivolumab plus 
ipilimumab than with chemotherapy [30.9% vs 17%; HR 0.83 (95% CI, 0.72 to 0.96)]. The rate of grade 3 or 4 treatment-related adverse events in all tr eated population (regardless of TMB or 
PD-L1 status) was 31.2% with nivolumab plus ipilimumab and 36.1% with chemotherapy, it was 
Protocol Amendment No.: 07
Date: 18-Aug-2021 37
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
slightly higher with ni volumab plus ipilimumab i n patients with high TMB tumor (37%), but the 
safety profile was overall consistent with previously reported d ata with no new safety signals.
Nivolumab added to chemotherapy has been evaluated in several c ohorts of chemotherapy-na√Øve 
subjects with advanced NSCLC in CA209012.16Nivolumab 10 mg/kg was combined with 
gemcitabine and cisplatin or pemetrexed and cisplatin. Nivoluma b 10 mg/kg and 5 mg/kg was 
combined with paclitaxel an d carboplatin. The safety profile of  nivolumab plus platinum-doublet 
chemotherapy reflects additive toxicities of the individual age nts, which were manageable using 
established safety guidelines. No dose- limiting tox icities were observed during first 6 weeks of 
treatment. The ove rall response r ate across all the nivolumab and chemotherapy c ohorts range 
from 33-47% and median duration of response was 27.3 weeks. The  1-year survival rate for all 
cohorts combined is 71%. 
In the ongoing CheckMate 227 trial, data in patients with tumor  of <1% PD-L1 expression became 
also available recently.17In the setting of first line NSCLC with <1% tumor PD-L1 expression, 
PFS was improved with nivolumab plus chemotherapy vs chemothera py (mPFS: 5.6m vs 4.7m; 
HR=0.74 [95% CI: 0.58 to 0.94]), mPFS of nivolumab plus ipilimu mab was 4.4 months (95%CI: 
3.1 to 6.0). ORR wa s 36.7% in nivolumab plu s chemotherapy arm, 23.1% in chemotherapy arm, 
and 25.1% in nivolumab  plus ipilimumab arm. mDOR was 7.2 months  in nivolumab plus 
chemotherapy arm, 4.7 months in chemotherapy arm, and 18.0 mont hs in nivolumab plus 
ipilimumab arm. The rate of gra de 3 or 4 treatm ent-related adve rse events was 52% with 
nivolumab plus chemotherapy, 35% with chemotherapy, and 25% wit h nivolumab plus 
ipilimumab, overall, for nivolumab plus chemotherapy, the safet y profile and efficacy are 
consistent with previously reported data as w ell as d ata from other P D-(L)1 blockades in 
combination with chemotherapy.
Both nivolumab plus ipilimumab and nivolumab plus chemotherapy compare favorably in terms 
of the expected clinical benefit including response r ate and overall s urvival observed with platinum 
doublet chemotherapy i n first line NSCLC. These data suggest th at nivolumab plus ipilimumab or 
nivolumab plus platinum doublet chemotherapy have the potential  to provide superior pathologic 
response and event-free surviva l compared to platinum doublet c hemotherapy as neoadjuvant 
therapy in early-stage NSCLC.18
In general, nivolumab plus ipilimumab or nivolumab plus platinu m doublet chemotherapy is well 
tolerated, with a favorable safety profile relative to anticipa ted toxicities based on an 
immunostimulatory mechanism of action. Nivolumab plus ipilimuma b and nivolumab plus 
platinum doublet chemotherapy are currently in phase 3 developme nt in the first-line metastatic 
and as monotherapy in the early stage NSCLC settings.As neoadjuvant therapy, in Stage I-III NSCLC, in ongoing phase 2t r i a l  ( Section 5.4.3 ) nivolumab 
as monotherapy showed promising anti-tumor activity in terms of  depth of pathological response 
while the potential benefit of neoadjuvant nivolumab plus ipilimumab are still under study. On the 
other hand, preliminary d ata from ongoing phase 2 trial (NADIM, Section 5.4.3 ) of neoadjuvant 
nivolumab plus platinum doublet chemotherapy showed striking pC R rate. Preliminary experience 
gained from these ongoing phase 2 trials with neoadjuvant nivol umab and nivolumab-based 
Protocol Amendment No.: 07
Date: 18-Aug-2021 38
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
combinations suggests these study treatments were well tolerate d with little adverse impact to the 
feasibility of s urgery. The platinum doublet chemotherapy regimens have w ell described safety 
profiles, characterized by myelosuppression and other regimen-specific non-hematologic 
toxicities, such as peripheral neuropathy, nausea/vomiting, and renal impairment. 
A detailed description of the chemistry, pharmacology, efficacy , and safety of nivolumab is 
provided i n the Investigator‚Äôs Brochure and local package inser t.
3.2.2 Nivolumab Mechanism of Action
Cancer immunotherapy rests on the  premise that tumors can be re cognized as foreign rather than 
as self and can be effectively attacked by an activated immune system. An effective immune 
response in this setting is thought to rely on immune surveilla nce of tumor antigens expressed on 
cancer cells that ultimately results in an adaptive immune resp onse and cancer cell death. 
Meanwhile, tumor progression may depend upon acquisition of tra its that allow cancer cells to 
evade immunosurveillance and escape effective innate and adapti ve immune responses.19,20,21
Current immunotherapy efforts attempt to break the apparent tol erance of the immune system to 
tumor cells and antigens by eith er introducing cancer antigens by therapeutic vaccination or by 
modulating regulatory checkpoints  of the immune s ystem. T-cell stimulation is a complex process 
involving the integration of numerous positive as well as negat ive co-stimulatory signals in 
addition to antigen recognition by the T- cell r eceptor.22Collectively, these signals govern the 
balance between T- cell activation a nd tolerance. 
PD-1 is a member of the CD 28 family of T-cell co -stimulatory receptors that also includes CD28, 
CTLA 4, ICOS, and BTLA.23PD-1 signaling has been shown to inhibit CD-28-mediated 
upregulation of IL-2, IL-10, IL-13, interferon-Œ≥ (IFN-Œ≥) and Bc l-xL. PD-1 expression has also been 
noted to inhibit T cell activation, and expansion of previously  activated cells. Evidence for a 
negative regulatory  rol e of  PD-1 com e s  from  studi es of  PD-1 def icient mice, which develop a 
variety of autoimmune phenotypes.24These results suggest that PD-1 blockade has the potential 
to activate anti-self T -cell responses, but these responses are  variable and dependent upon various 
host genetic factors. Thus, PD-1 deficiency or inhibition is no t accompanied by a universal loss of 
tolerance to self-antigens.
In vitro, nivolumab (BMS-936558) binds to PD-1 with high affini ty (EC50 0.39-2.62 nM), and 
inhibits the binding of PD-1 to its ligands PD-L1 and PD-L2 (IC 50 ¬±1 nM). Nivolumab binds 
specifically to PD-1 and not to rela ted members of the CD28 family such as CD28, ICOS, CTLA-4 
and BTLA. Blockade of the PD-1 pathway by nivolumab results in a  reproducible enhancement 
of both proliferation and IFN-Œ≥ release in the mixed lymphocyte  reaction (MLR). Using a CMV 
restimulation assay with human PBMC, the effect of nivoluma b on antigen specific recall response 
indicates that nivolumab augmented  IFN-Œ≥ secretion from CMV spe cific memory T cells in a 
dose-dependent manner versus isotype-matched control. In vivo b lockade of PD-1 by a murine 
analog of nivolumab enhances the anti-tumor immune response and result in tumor rejection in 
several immunocompetent mouse tumor models (MC38, SA1/N, and PA N02).25
Protocol Amendment No.: 07
Date: 18-Aug-2021 39
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
3.2.3 Ipilimumab Mechanism of Action
CTLA-4, an activation-induced T-cell surface molecule, is a mem ber of the CD28:B7 
immunoglobulin superfamily that comp etes with CD28 for B7. CTLA -4 mediated signals are 
inhibitory and turn off T cell-dependent immune responses.26Ipilimumab is a fully human 
monoclonal IgG1Œ∫ that binds to the CTLA-4 antigen expressed on a subset of T cells from human 
and nonhuman primates. The proposed mechanism of action for ipi limumab is interference of the 
interaction of CTLA-4 with B7 molecules on APCs, with subsequen t blockade of the inhibitory 
modulation of T-cell activation promoted by the CTLA 4/B7 inter action.
3.2.4 Nivolumab Combined with Ipilimumab Clinical ActivityCA209012 (Checkmate 012) is a multi- arm phase 1b trial evaluati ng the safety and tolerability of 
nivolumab in patients with chemotherapy-na√Øve advanced NSCLC, a s either a monotherapy or in 
combination with other agents including ipilimumab, at differen t doses and schedules. The primary 
endpoint of the  study was safety with secondary endpoints of ob jective response rates (ORR) and 
24-week PFS. Exploratory endpoints included OS and efficacy by PD-L1 expression. In the study, 
patients were tested for PD-L1 and 69% had evaluable PD-L1 expression. Participants were 
enrolled to receive nivolumab 3 mg/kg Q2W + ipilimumab 1 mg/kg Q 12W or Q6W (n = 77), and 
nivolumab 3 mg/kg Q2W (n = 52). ORR was 43% in all tr eated patients and 57% and 92% in 
patients with ‚â• 1% and ‚â• 50% tum or PD-L 1 expression, respectivel y, 6 investigator-assessed CRs 
(8%); including 3 pathologic responses were achieved in the niv olumab 3 mg/kg Q2W + 
ipilimumab 1 mg/kg  Q12W/Q6W cohorts. The median duration of re sponse (DOR) was not 
reached in the overall population or s ubpopulations.  Duration of  response ranged from 1.4+ to 
27.9+ months . 
The rate of treatment-related adverse events in the Q12W/Q6W (7 9%) arms were comparable to 
monotherapy (73%). In the study, Grades 3 to 4 AEs were 36% and  19% for the Q12W/Q6W and 
nivolumab monotherapy arms, respectively. Treatment-related Gra d e  3 - 4  A E s  l e d  t o  
discontinuation in 8% and 12% of patients in the Q12W/Q6W cohor ts and nivoluma b monotherapy 
arms, respectively. There were no treatment-related deaths. The  treatment-related select AEs in 
patients across all tr eatment arms were skin-related (31%), gastrointestin al (19%), endocrine 
(18%), and pulmo nary (6%). 
As described in Section 3.2.1 , ongoing phase 3 CheckM ate 227 study ra ndomized patients with 
stage IV or recurrent NSCLC that was not previously treated in various study treatment arms by 
tumor PD-L1 status. Recently, in the pre-specified analysis of patients with high tumor mu tational 
burden at a prospective cutoff of ‚â• 10 mutations/MB, progressio n-free survival was significantly 
longer in the group treated by nivolumab plus ipilimumab compar ed to chemotherapy, HR of PFS 
being 0.58 (97.5% CI 0.41, 0.81). The treatment effect was consi stent and independent of PD-L1 
expression, or histology. The ORR was also significantly greate r for the nivolumab plus 
ipilimumab group (45.3% vs 26.9%) and the responses appeared mo re durable with median DoR 
not reached (95% CI 12.2, NR) compared to 5 .4 month s (95% CI 4.2, 6.9) for chemotherapy. In 
patients with TMB <10 mut/Mb, similar efficacy was seen in term s of PFS and ORR between 
nivolumab plus ipilimumab and chemotherapy. The safety profile was overall consistent with 
Protocol Amendment No.: 07
Date: 18-Aug-2021 40
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
previously reported data with no new safety signals. In another  readout focusing on patients with 
tumor of <1% PD-L1 expression, nivolumab plus ipilimumab showed  similar efficacy to 
chemotherapy in terms of PFS and ORR but with much longer D oR, with a consistent safety profile 
of previously reported data. 
As of revised protocol 03, the nivolumab plus ipilimumab has st opped enrollment.
3.2.5 Immuno-oncology Treatment Combined with Chemotherapy Clinical 
Activity
The combination of immuno-oncology agents and traditional chemo therapy has been explored. In 
addition to the additive effects of combining drugs with differ ent mechanisms of action, emerging 
evidence indicates that one of the mechanisms of actions of che motherapy is via activation of the 
immune system through multiple pathways.13The subsequent cytotoxic cell d eath from 
chemotherapies and subsequent a ntigen release may provide  immun e stimulation. Certain 
chemotherapy regimens have a broad effect on cell d eath and physiological response. As an 
example, cyclophosphamide reduces the number of circulating Tre g cells, which are a key 
component in immunosuppre ssion and gemcitabine have also been s hown to reduce MDSCs and 
hence interferon-gamma, which have inhibitory roles in the immu ne response.27,28The dual role 
of cytotoxicity and immune activation from chemotherapy has pro vided the biological rationale 
for the development of combinations with immunotherapy.29
Nivolumab added to chemotherapy has been evaluated in several c ohorts of chemotherapy-naive 
patients with advanced NSCLC in study Checkmate 012. Nivolumab 10 mg/kg was combined with 
gemcitabine and cisplatin or pemetrexed + cisplatin. Nivolumab 10 mg/kg and 5 mg/kg was 
combined with paclitaxel and carboplatin.
The safety profile of nivoluma b plus platinum-doublet chemotherapy reflects additive toxiciti es of 
the individual agents, which were manageable using established safety guidelines. No 
dose-limiting toxicities were observed during first 6 weeks of treatment. The frequency of most 
immune-related select AEs was higher for the combination than w hat has been observed for 
nivolumab monotherapy. However, these treatment-related AEs, including pneumonitis, were 
effectively managed and did not lead to any d eaths. Pneumonitis of any grade was reported in 
7 subjects (13%): Grade 3-4 in 4 subjects (7%). Twelve (21%) sub jects discontinued due to 
treatment-related AEs ( Table 3.2.5-1 ).
Table 3.2.5-1: Safety in CA209012
Total (N=56)
All Grades Grade 3 Grade 4
Subjects with any 
treatment-related AE, % (n)95 (53) 41 (23) 4 (2)a
Treatment-related AE in >15% of Patients, % (n)
Fatigue 71(40) 5 (3) 0
Protocol Amendment No.: 07
Date: 18-Aug-2021 41
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 3.2.5-1: Safety in CA209012
Total (N=56)
All Grades Grade 3 Grade 4
Nausea 46 (26) 2 (1) 0
Decrease A ppetite 36 (20) 2 (1) 0
Alopecia 30 (17) 0 0
Anemia 27 (15) 4 (2) 0
Rash 27 (15) 2 (1) 0
Arthralgia 21 (12) 0 0
Diarrhea 21 (12) 2 (1) 0
Constipation 20 (11) 0 0
Peripheral Neuropathy 20 (11) 0 0
a Grade 4 events: neutrophil count decreased (n = 1), pneumonitis and neutropenia (n = 1 each; occurred in the same 
patient). 
The overall response rate across all the nivolumab and chemothe rapy cohorts ranged from 33-47% 
and median duration of response was 27.3 weeks (see Table 3.2.5-2 ). Activity was evalu ated by 
PD-L1 expression and was observed in subjects with both PD-L1 e xpressing and non-expressing 
tumors. Overall, 79% (44/56) of subjects had evaluable tumor samples. At the ‚â•1% expression 
level, the response rate was 48% and 43% for expressers and non -expressers, respectively. The 
1-year OS was 70% and 76% for expressers and non-expressers, re spectively. 
Table 3.2.5-2: Efficacy of First-Line Treatment of Nivolumab/Chemotherapy 
Combination in CA209012
Efficacy of First-Line Treatment of Nivolumab/Chemotherapy Combination in CA209012
Nivolumab 10 mg/kg Nivolumab 5 mg/kg
Gem/Cis
(n=12)Pem/Cis
(n=15)Pac/Carb
(n=15)Pac/Carb
(n=14)
ORR, % 33 47 47 43
SD, % 58 47 27 43
Median Duration of 
Response, Weeks45 24.4 27.3 27.3
12-mo OS rate, % 50 87 72 86
18-mo OS Rate, % 33 60 40 62
Median OS, Weeks 51 83 65 Not Reached
Protocol Amendment No.: 07
Date: 18-Aug-2021 42
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
As described in Section 3.2.1 in the ongoing CheckMate 227 trial, in the setting of first lin e NSCLC 
with <1% tumor PD-L1 expression, PFS was improved with nivoluma b plus chemotherapy vs 
chemotherapy (mPFS: 5.6m vs 4.7m; HR=0.74 [95% CI: 0.58 to 0.94 ]), mPFS of nivolumab plus 
ipilimumab was 4.4 months  (95%CI: 3.1 to 6.0). O RR was 36.7% in nivolumab plus chemotherapy 
arm, 23.1% in chemotherapy arm,  and 25.1% in nivolumab plus ipi limumab arm. mDOR was 
7.2 months in nivolumab plus chemotherapy arm, 4.7 months in chem otherapy arm, and 
18.0 months i n nivolumab plus ipilimuma b arm. The rate of grade 3 or 4 treatment-related adverse 
events was 52% with nivolumab plus chemotherapy, 35% with chemo therapy, and 25% with 
nivolumab plus ipilimumab. Overall, the safety profile and effic acy are consistent with previously 
reported data for nivolumab plus che motherapy, as well as data from other PD-(L)1 blockades in 
combination with chemotherapy.
3.3 Benefit/Risk Assessment
The early-stage (IB-III) NSCLC represents a population o f high unmet need with a 5-year s urvival 
rate of 25-50%. The current av ailable SOC, including adjuvant o r neoadjuvant platinum doublet 
chemotherapy, only provides a 5% absolute improvement in 5-year  OS.
Follow-up of adjuvant trials are long and may require decades b efore a new tr eatment is introduced 
into clinical practice. Preoperative or neoadjuvant chemotherap y has been assessed in a number of 
trials for participants with operable NSCLC. A meta-analysis based on 7 trials involving 
988 participants suggested that neoadjuvant chemotherapy improve d OS when given 
preoperatively in a similar magnitude to those observed with adjuvant chemotherapy. Several 
studies have also shown preoperative cytotoxic chemotherapy to be safe prior to surgical resection 
of NSCLC with no difference in extent of surgical procedures pe rformed, operative morbidity and 
mortality.
The clinical activity o f nivoluma b observed to date in NSCLC, including 2 positive phase 3 studie s 
demonstrati ng prol onged s urvival with nivolumab monotherapy compared to docetaxel in 
squamous and non-squamous NSCLC after platinum failure, suggest s the potential f or improved 
clinical outcomes. CA209057 (non-squamous NSCLC) study demonstrated OS was superior for 
participants receiving nivolumab compared to those receiving do cetaxel. In this study, interaction 
P values reported for PD-L1 e xpression s ubgroups by each of the pre-defined expression levels 
suggested a clinically important signal of a predictive associa tion. Higher confirmed ORRs in 
PD-L1 expressors were seen in the combination arm compare to th e nivolumab monotherapy arm 
in CA209012. Based on these data,  CA209816 will st ratify partic ipants based on PD-L1 status, 
disease stage at randomization, and gender.  
In CA209012, ni volumab plus ipilimumab provides a higher ORR (4 3%) than nivolumab 
alone.27,30In first-line metastatic NSCLC, this regimen also provided enco uraging overall survival, 
with an acceptable safety profile. Combination of anti-PD1 plus  chemotherapy has also shown 
encouraging ORR and PFS with an acceptable safety profile compa red to platinum doublet 
chemotherapy in first-line metastatic NSCLC. These data support  our b elief that combination of 
nivolumab with ipilimumab or platinum doublet chemotherapy will  demonstrate superior benefit 
over platinum chemotherapy doublets in the neoadjuvant setting with an acceptable safety profile. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 43
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
In general, nivolumab is well tolerated, with a favorable safety  profile relative to anticipated 
toxicities based on an immunostimulatory mechanism of action. O verall, the safety profile of 
nivolumab monotherapy as well as combination therapy is managea ble and generally consistent 
across completed and ongoing clinical trials with no maximum to lerated dose (MTD) reached at 
any dose tested up to 10 mg/kg. Most AEs were low-grade (Grade 1  to 2) with relatively few 
related high-grade (Grade 3 to 4) AEs. There was no pattern in the incidence, severity, or causality 
of AEs with respect to nivolumab dose level.
The ongoing phase 3 CheckMate 227 study randomized patients wit h stage IV or recurrent NSCLC 
not previously treated in various  study treatment arms by tumor  PD-L1 status. Recently, in the 
pre-specified analysis of patients with high tumor mu tational  burden at a prospective cutoff of ‚â• 10 
mutations/MB, PFS was significan tly longer in the group treated  by nivolumab plus ipilimumab 
compared to chemotherapy, HR of PFS being 0.58 (97.5% CI 0.41, 0.81). The treatment effect 
was consistent and independent of PD-L1 expression, or histology. The ORR was also significantly 
greater for the nivolumab p lus ipilimumab group (45.3% vs 26.9%) and the responses appeared 
more durable with median DoR not reached (95% CI 12.2, NR) compared to 5.4 months (95% CI 
4.2, 6.9) for chemotherapy. In patients with TMB <10 mut/Mb, si milar efficacy was seen in terms 
of PFS and ORR between nivolumab plus ipilimumab and chemothera py. The safety profile was 
overall consistent with previously reported data with no new saf ety signals. In another readout 
focusing on patients with tumor of <1% PD-L1 expression, nivolu mab plus ipilimumab showed 
similar efficacy to chemotherapy in terms of PFS and ORR but wi th much longer DoR, the safety 
profile was consistent with previously reported data.
In the setting of first line NSCLC with  <1% tumor PD-L1 e xpression in the ongoing CheckMate 
227 trial, PFS was improved with nivolumab plus chemotherapy vs  chemotherapy (mPFS: 5.6m 
vs 4.7m; HR=0.74 [95% CI: 0.58 to 0.94]), mPFS of nivolumab plu s ipilimumab was 4.4 months 
(95%CI: 3.1 to 6.0). ORR was 36.7% in  nivolumab plus chemothera py arm, 23.1% in 
chemotherapy arm, and 25.1% in nivolumab plus ipilimumab arm. m DOR was 7.2 months in 
nivolumab plus chemotherapy arm, 4.7 months in chemotherapy arm , and 18.0 months in 
nivolumab plus ipilimumab arm. The rate of grade 3 or 4 treatme nt-related adverse events was 
52% with nivolumab plus chemother apy, 35% with chemotherapy, and 25% with nivolumab plus 
ipilimumab, overall, for nivolumab plus chemotherapy, the safet y profile and efficacy are 
consistent with previously reported data as w ell as d ata from other P D-(L)1 blockades in 
combination with chemotherapy.As described in Section 3.2.1 , two ongoing phase 2 trials with nivolumab as monotherapy and 
nivolumab in combination with chemotherapy showed promising ant i-tumor activity in terms of 
depth of pathological response without adverse impact on surgic al results. Nivolumab and 
ipilimumab as neoadjuvant therapy remain under study, with data  pending. 
A pattern of immune-related AEs has been defined, for which man agement algorithms have been 
developed; these are provided in Appendix 4 . Most high-grade events were manageable with the 
use of corticosteroids or hormone replacement therapy (endocrin opathies) as instructed in these 
algorithms. Extensive d etails on the safety profile of nivolumab and ipilimumab are av ailable in 
the respective Investigator Brochures and will not be repeated herein.
Protocol Amendment No.: 07
Date: 18-Aug-2021 44
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
The potential benefit of nivolumab plus ipilimumab or nivolumab  plus platinum doublet 
chemotherapy as neoadjuvant therapy in Stage I-III NSCLC are no t yet known. The platinum 
doublet ch emotherapy regimens have w ell described safety profiles, characterized by 
myelosuppression and other reg imen-specific non-hematologic tox icities, such as peripheral 
neuropathy, nausea/vomiting, and renal impairment. 
In order to assess the potential benefit of nivolumab plus plat inum doublet chemotherapy over 
platinum doublet chemotherapy as neoadjuvant therapy in Stage I -III resectable NSCLC, this trial 
will rando mize participants to 2 arms: nivolumab plus platinum doublet chemotherapy, or platinum 
doublet ch emotherapy alone. Under revised protocol 02, particip ants already enrolled in the 
original 2-arm part and in the arm of nivolumab plus ipilimumab  in the 3-arm part per revised 
protocol 02 will continue scheduled trial procedures. To assure  an ongoing favorable risk/benefit 
assessment for participants enrolled onto CA209816, an independe nt Data Monitoring Committee 
(DMC) will be utilized to monitor the safety and activity of th e treatments throughout the conduct 
of the trial.4 OBJECTIVES AND ENDPOINTS
Table 4-1: Objectives and Endpoints
Objectives Endpoints
Primary
‚Ä¢To compare the event-free survival (EFS) by blinded 
independent central rev iew (BICR) in p articipants 
receiving nivolumab plus platinum doublet 
chemotherapy vs participants receiving platinum doublet 
chemotherapy in operable stage IB ( ‚â•4 cm), II, or 
resectable IIIA (N2) NSCLC‚Ä¢EFS defined as the length of time from 
randomization to any of the following events: 
any progression of disease precluding 
surgery, progression or recurrence disease 
(based on BICR asse ssment per RECIST  1.1) 
after surgery, or death due to any cause. 
Participants who don‚Äôt undergo surgery for 
reason other than progression will be 
considered to have an event at RECIST 1.1 
(based on BICR) progression or death. 
‚Ä¢To compare the pathologic complete response (pCR) rate 
in participants receiving nivolumab plus platinum doublet chemotherapy vs participants receiving platinum 
doublet chemotherapy in operable stage IB ( ‚â•4 cm), II, 
or resectable IIIA (N2) NSCLC‚Ä¢pCR rate is defined as number of randomized 
participants with absence of residual tumor in 
lung and lymph nodes as evaluated by blinded 
independent pathological review (BIPR), 
divided by the number of randomized 
participants for each treatment group.
Secondary
‚Ä¢To assess the major pathologic response (MPR) rate by 
BIPR of participants receiving nivolumab plus platinum 
doublet chemotherapy vs participants receiving platinum 
doublet chemotherapy in operable stage IB ( ‚â•4 cm), II, 
or resectable IIIA (N2) NSCLC‚Ä¢MPR rate, defined as number of randomized participants with ‚â§10% residual tumor in lung 
and lymph nodes as evaluated by BIPR, 
divided by the number of randomized 
participants for each treatment group. Viable 
tumors in situ carcinoma should not be included in MPR calculation.
Protocol Amendment No.: 07
Date: 18-Aug-2021 45
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 4-1: Objectives and Endpoints
Objectives Endpoints
‚Ä¢To compare the OS of participants receiving nivolumab 
plus platinum doublet chemo therapy vs participants 
receiving platinum doublet chemotherapy in operable 
stage IB (‚â• 4 cm), II, or resectable IIIA (N2) NSCLC‚Ä¢OS is defined as the time between the date of 
randomization and the date of death. OS will 
be censored on the last date a participant was known to be alive.
‚Ä¢To assess the time to death or distant metastases (TTDM) of participants receiving nivolumab plus platinum doublet chemotherapy vs participants receiving platinum 
doublet chemotherapy in operable stage IB ( ‚â•4 cm), II, 
or resectable IIIA (N2) NSCLC‚Ä¢TTDM is defined as the time between the date 
of randomization and the first date of distant metastasis or the date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the thorax using BICR according to RECIST 1.1. Patients who have not developed distant metastasis or died at the time of analysis will be censored on the date of their last evaluable 
tumor assessment.
Exploratory
‚Ä¢To assess clinical response rate (c RR) by BICR of 
participants receiving nivolumab plus platinum doublet 
chemotherapy vs participants receiving platinum doublet 
chemotherapy in operable stage IB ( ‚â•4 cm), II, or 
resectable IIIA (N2) NSCLC ‚Ä¢cRR is defined as proportion of all 
randomized participants whose overall radiological response prior to definitive surgery is either a com plete response or partial 
response per RECIST 1.1 criteria by BICR
‚Ä¢To assess the pCR rate, MPR rate , cRR, EFS, TTDM and OS in early-stage NSCLC participants treated with nivolumab plus platinum doublet chemotherapy compared to those treated with platinum doublet 
chemotherapy by PDL1 status (PD-L1 ‚â•1% , 
PD-L1< 1% /not evaluable/ indeterminate)   ‚Ä¢pCR r ate, MPR rate, cRR, EFS, TTDM, and 
OS as described above
‚Ä¢To assess the feasibility of s urgery and rate of peri- and 
post-operative complications (within 90 days of surgery) 
in participants receiving  nivolumab plus platinum 
doublet chemotherapy compared to participants receiving 
platinum doublet ‚Ä¢Proportion of d elayed or can celed surgery, 
duration of surgery, le ngth of hospital stay, 
surgical approach including completeness of 
surgery, incid ence of AE/SAE associated with 
surgery, including pneumonitis, ARDS, 
re-admission to the Intensive Care Unit, atrial fibrillation or other s upraventricular 
tachycardia (SVT) to 90 days post-surgery 
‚Ä¢To assess the safety and tolerability of nivolumab plus 
platinum doublet chemotherapy compared to platinum 
doublet chemotherapy in early stage NSCLC‚Ä¢Safety and tolerability will be measured by 
incidence of AE, SAE, immune-related AEs, 
deaths, and laboratory abnormalities
‚Ä¢To describe the pCR rate, MPR rate , c RR, EFS, OS, 
TTDM, feasibility of surgery, rate of peri- and post-operative complications (within  90 days of surgery), 
safety and tolerability in early-stage NSCLC participants treated with nivolumab plus ipilimumab and by PDL1 
status (PD-L1 ‚â•1% , PD-L1< 1%/not 
evaluable/indeterminate)‚Ä¢pCR rate, MPR rate, c RR, EFS, OS, TTDM, 
feasibility of surgery, rate of peri- and post-
operative complications, safety and tolerability as described above
Protocol Amendment No.: 07
Date: 18-Aug-2021 46
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 4-1: Objectives and Endpoints
Objectives Endpoints
‚Ä¢To assess pharmacokinetics of the nivolumab plus 
ipilimumab or nivolumab plus platinum doublet chemotherapy in participants with early stage NSCLC‚Ä¢Pharmacokinetic endpoints (See Section 9.5 ) 
‚Ä¢To assess the participant‚Äôs ove rall health status and health 
utility using the 3-level version of the EQ-5D-3L visual analog scale (VAS) and utility index, respectively‚Ä¢Change in EQ-5D-3L scores
‚Ä¢To assess Event Free survival on next line of therapy (EFS2) in early-stage NSCLC participants treated with nivolumab plus platinum doublet chemotherapy compared to those treated with platinum doublet‚Ä¢Event Free survival on next line of therapy (EFS2)
‚Ä¢To evaluate tumor mutation burden as a potential predictive biomarker of efficacy (such as EFS and OS) of nivolumab plus platinum doublet chemotherapy and of 
platinum-doublet chemotherapy, using data generated 
from tumor and blood (germ-line control) specimens.
‚Ä¢To explore potential predictive biomarkers of  nivolumab plus platinum doublet chemotherapy efficacy (such as EFS and OS) in peripheral blood and tumor specimens  
 
 ‚Ä¢Biomarker endpoints (See Section 9.8 )
5 STUDY DESIGN
5.1 Overall Design
This is an open-label, randomized clinical trial of up to 3 cyc les of neoadjuvant nivolumab 
(3 mg/kg every 2 weeks) and a single dose of 1 mg/kg dose of ipil imumab, nivolumab 360mg flat 
dose plus platinum doublet chemotherapy (up to 3 cycles), or pl atinum doublet chemotherapy (up 
Protocol Amendment No.: 07
Date: 18-Aug-2021 47
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
to 3 cycles) as neoadjuvant treatment in participants with early  stage (Stage IB [ ‚â•4 cm], II, and 
resectable IIIA [N2]) NSCLC. 
The original study design (before revised protocol 02) had two arms. After signing the informed 
consent form and upon confirmation of the participant‚Äôs eligibi lity, participants were randomized 
in an open-label fashion (1:1 ratio) to either neoadjuvant nivolumab plus ipilimumab or platinum 
doublet chemotherapy.
Revised protocol 02 added a new, neoadjuvant nivolumab plus plat inum doublet chemotherapy 
arm. When the third arm had opened and as each site had receive d IRB/EC approval of revised 
protocol 02, the IRT switched to a 1:1: 1 randomization at the respective site.  Starting from that 
point on, the sites were only enrolling under revised protocol 02. 
Revised protocol 03 withholds rando mization into the arm of neoadjuvant nivolumab plus 
ipilimumab but continues randomizing eligible participants into  either neoadjuvant nivolumab plus 
platinum doublet chemotherapy arm  or platinum doublet chemotherapy arm. Participants already 
randomized in the original 2-arm part (neoadjuvant nivolumab pl us ipilimumab vs neoadjuvant 
chemotherapy) and in the arm of neoadjuvant nivolumab plus ipil imumab in 3-arm part defined 
by revised protocol 02 will remain in trial and continue schedu led trial procedures.
Participants will be randomized between 2 arms in a 1:1 r atio to neoadjuvant nivolumab plus 
platinum doublet chemot herapy or platinum doub let chemo therapy. Eligible participants will be 
stratified by:
‚Ä¢PD-L1 expression ( ‚â•1% or <1%/not evaluable/indeterminate)
‚Ä¢Disease stage (IB/II vs IIIA)
‚Ä¢Gender
PD-L1 status will be determined by immunohistochemical (IHC) st aining of PD-L1 protein in the 
submitted tumor sample and categorized as follows: 
‚Ä¢PD-L1 positive - defined as ‚â•1% tumor cell membrane staining positive in a minimum of 
100 evaluable tumor cells
‚Ä¢PD-L1 negative ‚Äì defined as < 1% tumor cell membrane staining positive in a minimum of 
100 evaluable tumor cells
‚Ä¢PD-L1 not evaluable/indeterminate - defined as participants with insufficient sample quantity 
or quality to stain for PD-L1 status or those participants in whose samples PD-L1 status could 
not be determined despite appropriate amounts of tissue sample.  For the purpose of 
stratification, this category w ill be grouped with PD-L1 negative participants. No more than 
10% of participants enrolled in this trial will be PD-L1 not ev aluable/indeterminate category.
Screening begins by establishi ng the particip ant‚Äôs initial elig ibility and signing of the informed 
consent (ICF). Tum or tissue (archival [slides/block ‚â§3 month] or recent tumor biopsy) must be 
submitted to a third-party vendor for determination of PD-L1 status prior to randomization.
All screening assessments and procedures must be performed in accordance with Table 2-1.
Protocol Amendment No.: 07
Date: 18-Aug-2021 48
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
The Treatment Phase begins when the randomization call is made into the Interactive Response 
Technology (IRT). The participant will be randomly assigned to 1 of the 2 treatment arms: Arm B 
or Arm C. The first dose of study t reatment must begin within 7  days of randomization.
‚Ä¢Arm A treatment: Participants randomized into Arm A received nivolumab 3 mg/kg I V over 
30 minutes every 2 w eeks for up to 3 doses (ie, 6 weeks of treat ment; each cycle is 14 days). 
With Cycle 1 only, nivolumab was followed by a single dose ipil imumab 1 mg/kg IV over 30 
minutes.
‚Ä¢Arm B treatment: Participants randomized into Arm B will r eceive investigator-choice 
platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles (ie, 9 weeks of 
treatment; each cycle is 21 days):
‚Ä¢Regimen 1: 
‚àíVinorelbine 25 mg/m2 or 30 mg/m2IV (per local prescribing information) push over 
10 minutes or per institutional standard on Days 1 and 8
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following vinorelbine
‚Ä¢Regimen 2:‚àíDocetaxel 60 mg/m
2or 75 mg/m2  IV (per local prescribing information) over 60 minutes 
or per institutional standard on Day 1
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following docetaxel
‚Ä¢Regimen 3 (squamous histology):
‚àíGemcitabine 1000 mg/m2or 1250 mg/m2(per local prescribing information) IV over 
30 minutes or per  institutional standard on Days 1 and 8
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following gemcitabine
‚Ä¢Regimen 4 (non-squamous histology only):
‚àíPemetrexed 500 mg/m2IV over 10 minutes or per institutional standard on Day 1
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following pemetrexed
‚Ä¢Regimen 5:‚àíPaclitaxel 175 or 200 mg/m
2IV over 180 minutes or per institutional standard on Day 1
‚àíCarboplatin AUC 5 or 6 IV over 30 minutes or per institutional standard on Day 1, 
immediately following paclitaxel
Arm C treatment: Participants randomized into Arm  C will receive nivolumab 360 m g IV plus 
platinum doublet chemotherapy in  3-week cycles up to a maximum of 3 cycles of chemotherapy 
(ie, 9 weeks of treatment; each cycle is 21 days)
Protocol Amendment No.: 07
Date: 18-Aug-2021 49
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢Non-squamous NSCLC: nivolumab at a flat dose of 360 mg as 30-mi nute IV infusion on Day 
1, followed by pemetrexed at a dose of 500 mg/m2IV over 10 minutes or per institutional 
standard and cisplatin at a dose of 75 mg/m¬≤ IV over 120 minute s or per institutional standard 
of a 3-week treatment cycle, for up to 3 cycles.
‚Ä¢Squamous NSCLC: nivolumab at a dose of flat dose of 360 mg as 3 0 minute IV infusion on 
Day 1, followed by gemcitabi ne at a dose of 1000 mg/m2or 1250 mg/m2(per local prescribing 
information) for a 30 minute IV infusion or per institutional standard and cisplatin at a dose of 
75 mg/m2as a 120-minute IV infusion or per institutional standa rd, of a 3-week t reatment cycle 
for up to 3 cycles. Gemcitabine will also be administered at a dose of 1000 mg/m2or 
1250 mg/m2as a 30 minute IV infusion or pe r institutional standard on day  8 of each 3-week 
treatment cycle.
‚Ä¢Any histology: nivolumab at a f lat dose of 3 60 mg as 30-minute IV infusion on Day 1, followed 
by paclitaxel 175 or 200 mg/m2IV over 180 minutes or per institutional standard and 
carboplatin AU C 5 or 6 IV over 30 minutes or per institutional standard of a 3-week treatment 
cycle, for up to 3 cycles.
Within 7 days of randomization, the participants must receive t he first dose of study medication. 
Participants may be dosed no less than 12 days between nivoluma b doses in Arm A and no less 
than 18 days between nivolumab doses in Arm C. If a dose is del ayed for any reason, participants 
should be dosed no later than 7 days following a planned dose o n any arm. If more than 7 days 
delay is needed for any reason, the intended dose should be skipped. If a participant receiving chemotherapy on a Day 1 and Day 8 schedule (ie, cisplatin/gemcit abine) is unable to receive Day 
1 of chemotherapy but recovers in time to receive the Day 8 dos e, the Day 8 dose of chemotherapy 
may be administered. Doses that are skipped or missed will not be replaced. Surgery s hould be 
performed within 6 weeks after completing up t o 3 cy cles (last dose) of neodjuvant treatment as 
indicated by the institutional SOC.  
‚Ä¢For participants who are unable to tolerate cisplatin, the reas ons for intolerability should be 
documented. If the investigator would like to use a carboplatin -containing regimen, the 
investigator should discuss this with and obtain a pproval from the  Medical Monitor prior to 
utilization, except for opting for carboplatin plus paclitaxel.  
‚Ä¢Carboplatin w ill be administered at a dose of AUC 5 or 6 as a 30-minute IV i nfusion or per 
institutional standa rd, on Day  1 of eac h 3-week cy cle.
‚Ä¢Carboplatin should be given follo wing gemcitabine, docetaxel, v inorelbine, pemetrexed, or 
paclitaxel on Day 1 of each cycle, and the carboplatin dose will  be calculated using the Calvert 
formula as follows:
‚Ä¢Carboplatin dose (mg) = Target AUC x [(CrCl (mL/min) + 25]
‚Ä¢Creatinine clearance (CrCl) calculation is b ased on the Cockroft-Gault formula) and should 
include the most recent serum creatinine and most recent weight . NOTE: If calcu lation of the 
Protocol Amendment No.: 07
Date: 18-Aug-2021 50
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
CrCl by the Cockroft-Gault formula yields a result of > 125 mL/ min, then a CrCl should be 
calculated by an alternative formula per institutional standard s or capped at 125 mL/min.
‚Ä¢The dose of carboplatin may be capped per local standards.
All Arms
PET/CT including contrast from the base of the skull to upper thighs will be performed at baseline 
(within 28 days prior t o randomization) and within 14 days prior to planned definitive surgery. A 
separate CT, with contrast, of the chest, abdomen, and all other suspected sites of disease (as well as the PET/CT) is required if the CT component of a PET/CT is n ot of sufficient diagnostic quality 
for RECIST 1.1 measurements. Subsequent radiologic assessments C T, with contrast, of the chest 
including adrenal glands and CT or MRI of other additional susp ected/known sites of disease will 
be performed in accordance with Table 2-3 and Table 2-4. Tumor assessments must continue per 
protocol until disease recurrence/progression is confirme d by BICR per RECIST 1.1 ( Appendix 5 ),
even after the initiation of subsequent anti-cancer therapies. Exceptions are cases where disease 
progression does not preclude surgery, regardless of whether it  has been confirmed by BICR, 
participants should proceed to definitive surgery and continue to get tumor assessments per Table 
2-3and Table 2-4. Tumor assessments should be done as per Table 2-3 for those who did not get 
definitive surgery. Pharmacokinetics assessments are described in Section 9.5 , and biomarker 
assessments are described in Section 9.8. OS will be followed continuously every 3 months via in-
person or phone contact after Post-neoadjuvant Follow-up Visit 2 or after completion of adjuvant 
therapy, when applicable.
Following the completion of neoadjuvant treatment, all par ticipants who r emain ope rative 
candidates will undergo definitive surgery for their NSCLC with i n  6w e e k s  a f t e r  c o m p l e t i n g  
neoadjuvant treatment. 
Prior to surgery, any treatment-r elated toxicity s hould have resolved to ‚â§Grade 1 or returned to 
baseline (except for alopecia, fatigue, and neuropathy). Invest igators should discuss residual 
endocrine toxicities or mild renal impairment with the Medical Monitor. 
All AEs, serious adverse event (SAE), and drug-related AEs resulting in surgical delays and 
post-surgical complications will be  collected. Peri-operative c omplications, including a delay in 
planned surgery, pneumonitis, ARDS, re-admission to the Intensi ve Care Unit, atrial fibrillation 
or other SVTs, potential immune-related toxici ties, and post-oper ative complications will be 
collected. Study drug dose omissi on or delays due to AEs will not be replaced for either arm, and 
participants should proceed to surgery within the predefined ti meframe after standard preoperative
evaluation. Surgical complications occurring within 90 days of surgery w ill be documented and 
followed until resolution. 
All AEs and SAEs will be documented for a minimum of 100 days a fter the last dose of 
neoadjuvant therapy or 90 days post-surgery, whichever is longer , and for 30 days after the last 
dose of adjuvant therapy in participants who receive adjuvant t herapy. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 51
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Following definitive surgery, participants in each arm may rece ive up to 4 cycles of adjuvant 
chemotherapy with or without radiation per institutional standa rd at the discretion of the 
investigator. Investigators may choose from the following post- operative regimens:
‚Ä¢Regimen 1:
‚àíVinorelbine 25 mg/m2or 30 mg/m2IV (per local prescribing information) push over 
10 minutes or per institutional standard on  Days 1 and 8
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following vinorelbine
‚Ä¢Regimen 2:
‚àíDocetaxel 60 mg/m2or 75 mg/m2IV (per local prescribing information) over 60 minutes 
or per institutional standard on Day 1
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following docetaxel
‚Ä¢Regimen 3 (squamous histology):‚àíGemcitabine 1000 mg/m
2or 1250 mg/m2IV (per local prescribing information) over 
30 minutes or per instituti onal standard on Days 1 and 8
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following gemcitabine
‚Ä¢Regimen 4 (non-squamous histology only):
‚àíPemetrexed 500 mg/m2IV over 10 minutes or per institutional standard on Day 1
‚àíCisplatin 75 mg/m2IV over 120 minutes or per institutional standard on Day 1, 
immediately following pemetrexed
‚Ä¢Regimen 5:‚àíPaclitaxel 175 or 200 mg/m
2IV over 180 minutes or per institutional standard on Day 1
‚àíCarboplatin AUC5 or 6 IV over 30 minutes or per institutional s tandard on Day 1, 
immediately following paclitaxel
For participants who are unable to tolerate cisplatin, the reas ons for intolerability should be
documented. If the investigator would like to use a carboplatin  regimen, the investigator should 
discuss this with and obtain approval from the Medical Monitor prior to utilization, except for 
opting for carboplatin plus paclitaxel.
Postoperative chemothera py should not  commence un til pre-operative, tr eatment-related toxicity 
has returned to baseline or resolved to ‚â§Grade 1 (exceptions for fatigue , alopecia, and neuropathy). 
Investigators should discuss residual endocrine toxicities or m ild renal impairment with the 
Medical Monitor.Assessmen ts during adjuvant therapy are outlined in Table 2-4.
Protocol Amendment No.: 07
Date: 18-Aug-2021 52
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Post-operative radiation shoul d be administered per institutional standard of care. As radiat ion may 
interfere with imaging interpretation, efforts should be made t o schedule radiotherapy so that 
scheduled tumor assessments do not cross over into the radiatio n period.
The Survival Follow-Up Phase begins 3 months after post-neoadjuvant Follow-up Visit 2 or after 
completion of adjuvant therapy, when applicable. Participants w ill be followed every 3 months for 
survival. Survival follow-up visits may be performed by phone c ontact or office visit.
The study design schematic is presented in Figure 5.1-1 .
Protocol Amendment No.: 07
Date: 18-Aug-2021 53
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Figure 5.1-1: Study Design Schematic
Protocol Amendment No.: 07
Date: 18-Aug-2021 54
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
5.1.1 Data Monitoring Committee and Other External Committees
When required, adjudicated events will be submitted to the DMC and Health Authori ties for review 
on a specified timeframe in accordance with the adjudication do cumentation.
An independent Data Monitoring Committee (DMC) w ill be establis hed to provide oversight of 
safety and efficacy considerations, study conduct, and risk-ben efit ratio in protocol CA209816. An 
interim DMC review will occur after 15 participants have enroll ed into Arm A and after 15 
participants have enrolled into Arm C and have completed surgery. Following review, the DMC 
will recommend continuation, modification, or discontinuation o f this study based on reported 
safety data. Representatives of the Sponsor w ill serve only as c oordinators of the committee, 
without having full member responsibilities or privileges. In a ddition, the Sponsor will 
independently review safety data in a blinded manner during the  conduct of this trial to ensure that 
any safety issues are identified and addressed. Available effic acy data will also be reviewed by the 
DMC during the conduct of the study. Details of the DMC respons ibilities and procedures will be 
specified in the DMC charter.
Independent Radiology/Pathology Review
Independent pathology and radiol ogy review will be established for central review and 
confirmation of endpoints. Images and tumor/lymph node samples will be submitted to these 
third-party vendors for central review. Sites will be trained p rior to enrolling the first study 
participant. Images and pathology  samples acqui sition gui delines and submission process will be 
outlined in the study Imaging/Laboratory Manuals to be provided  by the vendors. 
Independent Pathology Review: Tumor and lymph node collection fr om definitive surgical 
resection and sampling of fresh tumor sample in RNAlater for bio marker studies (as applicable 
dependent on size of residual tumor) is mandatory on the day of  surgery. RNAlater sample will 
not be collected in China. Processing of the remainder of the s pecimens for histopathologic 
analysis should be performed  within 72 hours of the procedure. Sections will be used for central 
pathology review assessing pathologic complete response (pCR) a nd major pathological response 
(MPR). Any tumor, tumor bed, or lymph node specimens that are r eviewed locally must be 
submitted for central pathology review. Gross examination on th e entire specimen should be 
performed which includes all tum or, associated ly mph node tissue, and uninvolved parenchyma. 
The specimen should be sectioned at 0.5 cm intervals, and block s should be submitted for the full 
cross section for every other 0.5 cm interval. For very large t umors with no gross evidence of 
response, a minimum of 1 slide/cm is required for assessment of  pathologic response. When 
estimating viable tumor, in situ carcinoma should not be includ ed. Pathology specimen collection 
and processing guidelines are outlined in the CA209816 Laborato ry Manual. A blinded pathology 
review process will be utilized to assess for confirmation of e ndpoints.
Independent Radiology Review: Radiologic tumor assessments will  be sent to and reviewed by a 
Blinded Independent Central Review (BICR) from a third-party ra diology vendor on an on-going 
basis. At the time of investigator assessed radiographic progres sion per RECIST 1.1, the site must 
request a BICR- review confirmation of progression or recurrence . However, BICR confirmation 
of progression should not be requested if investigator j udges the progression does not preclude 
Protocol Amendment No.: 07
Date: 18-Aug-2021 55
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
surgery. Participants should proceed to definitive surgery and t umor assessments post surgery 
should be continue d per schedule of activities. Details of the Blinded Independent Central Review 
responsibilities and pr ocedures will be sp ecified in the Blinded Independent Central Review 
charter.
Participants whose disease progression or recurrence is not con firmed by central review will be 
required to continue tumor assessments (if clinically feasible)  according to the protocol-specified 
schedule, even after the initiation of subsequent anti-cancer t herapies. Subsequent tumor 
assessments must be submitted to the third party radiology vend or for subsequent review and may 
be discontinued when the investigator and independent radiologi sts both assess the participant to 
have met RECIST 1.1 criteria for progression or recurrence.5.2 Number of Participants
Approximately 350 participants w ill be randomized in a 1:1 rati o (175 participants in each arm) to 
the 2 arms (neoadjuvant nivolumab plus platinum doublet chemoth erapy and platinum doublet 
chemotherapy), from 1:1:1 rando mization i n revised protocol 02 and 1:1 randomizatio n in revised 
protocol 03. 
In addition, it is expected to have around 70 participants rando mized in the original 2-arm st udy 
(Arm A and Arm B) and approximately another 75 participants rand omized in the arm of 
neoadjuvant nivolumab plus ipilimumab (Arm A) when the study ha d 3 arms. 
5.3 End of Study Definition
The start of the trial is defined as the first participant‚Äôs fi rst visit. The analysis of pCR rate will 
take place after 350 participants on Arms B and C from 1:1:1 randomization defined by revised 
protocol 02, and 1:1 randomization by revised protocol 03 have the opportunity for surgery. After 
this analysis, participants will be followed for EFS and OS. Two formal interim analyses for EFS 
are planned after 148 events and 167 events have been observed in the participants on Arms B and 
C, which is projected  to occur a pproximately 48 and 58 months after 1:1:1 randomization (the 
second interim analysi s will take  place when 167 events are observed  
). Thes e formal comparisons of EFS will 
allow for determination of superiority. The final analysis (FA) of EFS will be c onducted after 
approximately 185 participants in Arms B and C have experienced an event (approximately 73
months from 1:1:1 ra ndomization), or 4 years after the last par ticipant‚Äôs randomization.  
 
5.4 Scientific Rationale for Study Design
5.4.1 Rationale for Open-Label Design
This study will use an open-label design. Due to the obvious di fference in chemotherapy- and 
immunotherapy-related toxicities, histology-dependent chemother apy options, different dose 
modification rules for safety management, including different d ose delay rules per arm, and 
different premedication requirements according to chemotherapy,  an open-label design is 
Protocol Amendment No.: 07
Date: 18-Aug-2021 56
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
appropriate. An open-label design will also help ensure that im mune-related tox icities in 
participant receiving immunotherapy are promptly identified and  managed.
Because this study will be open-label, independent pathology an d radiology review will be used 
for central review and confirmation of pathologic and clinical responses in all randomized 
participants to determine all response-related endpoints.
5.4.2 Rationale for Preoperative Systemic Therapy in NSCLC
Follow-up of adjuvant trials may  require decades until a new tr eatment can be introduced into the 
early treatment setting. Preoperative chemotherapy has been ass essed in a number of trials for 
patients with resectable NSCLC, though most trials were closed early when the adjuvant 
chemotherapy data revealed a survi val advantage. A meta-analysi s based upon 7 trials involving 
988 participants suggested that neoadjuvant chemotherapy improv ed OS when given 
preoperatively (5-year survival 20% vs 14% without neoadjuvant chemotherapy). This 
improvement in survival is similar to that noted in the meta-an alyses of predominantly adjuvant 
chemotherapy.31,32
Several studies have shown preoperative cytotoxic chemotherapy to be safe prior to surgical 
resection of NSCLC with no difference in extent of s urgical procedures pe rformed, operative 
morbidity, and mortality.6,33,34Immune checkpoint inhibition has the potential to provide benef its 
in early-stage disease. Among these benefits are the opportunity to evaluate EFS in a 
moderate-sized population of early-stage NSCLC patients and the  potential to demonstrate 
long-term, disease-free s tatus in these patients .7,35,36,37
5.4.3 Rationale for Immuno-oncology Treatment in Neoadjuvant NSCLC
In contrast to the adjuvant setting in which only micrometastat ic disease is present, one may 
hypothesize that the higher tum or burden present at the time of  induction treatment may be 
necessary for abundant antigen release and presentation to the immune system, and consequently, 
development of a robust immune response to immune checkpoint in hibitors. 
In an ongoing feasibility trial with nivolumab monotherapy, a m ajor pathologic res ponse (MPR) 
rate was observed in 45% (9/20) of stage IB-IIIA NSCLC particip ants who were evaluable post-
surgery after 2 cycles of nivolumab. Two patients (10%, 2/20) a chieved a pathologic complete
response. Major pathologic response was defined as ‚â§10% residual viable tumor at resection.38
Responses were observed across histology and regardless of PD-L1  expression. High tumor 
mutation burden and neoantigen density was associated with pathological response following 
neoadjuvant nivolumab treatment. With a median post-op follow-u p of 12 months (range of 0.8 to 
19.7 months), 1 patient with MPR had a mediastinal lymph-node r ecurrence that was treated with 
concurrent chemoradiation and was free from further progression at more than 12 months of 
follow-up. Two patients without MPR have recurrence of lung cancer (1 solitary brain metastasis 
which was treated with radiotherapy and has no evidence of furt her recurrence at more than 16 
months of follow-up; 1 systemic rec urrence 1 year after surgery and died from recurrent disease 4 
months later). Two additional deaths were reported including 1 disease progression in an 
unresected patient and 1 death not related to drug or disease).
Protocol Amendment No.: 07
Date: 18-Aug-2021 57
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Nivolumab was well toler ated with a safety profile comparable to that observed in the p hase 3 
program. Administration of nivolumab in the neoadjuvant setting  was deemed to be feasible with 
no surgical delays or post-surgical complications (within 30 days post-surgery). This trial was 
recently expanded to include an additional 30 participants, who  will be tr eated with nivolumab 
monotherapy (n=15) and nivolumab plus ipilimumab (n=15). In addition, nivoluma b monotherapy 
will be extended to 3 cycles. It is hypothesized that the additi on of a single dose of ipilimumab to 
3 doses of nivolumab and the addition of chemotherapy to nivolu mab will result in the achievement 
of higher rate and deeper pathologic responses while maintainin g an acceptable safety profile.
The 45% MPR rate from nivolumab in neoa djuvant NSCLC compares with a r ate of approximately 
20% from platinum doublet chemotherapy in this con text. The pCR of 10% also compar es 
favorably to the histo rically obse rved pCR r ate of approximately 4% with platinum doublet 
chemotherapy. 
In another ongoing phase 2 trial , patients with resectable stage IIIA N2 NSCLC r eceive 3 cycles 
of neoadjuvant therapy consisting of nivolumab 360mg IV plus pa clitaxel/carboplatin IV Q3W 
then proceed to definitive surgery after which patients receive  1 year adjuvant nivolumab.39In the 
first 22 patients in whom surgical resection was performed foll owing neoadjuvant therapy, pCR 
was recorded in 13 patients (60%), MPR was noted  in a further 4  patients (18%). Neoadjuvant 
nivolumab plus paclitaxel/carboplatin was well tolerated and su rgery was not delayed. 
These findings, coupled with encouraging survival data from niv olumab plus ipilimumab and anti-
PD1 plus chemotherapy in first-line advanced NSCLC suggest that  nivolumab plus ipilimumab, 
especially nivolumab plus platinum doublet chemotherapy, may im prove both EFS and pathologic 
response relative t o plati num doublet chemotherapy, while provi ding an acceptable safety profile 
in the neoadjuvant treatment of NSCLC.27
5.4.3.1 Rationale for Combination of Nivolumab and Ipilimumab (Arm A):
Combining immunotherapeutic agents with different mechanisms of  action offers the possibility 
of synergistic response. PD-1 and CTLA-4 are both co-inhibitory  molecules, but evidence suggests 
that they use distinct mechanisms, to limit T-cell activation. P reliminary indirect data from 
peripheral T-cell assessments suggests that a given T-cell chec kpoint inhibitor may modulate host 
immune cell phenotype rendering them more susceptible to altern ate checkpoint inhibitors and 
thereby enhancing anti-tumor activity.
Preclinical data indicate that the combination of PD-1 and CTLA -4 receptor blockade may 
improve antitumor activity. In vitro combinations of nivolumab plus ipilimumab increase IFN-Œ≥ 
production 2- to 7-fold over either agent alone in a mixed lymphocyte reaction. Increased 
antitumor activity of the combination was also observed in 3 of  5 syngeneic murine cancer models. 
In a murine melanoma vaccine model, blockade with either CTLA-4  or PD-1 antibodies increased 
the proporti on of CTLA-4 and PD-1-e xpressing CD4/CD8 tumor infiltrating T effector cells, and 
dual blockade increased tumor infiltration of  T effect or cells and decreased intratumoral 
T regulatory cells, as compared to either agent alone.40
Protocol Amendment No.: 07
Date: 18-Aug-2021 58
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
The combination of nivolumab and ipilimumab was evaluated in CA 209004 (MDX1106 -04), a 
phase 1b, multiple ascending dose study in participants with tr eatment-naive and 
previously-treated advanced melanoma. Results showed promising activity with higher but 
tolerable toxicity than ipilimumab alone. Based on these data, CA209069, a phase 2 study, 
compared the combination to ipilimumab alone in treatment-na√Øve  participants with advanced 
melanoma: nivolumab  1 mg/kg and ip ilimumab 3 mg/kg every 3 weeks for 4 doses followed by 
nivolumab 3 mg/kg every 2 weeks versus ipilimumab 3 mg/kg every 3 weeks for 4 doses.41In 
participants with BRAF wild type tumors, the ORR was 61% (44/72), including 22% (16/72) CRs 
in the group treated with the combination, compared to 11% (4/3 7) with 0 CRs in those treated 
with ipilimumab alone. The median PFS was not reached in the co mbination versus 4.4 months 
for ipilimumab alone (HR = 0.4). Recently, a phase 3 study (CA209 067, n = 945) reported 
significantly improved PFS and ORR with the combinati on of nivolumab and ip ilimumab versus 
ipilimumab alone in previously unt reated melanoma. The median PF S was 6.9 months (95% 
confidence interval [CI], 4.3 to 9.5) in the nivolumab group, 11.5 months (95% CI, 8.9 to 16.7) in the nivolumab plus ipilimumab group, and 2.9 months (95% CI, 2. 8 to 3.4) in the ipilimumab 
group. Significantly longer PFS was observed in the nivolumab p lus ipilimumab group than in the 
ipilimumab group (ha zard ratio for death or disease progression , 0.42; 99.5% CI, 0.31 to 0.57; 
P < 0.001) and in the nivolumab group than in the ipilimumab group (hazard ratio, 0.57; 99.5% 
CI, 0.43 to 0.76; P < 0.001). The hazard ratio for the comparison  between the nivolumab plus 
ipilimumab group and the nivolumab group was 0.74 (95% CI, 0.60 to 0.92).
42
In addition, deep and durable responses were observed in previo usly treated, extensive stage small 
cell lung cancer (SCLC), with a response r ate of 31.1% with the combination of nivolumab and 
ipilimumab.43
Based on the initial data in melanoma and the activity observed with nivolumab and ipilimumab 
in lung cancer, the nivolumab plus ipilimumab combination has been also evaluated as first-line 
therapy in participants with advanced NSCLC. In CA209012, early  combination cohorts evaluated 
2 dosing schedules that were studied in the CA209004 study in me lanoma.44
‚Ä¢Nivolumab 1 mg/kg + ipilimumab 3 mg/kg, every 3 weeks for 4 dos es, followed by nivolumab 
3 mg/kg q 2 weeks (Arms G and H, n=24);
‚Ä¢Nivolumab 3 mg/kg + ipilimumab 1 mg/kg, every 3 weeks for 4 dos es, followed by nivolumab 
3 mg/kg q 2 weeks (Arms I and J, n=25)
These regimens resulted in signi ficant toxicity, with 39% of pa rticipants discontinuing treatment 
due to a treatment-related adverse event. Thus, additional comb ination cohorts were initiated 
(Arms N, O, P, Q), using lower doses of both nivolumab and ipili mumab, or the approved dose of 
nivolumab with less frequent dosing of ipilimumab. These new re gimens were better tolerated, 
and the safety data are not dissimilar to what has been observe d in the nivolumab monotherapy 
cohort (Arm F in CA209012) ( Table 5.4.3.1-1 ).
Protocol Amendment No.: 07
Date: 18-Aug-2021 59
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 5.4.3.1-1: Treatment-related Adverse Events from Selected Cohorts in 
CA209012
ArmaNo. 
Participa
nts/ armFollow-up 
time 
(median, 
wks)No. 
Participants 
still on 
treatmentNo. 
Participants 
with drug-
related AEsNo. 
Participants 
with grade 3-
4 drug-
related AEsNo. participants 
d/c due to drug-
related AEs 
(all grades)
Nb31 72 6 (19%) 24 (77%) 9 (29%) 4 (13%)
Ob40 27 14 (35%) 29 (73%) 14 (35%) 3 (8%)
Pb38 37 20 (53%) 28 (74%) 11 (29%) 2 (5%)
Qb39 34 15 (39%) 27 (69%) 11 (28%) 4 (10%)
Fc52 62 5 (10%) 37 (71%) 10 (19%) 5 (10%)
aN:nivolumab 1 mg/kg plus ipilimumab 1 mg/kg every 3 weeks x 4, f ollowed by nivolumab 3 mg/kg every 2 weeks; 
O: nivolumab 1 mg/kg every 2 weeks plus ipilimumab 1 mg/kg ever y 6 weeks; P: nivolumab 3 mg/kg every 2 weeks 
plus ipilimumab every 12 weeks; Q: nivolumab 3 mg/kg every 2 we eks plus ipilimumab 1 mg/kg every 6 weeks; 
F: nivolumab 3 mg/kg every 2 weeks
bbased on August 2015 database lock
cbased on March 2015 database lock
Recently, the  pooled results from the  CA209012 (Checkmate 012) nivolumab 3 m g/kg Q2W and 
ipilimumab 1 mg/kg Q12W and Q6W cohorts showed continued clinic al benefit (OS and PFS) 
with nivolumab plus ipilimumab in all patients and those with ‚â•1% and ‚â•50% tumor PD-L1 
expression.45ORR was 43% in all treated patients and 57% and 92% in patients  with ‚â• 1% and 
‚â•50% tumor PD-L1 expression, respectively, consistent with the p revious report. Additionally, 
6 investigator-assessed complete re sponses ([CRs] 8%; including 3 pathologic responses) were 
achieved in the Q12W/Q6W cohorts.46Median duration of response had not yet been reached in 
the overall  population or in subgroups with <1%, ‚â•1%, or ‚â•50% PD-L1 expression; durati on of 
response ra nged from 1.4+ to 27.9+ months. All treated patients (n = 77) showed a 1 year OS of 
76% and 2 year OS of 49%. When analyzed by PD-L1 e xpression, patients with ‚â•1% PD-L1 
(n = 47) had a 1 years OS of 87% and 2 year OS of 58%, which incr eased to 100% and 62%, 
respectively for ‚â•50% PD-L1 patients. Nivolumab plus ipilimumab remained tolerabl e, as most 
treatment-related AEs w ere manageable and no new safety concern s were identified in follow-up.
As described in Section 3.2.1 , ongoing phase 3 CheckM ate 227 study ra ndomized patients with 
stage IV or recurrent NSCLC that was not previously treated in various study treatment arms by 
tumor PD-L1 status. Recentl y, in the pre-specified analysis of patients with high tumor mu tational
burden at a prospective cutoff of ‚â•10 mutations/MB, progression-free survival was significantly 
longer in the group treated by nivolumab plus ipilimumab compar ed to chemotherapy, HR of PFS 
being 0.58 (97.5% CI 0.41, 0.81). The treatment effect was cons istent and independent of PD-L1 
Protocol Amendment No.: 07
Date: 18-Aug-2021 60
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
expression or histology. The ORR was also significantly greater  for the nivolumab plus 
ipilimumab group (45.3% vs 26.9%) and the responses appeared mo re durable with median DoR 
not reached (95% CI 12.2, NR) compared to 5 .4 month s (95% CI 4.2, 6.9) for chemotherapy. In 
patients with TMB < 10 mut/Mb, similar efficacy was seen in ter ms of PFS and ORR between 
nivolumab plus ipilimumab and chemotherapy. The safety profile was overall consistent with 
previously reported data with no new safety signals. In another  readout focusing on patients with 
tumor of <1% PD-L1 expression, nivolumab plus ipilimumab showed  similar efficacy to 
chemotherapy in terms of PFS and ORR but with much longer DoR, the safety profile was 
consistent with previously reported data.
5.4.3.2 Rationale for PD-1 Inhibitor with Chemotherapy (Arm C)
The interaction of a tumor with the immune system is complex. T umors and the tumor 
microenvironment are known to express a variety of factors that  impede a robust immune response 
from eliminating the  tumor. Soluble and membrane-bound factors have been shown to inhibit the 
cytolytic activity of tumor infiltrating T-cells (eg, PD-L1 exp ression; TGF-beta). In addition, some 
tumor-derived factors are able to enhance the immune system cou nter-regulatory systems 
(eg, increased T-regulatory cells). Finally, suboptimal tumor an tigen delivery and presentation has 
been postulated as another mechanism by which tumors can succes sfully evade immune system 
recognition. 
Cancer therapeutics such as ch emotherapy may modulate tumor/immu ne-system interactions in 
favor of the immune system. Chemotherapy can result in tumor cell death with a resultant increase 
in tumor antigen delivery to antigen-presenting cells. Tumor ce ll death may also lead to a reduction 
in soluble and membrane-bound factors inhibiti ng tumor-inf iltrating T-cells. Chemotherapy may 
also disrupt immune system regulatory networks by decreasing nu mbers of T-regulatory cells.
Nivolumab added to chemotherapy has been evaluated in several c ohorts of chemotherapy-naive 
subjects with advanced NSCLC in study CA209012. Nivolumab 10 mg /kg was combined with 
gemcitabine and cisplatin and pemetrexed + cisplatin. Nivolumab  10 mg/kg and 5 mg/kg was 
combined with paclitaxel and carboplatin. 
The safety profile of nivoluma b plus platinum-doublet chemotherapy reflects additive toxiciti es of 
the individual agents, which were manageable using established safety guidelines. No 
dose-limiting toxicities were observed during first 6 weeks of treatment. The frequency of most 
immune-related select AEs was higher for the combination than w hat has been observed for 
nivolumab monotherapy. However, these treatment-related AEs, including pneumonitis, were 
effectively managed and did not lead to any d eaths. Pneumonitis of any grade was reported in 
7 subjects (13%): Grade 3-4 in 4 subjects (7%). Twelve (21%) sub jects discontinued due to 
treatment-related AEs ( Table 5.4.3.2-1 ).
The overall response rate across all the nivolumab and chemothe rapy cohorts ranged from 33-47% 
and median duration of response was 27.3 weeks. In the 15 partic ipants that received nivolumab 
10 mg/kg plus pemetrexed and cisplatin, 47% achieved a PR or CR. In the 12 participants that 
received nivolumab 10 mg/kg plus gemcitabine and cisplatin, 33%  achieved a CR or PR. The 
1-year survival rate was 87% ( Table 5.4.3.2-2 ). 
Protocol Amendment No.: 07
Date: 18-Aug-2021 61
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Activity was evaluated by PD-L1 expression and was observed in subjects with both PD-L1 
expressing and non-expressing tumors. Overall, 79% (44/56) of s ubjects had evaluable tumor 
samples. At the ‚â•1% expression level, the response r ate was 48% and 43% for expressers and 
non-expressers, respectively. The 1-year OS was 70% and 76% for  expressers and non -expressers, 
respectively.
Table 5.4.3.2-1: Safety Evaluation in CA209012
Total (N=56)
All Grades Grade 3 Grade 4
Subjects with any treatment-
related AE, % (n)95 (53) 41 (23) 4 (2)a
Treatment-related AE in >15% of Patients, % (n)
Fatigue 71(40) 5 (3) 0
Nausea 46 (26) 2 (1) 0
Decrease A ppetite 36 (20) 2 (1) 0
Alopecia 30 (17) 0 0
Anemia 27 (15) 4 (2) 0
Rash 27 (15) 2 (1) 0
Arthralgia 21 (12) 0 0
Diarrhea 21 (12) 2 (1) 0
Constipation 20 (11) 0 0
Peripheral Neuropathy 20 (11) 0 0
aGrade 4 events: neutrophil count decreased (n = 1), pneumonitis and neutropenia (n = 1 each; occurred in the same 
patient). 
Protocol Amendment No.: 07
Date: 18-Aug-2021 62
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 5.4.3.2-2: Efficacy of First-Line Treatment of Nivolumab/C hemotherapy 
Combination in CA209012
Efficacy of First-Line Treatment of Nivolumab/Chemotherapy Combination in CA209012
Nivolumab 10 mg/kg Nivolumab 5 
mg/kg
Gem/Cis
(n=12)Pem/Cis
(n=15)Pac/Carb
(n=15)Pac/Carb
(n=14)
ORR, % 33 47 47 43
SD, % 58 47 27 43
Median Duration of 
Response, Weeks45 24.4 27.3 27.3
12-mo OS rate, % 50 87 72 86
18-mo OS Rate, % 33 60 40 62
Median OS, Weeks 51 83 65 Not Reached
As described in Section 3.2.1 , in the ongoing CheckMate 227 trial, in the setting of first l ine 
NSCLC with <1% tumor PD-L1 expression, PFS was improved with ni volumab plus 
chemotherapy vs chemotherap y (mPFS: 5.6m vs 4.7m; HR=0.74 [95% CI: 0.58 to 0.94]), mPFS 
of nivolumab plus ipilimumab was 4.4 months (95%CI: 3.1 to 6.0) . ORR was 36.7% in nivolumab 
plus chemotherapy arm, 23.1% in  chemotherapy arm, and 25.1% in nivolumab plus ipilimumab 
arm. mDOR was 7.2 months in nivolumab plus chemotherapy arm , 4.7 months in chemotherapy 
arm, and 18.0 months in nivolumab plus ipilimumab arm. The rate  of grade 3 or 4 treatment-related 
adverse events was 52% with nivolumab plus chemotherapy , 35% with chemotherapy, and 25% 
with nivolumab plus ipilimumab, overall, for nivolumab plus che motherapy, the safety profile and 
efficacy are consistent with previously reported data as well a s data from other PD-(L)1 blockades 
in combination with chemotherapy.
5.4.4 Rationale for Pathologic Response
Pathologic complete response (pCR) has been long known to c orrelate with survival after tumor 
resection. Recently, th e FDA approved pe rtuzumab based on patho logic response rate for the 
treatment of locally advanced breast cancer. In the ongoing fea sibility trial with nivolumab 
monotherapy, 2 out of 20 (10%) patients achieved  pCR. In anothe r ongoing phase II trial (NADIM) 
to evaluate neoadjuvant nivolumab plus chemotherapy, 13 out of 22 (60%) patien ts achieved pCR. 
These compare favorably to the approximate 4% pCR in NSCLC observed histori cally with 
neoadjuvant chemotherapy. It is predicted that patients treated  with the combination o f nivolumab 
plus ipilimumab, especially nivolumab plus platinum doublet chem otherapy, will achieve a higher 
pCR r ate than in patients treated with nivolumab monotherapy. Theref ore, pCR will be one of 
primary objectives.
In a recent publication by Hellmann and colleagues, major patho logic response (MPR), defined as 
‚â§10% viable tumor, was proposed  as a better surrogate for s urvival and is observed in 
Protocol Amendment No.: 07
Date: 18-Aug-2021 63
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
approximately  22% of NSCLC p atients treated with neoadjuvant chemotherapy.47This proposed 
surrogate for survival was supported by the data from a prospective study and retrosp ective 
study.48, 49Pataer and colleagues used a score system that quantifies the percentage of viable tumor 
cells and demonstrated that there is a statistically significan t correlatio n betwee n higher percentage 
of viable cells and shorter disease-free and OS in patients who  received induction treatment. This 
correlation was not evident in patients treated with upfront su rgery alone. The 5-year recurrence-
free survival for patients with and without a pathologic response were 78% and 35%, respectively 
(P < 0.001). The 5-year overall survival f or patients with and without a pathologic response were 
85% and 40%, respectively (P < 0.0001). In the on-going feasibi lity CA209159 trial with 
nivolumab monotherapy, a MPR rate of 45% (9/20) was observed in  stage IB-IIIA NSCLC 
participants who were evaluable post-surgery after 2 cycles of nivolumab. In NADIM, further to 
60% pCR rate, MPR was also noted in 4 additional patients (18%) . These results compare 
favorably to the MPR rate of approximately 22% observed with hi storical neoadjuvant 
chemotherapy. These results further support the explorati on of MPR a s a secondary objective for 
the CA209816 trial.
5.4.5 Rationale for Patient Population
The OS benefit of several adjuvant therapies in this population  is presented in Table 3.1-1. The 
choice of stage II and res ectable IIIA (N2) NSCLC was made because these participants hav e a 
high risk of tumor relapse and death with current standard ther apy, including surgery with 
preoperative or postoperative chemotherapy. There is an urgent need for improved, novel therapies 
for this group of participants. Participants with stage IB NSCL C with primary tumors of ‚â•4 cm 
diameter have been included because these participants are also at a high risk of tumor relapse and 
may be considered candidates for standard adjuvant chemotherapy .2,50It is anticipated that 
participants enrolled on this study may require adjuvant chemot herapy with  or without radiation, 
and the administration of adjuvant chemotherapy will commence i f considered clinically indicated 
in the postoperative period.
5.4.6 Rationale for Choices of Platinum-based Chemotherapy Doublet
The regimens selected for use in this study are commonly used a djuvant and neoadjuvant therapies 
in the clinical setting. A significant difference in outcome was not seen between participants using 
the regimens proposed in this trial.51Cisplatin-based therapy has been shown to significantly 
improve survival.52Several clinical trials have found a significant improvement in OS when using 
platinum-based chemotherapy regimens.53,54,55,56,57In revised protocol 03, paclitaxel/carboplatin 
is added among available chemotherapy options based on the prom ising data of using this doublet 
as backbone to combine with nivolumab in neoadjuvant therapy. B esides, meta-analysis of 
individual participant data from neoadjuvant trials did not ide ntify evidence of a difference in 
effect of chemotherapy by whether regimens were cisplatin or ca rboplatin-based (interaction 
p=0.48).58
Protocol Amendment No.: 07
Date: 18-Aug-2021 64
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
5.5 Justification for Dose
5.5.1 Rationale for Shorter Infusion Times for Nivolumab
Nivolumab has been administered safely over 60 minutes at doses  ranging up to 10 mg/kg safely 
over long treatment duration. In St udy CA209010 (a phase 2, ran domized, double-blinded, 
dose-ranging study of nivolumab in participants with advanced/m etastatic clear cell RCC), a dose 
association was observed for infusion site reactions and hypers ensitivity reactions (1.7% at 
0.3 mg/kg, 3.7% at 2 mg/kg and 18.5% at 10 mg/kg). All the event s were Grade 1-2 and were 
manageable. An infusion duration of  30 minutes for 3 mg/kg of nivolumab and for a flat dose of 
360 mg (30% of the dose  provided at 10 mg/kg and 45% of dose pr ovided at 10 mg/kg assuming 
an average body weight of 80 kg, resp ectively) is not expected to present any safety concern s 
compared to the prior experience at 10 mg/kg nivolumab dose infu sed over a 60-minute duration.
Of note, CA209153, a phase 3b/4 safety study of nivolumab i n participants with metastatic NSCLC 
who have progressed during or af ter at least 1 pri or systemic regime n, used a 30-minute i nfusion 
in a cohort of participants with no safety issues. 
Overall, infusion reactions including high-grade hypersensitivi ty reactions have been uncommon 
across nivolumab. Overall, a change in safety profile is not an ticipated with 30-minute infusion of 
nivolumab.
5.5.2 Rationale for Nivolumab 360 mg Flat Dose
Nivolumab monotherapy has been extensively studied in NSCLC pat ient population in studies 
CA209003, CA209063, CA209017, and CA209057 with body weight nor malized dosing (mg/kg). 
Nivolumab pharmacokinetics (PK) and exposures of subjects in th ese studies have been 
characterized by population pharmacokinetic (PPK) analysis of data collected from these studies, 
together with PK data from several Phase 1, 2, and 3 clinical studies of nivolumab mo notherapy 
in solid tumors. Nivolumab PK was determined to be linear, with dose proportional exposures over 
a dose range of 0.1 to 10 mg/kg. Nivolumab clearance and volume  of distribution was found to 
increase with increasing body weight, but the increase was less  than proportional, indicating that 
a mg/kg dose represents an over-adjustment for the effect of body weight on nivolumab PK.
Flat dosing offers several adva ntages over body weight normaliz ed dosing, including reduced 
potential for dosing errors and shortened dosage preparation ti me. A flat dose of 360 mg every 3 
weeks is expected to produce the equivalent average exposure to  3 mg/kg every 2 weeks at the 
median body weight  of ~80 kg in nivolumab-treated subjects.
A PPK model predicted overall nivolumab exposures across subjec ts with a wide range of body 
weight (35-160 kg) for a 360 mg every 3 weeks flat dose to be similar to that from 3 mg/kg every 
2 weeks. Although the flat dose is expected to lead to higher e xposure in lighter patients, relative 
to the exposure in heavier patients given the relationship betw een nivolumab PK and body weight, 
the predicted median and 95th percentile of exposures from these regimen s are maintained w ell 
below those in 10 mg/kg every 2 weeks, which was established as a safe and well-tolerable dose.  
In addition, data from the Japanese Phase 1 study ONO- 4538-01 did not demonstr ate dose-limiting 
toxicity at nivolumab up to 20 mg/kg every 2 weeks in Japanese patients and showed similarity in 
Protocol Amendment No.: 07
Date: 18-Aug-2021 65
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
PK properties between Global and Japanese population. Therefore, the proposed 360 mg flat dose 
is expected to be safe and tolerable in an Asian population.
Nivolumab 5 or 10 mg every 3 weeks plus platinum-based chemothe rapy was evaluated in 
CA209012 and deemed to be tolerable. In addition, nivolumab 360  mg every 3 weeks plus 
platinum based chemotherapy is further being evaluated on sever al global randomized phase 3 
trials including CA209227 and CA209722.6 STUDY POPULATION
For entry into the study, the following criteria MUST be met.
6.1 Inclusion Criteria
1) Signed Written Informed Consent
a) Participants must have signed and dated an IRB/IEC approved w ritten informed consent 
form in accordance with regulatory and institutional guidelines . This must be obtained 
before the performance of any protocol related procedures that are not part of normal 
participant care. 
b) Participants must be willing and able to comply with scheduled visits, treatment schedule, 
and laboratory testing.
2) Type of Participant and Target Disease Characteristics
a) Eastern Cooperative Group (ECOG) Performance Status 0-1 (Appendix 3 )
b) Participants with histologically confirmed Stage IB ( ‚â•4 cm), II, IIIA (N2) NSCLC (per 
the 7th International Association for the Study of L ung Cancer) with disease that is 
considered resectable.
59
c) Measurable disease according to RECIST version 1.1  
d) Participants must have a tumor tissue sample available for PD -L1 IHC testing performed 
by a third-party analyzing lab during the screening period:i) Either a formalin-fixed, paraffin-embedded (FFPE) tissue bloc k or unstained tumor 
tissue sections, with an associated pathology report, must be s ubmitted for biomarker 
evaluation prior to randomization. The tumor tissue sample may be fresh or archival if 
obtained within 3 months prior to enrollment. 
ii) Tissue must be a core needle biopsy, excisional or incisiona l biopsy. Fine needle 
biopsies obtained by EBUS is not considered adequate for biomar ker review and 
randomization. Core needle biopsies ob tained by EBUS are acceptable for 
randomization. 
e) Absence of major associated pathologies that increase the sur gery risk to an unacceptable 
level 
f) All suspicious mediastinal lymph nodes including those that a re pathologically enlarged or 
FDG avid on PET/CT require further sampling for pathological co nfirmation if accessible 
by mediastinoscopy, thoracoscopy, or EBUS. 
g) Pulmonary function capacity (eg, FVC, FEV1, TLC, FRC, and DLco ) capable of tolerating 
the proposed lung resection according to the surgeon. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 66
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
3) Age and Reproductive Status
a) Males and Females, ages ‚â•18 or age of majority 
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units  of HCG) within 24 hours 
prior to the start of study treatment.
c) Women must not be breastfeeding
d) Women of childbearing potential (WOCBP) must agree to follow instructions for 
method(s) of contraception ( Appendix 6) for the duration of treatment with nivolumab and 
5 months after the last dose of study treatment (ie , 30 days [duration of ovulatory cycle]) 
plus the time required for the investigational drug to undergo approximately 5 half-lives 
(for participants treated in Arm A and Arm C).
e) WOCBP must also agree to follow instructions for method(s) of  contraception from the 
time of enrollment for the duration of treatment with chemothera py plus 5 half-lives of 
chemotherapy plus 30 days (duration of ovulatory cycle) for a total of 30 days 
post-treatment completion or a durati on specified by the local labels of the chemotherapy 
drugs received, whichever is longer (for participants treated i n Arm B and Arm C). 
f) Males who are sexually active with WOCBP must agree to follow  instructions for 
method(s) of contraception (Appendix 6) for the duration of tre atment with nivolumab and 
7 months after the last dose of study treatment (ie, 90 days [d uration of sperm turnover] 
plus the time required for the investigational drug to undergo a pproximately 5 half-lives) 
(for participants treated in Arm A and Arm C). In addition, mal e participants must be 
willing to refrain from sperm donation during this time. 
g) Males who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception for the duration of treatment with s tudy treatment(s) with 
chemotherapy plus 5 half-lives of the study treatment plus 90 d ays (duration of sperm 
turnover) for a total of 90 days post-treatment completion or a  duration specified by the 
local labels of the chemotherapy drugs received, whichever is l onger (participants in Arm 
B and Arm C). In addition, male participants must be willing to  refrain from sperm 
donation during this time. 
h) Azoospermic males are exempt from cont raceptive requir ements. WOCBP who are 
continuously not heterosexually active are also exempt from con traceptive requirements, 
and st ill must  undergo pregnancy testing as described in this section.
Investigators shall counsel WOCBP, and male  participants who ar e sexually active with WOCBP, 
on the importance of pregnancy prevention and the implications of an unexpected pregnancy. 
Investigators shall advise on th e use of highly effective metho ds of contracep tion (Appendix 6), 
which have a failure rate of < 1% when used consistently and correctly.
Protocol Amendment No.: 07
Date: 18-Aug-2021 67
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
6.2 Exclusion Criteria
1) Medical Conditions
a) Presence of locally advanced  unresectable (regardless of stag e) or metastatic disease 
(stage IV). 
b) Participants with known EGFR mutations or ALK translocation. If testing is done, an 
FDA-approved assay should be used, and testing will be performed locally.
c) Participants with brain metastas es are exclude d from this stu dy, and all participants with 
stage II or higher disease and those with suspicion of brain metastases should have MRI or 
CT of the brain with pre- and post- contrast within 28 days prior  to randomization.
d) Participants with ‚â•Grade 2 peripheral neuropathy 
e) Participants with an active, known or suspected autoimmune di sease. Participants with type 
I diabetes mellitus, hypothyroidism only requiring hormone repl acement, skin disorders 
(such as vitiligo, psoriasis, or alopecia) not requiring system ic treatment, or conditions not 
expected to recur in the absence of an external trigger are per mitted to enroll.
f) Participants with a conditi on requiring systemic treatment wi th either corticosteroids 
(> 10 mg daily prednisone equivalent) or other immunosuppressive m edications within 
14 days of randomizatio n. Inhaled or topical steroids, and adren al replacement steroid 
doses > 10 mg daily prednisone equivalent, are permitted in the a bsence of active 
autoimmune disease
g) Known history of positive test for human immunodeficiency vir us (HIV) or known 
acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be performed 
at sites where mandated locally.
h) Participants with serious or uncontrolled medical disorders 
i) Participants with large-cell neuroendocrine carcinoma tumor h istology
2) Prior/Concomitant Therapy
a) Prior administration of chemotherapy or any other cancer ther apy for early stage NSCLC.
b) Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or a nti-CTLA-4 antibody or any 
other antibody targeting T cell co-regulatory pathways.
3) Physical and Laboratory Test Findings
a) Screening laboratory values must meet the following criteria (using CTCAE v4):
i) WBC < 2000/ŒºL
ii) Neutrophils <1500/ŒºL
iii) Pl atelets < 100x103/ŒºL
iv) Hemoglobin <9.0 g/dL
v) Serum creatinine >1.5 x ULN or calculated creatinin e clearance (CrCl) < 50 mL/min 
(using the Cockcroft-Gault formula)
Female CrCl = (140- age in years) x weight in kg x 0.85
72 x serum creatinine in mg/ dL
Male CrCl = (140- age in years) x weight in kg x 1.00
72 x serum creatinine in mg/ dL
vi) AST > 3.0 x ULN 
Protocol Amendment No.: 07
Date: 18-Aug-2021 68
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
vii) ALT >3.0 x ULN 
viii) Total  Bilirubin >1.5 x ULN (except participants with Gilbert Syndrome who must 
have a total bilirubin level of < 3.0 x ULN). 
b) Participants with active hepatitis B (positive hepatitis B s urface antigen [HBsAg] or 
hepatitis C virus (HCV) (positive HCV RNA)
i) Participants with past HBV infection or resolved HBV infection  (defined as the 
presence of hepatitis B core antibody [HBcAb] and the absence o f HBsAg) are eligible. 
HBV DNA must be obtained in these patients prior to randomizati on. HBV carriers or 
those participants requiring antiviral therapy are not eligible  to participate. 
ii) Participants positive for HCV antibody are eligible only if PCR is negative for HCV 
RNA. 
c) Prior malignancy active within the previous 3 years except fo r locally curable cancers that 
have been apparently cured, such as basal or squamous cell skin  cancer, superficial bladder 
cancer, or carcinoma in situ of the prostate, cervix, or breast.
d) Participants with serious or uncontrolled medical disorders
4) Allergies and Adverse Drug Reaction
a) History of allergy or hypersensitivity to study  drug components
5) Other Exclusion Criteria
a) Prisoners or participants who are involuntarily incarcerated.  (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to continue 
as a participant. Strict conditions apply and Bristol-Myers Squ ibb Company approval is 
required.
b) Participants who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness
Eligibility criteria for this study have been carefully consider ed to ensure the safety of the study 
parti cipants and that the resul ts of the study  can be used. It is imperative that participants fully 
meet all eligibility criteria.
6.3 Lifestyle Restrictions
Not applicable. No restrictions are required.
6.4 Screen Failures
Screen failures are defined as participants who consent to part icipate in the clinical study but are 
not subsequently randomized. A minimal set of screen failure in formation is required to ensure 
transparent reporting of screen failure participants, to meet t he Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements, and to respond to queries from regulatory 
authorities. Minimal information in cludes date of consent, demo graphy, screen failure details, 
eligibility criteria, and any serious AEs.
Protocol Amendment No.: 07
Date: 18-Aug-2021 69
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
6.4.1 Retesting During Screening or Lead-In Period
Participant Re-enrollment: This study permits the re-enrollment  of a participant who has 
discontinued the study as a pre -treatment fail ure (ie, participant has not been ra ndomized / has not 
been treated). If re-enrolled, the participant must be re-consented. Participants are allowed to 
re-enroll twice. Eligibility will need to be confirmed if a participant is re-enrolled. 
Retesting of laboratory parameters and/or other assessments wit hin any single Screening or 
Lead-in period will be  permitted up to 3 times (in addition to any parameters that require a 
confirmatory value). The most current result prior to randomization is the value by which study inclusion will be 
assessed, as it represents the participant‚Äôs most current, clin ical state.
7 TREATMENT
Study treatment is defined as any investigational treatment(s),  marketed product(s), placebo or 
medical device intended to be administered to a st udy participant acc ording to the st udy 
randomization or tr eatment allocation
Study treatment includes both Inve stigational [Medicinal] Produ ct (IP/IMP) and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and ca n consist of the following:
All products, active or placebo, being tested or used as a comp arator in a clinical trial. 
An investigational product, als o known as investigational medic inal product in some regions, is 
defined a pharmaceutical form of an active substance or placebo  being tested or used as a reference 
in a clinical study, including products already with a marketing  authorization but used or 
assembled (formulated or packaged) differently than the authori zed form, or used for an 
unauthorized indication, or when used to gain further informati on about the authorized form.
Other medications used as support or escape medicati on for preventative,  diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diag nosis, may be considered as 
non-investigational products.
Protocol Amendment No.: 07
Date: 18-Aug-2021 70
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 7-1: Study treatments for CA209816
Product Description / 
Class and Dosage FormPotencyIP/
Non-IMPBlinded or 
Open LabelPackaging / AppearanceStorage Conditions
(per label)
BMS-936558-01
Solution for 
Injection/Nivolumaba10 mg/mL IP Open-label5 or 10 (100 mg) vials per carton; Clear to 
opalescent, colorless to pale yellow liquid. Few 
particulates may be present.2 to 8¬∞ C. Protect from light 
and freezing
Ipilimumab Solution for 
Injection5 mg/mL IP Open-label4 vials/carton. Clear to opalescent, colorless to 
pale yellow liquid. May contain particles2 to 8¬∞ C. Protect from light 
and freezing
Vinorelbine NC Concentrate 
for Solution for Infusionb 10 mg/mL IP Open-label1 vial/carton. Clear, colorless to pale yellow 
solution.Product should be stored as 
per market product conditions.
Gemcitabine Concentrate 
for Solution for Infusionb1000 
mg/vial
(38 mg/mL)IP Open-label1 vial/carton. Clear, colorless or light straw-
colored solutionProduct should be stored as 
per market product conditions.
Gemcitabine Powder for 
Solution for Infusionb1000 
mg/vialIP Open label1 vial per carton. White to off-white plug or 
powderProduct should be stored as 
per market product conditions.
Docetaxel Concentrate for 
Solution for Infusionb 10 mg/mL IP Open-label1 vial/carton. Pale yellow to brownish yellow 
solutionProduct should be stored as 
per market product conditions.
Pemetrexed Powder for 
Concentrate for Solution for 
Infusionb500 mg/vial IP Open-label1 vial/carton. White to either light yellow or 
green-yellow lyophilised powderProduct should be stored as 
per market product conditions.
Cisplatin Concentrate for 
Solution for Infusionb100 mg/vial 
(1 mg/mL)IP Open-label 4 vials per carton. Clear, colorless solutionProduct should be stored as 
per market product conditions.
Protocol Amendment No.: 07
Date: 18-Aug-2021 71
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 7-1: Study treatments for CA209816
Product Description / 
Class and Dosage FormPotencyIP/
Non-IMPBlinded or 
Open LabelPackaging / AppearanceStorage Conditions
(per label)
Carboplatin Solution for 
Injectionb450 mg/vial 
(10 mg/mL)IP Open-label4 vials/carton. Clear, colorless or slightly yellow 
solution.Product should be stored as 
per market product conditions.
Paclitaxel Solution for 
Injectionb100mg/vial
(6mg/mL)IP Open-label4 vials/carton. Clear, colorless or slightly yellow 
viscous solution.Product should be stored as 
per market product conditions.
aMay be labeled as either ‚ÄúBMS-936558-01‚Äù or ‚Äúnivolumab‚Äù
bThese products may be obtained as local commercial product in certain countries if allowed by local regulations. In these cases, products may be a differ ent pack 
size/potency than listed in the table. These products should be  prepared, stored, stored and administered with the Package Insert or Summary of Product 
Characteristics.
Note: As of revised protocol 03, enrollment in nivolumab + ipil imumab arm has stopped enro llment.
Protocol Amendment No.: 07
Date: 18-Aug-2021 72
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
7.1 Treatments Administered
The selection and timing of dose for each participant is presented in Table 7.1-1.
Table 7.1-1: Selection and Timing of Dose
Study TreatmentUnit dose strength(s)/
Dosage level( s)Dosage formulation
Frequency of AdministrationRoute of 
Administration
BMS-936558-01
Nivolumab10 mg/mL3 mg/kg every 2 weeks for up to 
3 cycles (Arm A)
360 mg every 3 weeks for up to 
3 cycles (Arm C)IV
Ipilimumab 5 mg/mL 1 mg/kg at Cycle 1 only IV
Vinorelbine6010 mg/mL25 mg/m2or 30 mg/m2on Days 1 and 
8 of a 3-week cycle for up to 3 cy clesaIV
Gemcitabine6138 mg/mL1000 mg/m2or 1250 mg/m2 on Days 1 
and 8 of a 3-week cycle for up to 3 cyclesaIV
Docetaxel6210 mg/mL60 mg/m2or 75 mg/m2 on Day 1 of a 
3-week cycle for up to 3 cyclesaIV
Pemetrexed63500 mg/vial500 mg/m2 on Day 1 of a 3-week cycle 
for up to 3 cyclesaIV
Cisplatin641 mg/mL75 mg/m2 on Day 1 of a 3-week cycle 
for up to 3 cyclesaIV
Carboplatin6510 mg/mLAUC 5 or 6 on Day 1 of a 3-week 
cycle for up to 3 cyclesa,b IV.
Paclitaxel 
(Taxol PI TBC)66,67 6 mg/mL175 or 200 mg/m2 on Day 1 of a 
3-week cycle for up to 3 cyclesaIV
aFollowing definitive surgery, participants may receive up to 4 cycles of adjuvant chemotherapy with or wit hout 
radiation at the discretion of the investigato r.
bCarboplatin is initiated at a dose of AUC 5 or 6 when combined with paclitaxel.
Note: As of revised protocol 03, e nrollment in nivolumab + ipilimumab arm has stopped 
enrollment.
Nivolumab and Ipilimumab (Arm A )
NOTE: As of revised protocol 03, enrollment has stopped in Arm A. 
Participants are to receive nivolumab at a dose of 3 mg/kg as a  30-minute infusion on Day 1 of 
each treatment cy cle every 2 weeks for a maximum of 3 doses. In Cycle 1, partici pants will also 
receive a single dose of ipilimumab 1 mg/kg as a 30-minute infu sion on Day 1. Participants are to
begin study treatment within 7 calendar days of rando mization. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 73
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Dosing calculations should be based on the body weight assessed at baseline. It is not necessary to 
re-calculate subsequent doses if the participant weight is with in 10% of the weight used to calculate 
the previous dose. All doses should be rounded up or to the nearest milligram or per institutional 
standard.
When study drugs (nivolumab and ipilimumab) are to be administe red on the same day, nivolumab 
is to be administered first. Nivolumab infusion must be promptl y followed by a saline flush to 
clear the line of nivolumab before starting the ipilimumab infu sion. The second infusion will 
always be the ipilimumab study drug and will start after the in fusion line has been flushed, filters 
changed and participant has been observed to ensure no infusion  reaction has  occurred. The time 
in between infusions is exp ected to be approximately 30 minutes but may be more or less 
depending on the situation.
There will be no dose escalations or reductions of nivolumab or  ipilimumab allowed. Participants 
may be dosed no less than 12 days from the  previous dose. Premedications are not recommended 
for the first dose of nivolumab and ipilimumab.
Participants should be carefully monitored for infusion r eactions during nivolumab and 
ipilimumab administration. If an acute infusion reaction is not ed, participants should be managed 
according to  Section 7.4.3 .
Doses of nivolumab and ipilimumab may be interrupted, delayed, or discontinued depending on 
how well the participants tolerates the treatment. If a partici pant requires a dose delay of > 7 days, 
the dose should be skipped.  Dose delay criteria can be found in Section 7.4.2.1 , and discontinuation criteria can be found in 
Section 8.1.1.1 . Criteria to resume treatment can be found in Section 8.1.2.1 .
Please see the nivolumab IB, ipilimumab IB, and pharmacy manual  for specific infusion 
preparation recommendations.
Nivolumab plus Platinum Doublet Chemotherapy (Arm C)
Participants are to begin study treatment within 7 calendar day s of randomizat ion. Participants are 
to receive nivolumab 360 mg IV plus histology dependent platinu m doublet chemotherapy in 
3-week cycles up to a maximum of 3 cycles:
‚Ä¢Non-squamous NSCLC: nivolumab at a flat dose of 360 mg as 30-mi nute IV infusion on Day 
1, followed by pemetrexed at a dose of 500 mg/m
2IV over 10 minutes or per institutional 
standard with cisplatin at a dose of 75 mg/m¬≤ IV over 120 minut es or per institutional standard, 
of a 3-week treatment cycle, for up to 3 cycles.
‚Ä¢Squamous NSCLC: nivolumab at a flat dose of 360 mg as 30 minute  IV infusion on day 1, 
followed by gemcitabine at a dose of 1000 mg/m2or 1250 mg/m2(per local prescribing 
information) IV over 30 minutes or per institutional standard w ith cisplatin at a dose of 75 
mg/m2IV over 120 minutes or per institutional standard, of a 3-week treatment cycle for up to 
3 cycles.  Gemcitabine will also be administered at a dose of 1 000 mg/m2or 1250 mg/m2for 
a 30 minute IV infusion or per institutional standard on day 8 of each 3-week treatment cycle.
Protocol Amendment No.: 07
Date: 18-Aug-2021 74
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢Any histology: nivolumab at a f lat dose of 3 60 mg as 30-minute IV infusion on Day 1, followed 
by paclitaxel 175 or 200 mg/m2IV over 180 minutes or per institutional standard and 
carboplatin AU C 5 or 6 IV over 30 minutes or per institutional standard of a 3-week treatment 
cycle, for up to 3 cycles.
‚Ä¢Dosing calculations for chemother apy should be based on the bod y surface area calculation 
assessed as per standard of care. The dose should remain the same if the participant‚Äôs weight 
is within 10% of the baseline weight or prior dose weight All d oses should be rounded up or 
to the nearest milligram or per institutional standard.
When study drugs (nivolumab and chemotherapy) are to be adminis tered on the same day, 
nivolumab is to be administered fi rst. Nivolumab  infusion must be promptly followed by a saline 
flush to clear the line of nivolu mab before starting the chemotherapy infusion. The time in between 
infusion of nivolumab and chemoth erapy is expected to be approxi mately 30 minutes but may be 
more or less depending on the situation 
There will be no dose escalations or reductions of nivolumab al lowed. Participants may be dosed 
no less than 18 days from the previous dose. Premedications are  not recommended for the first 
dose of nivolumab.Participants should be carefully monitored for infusion reactio ns during nivolumab a dministration. 
If an acute infusion reaction is noted, participants should be managed according to  Section 7.4.3 .
Dose of nivolumab may be interrupted, delayed, or discontinued depending on how well the 
participants tolerates the treatm ent. If a participant requires  a dose delay of > 7 days, the dose 
should be skipped.  Dose delay criteria can be found in Section 7.4.2.1 , and discontinuation criteria can be found in 
Section 8.1.1.1 . Criteria to resume treatment can be found in Section 8.1.2.1
Please see the nivolumab IB, ipilimumab IB, and pharmacy manual  for specific infusion 
preparation recommendations.Refer to instructions below for instructions for pemetrexed/cis platin, gemcitabine/cisplatin, and 
paclitaxel/carboplatin administration. 
Doses of gemcitabine and/or cisplatin may be modified, delayed,  or discontinued depending on 
how well the participant tolerates the treatment. Dose modifica tions for toxicity will be performed 
according to Section 7.4.1 . Dose delay criteria can be found in  Section 7.4.2.2 , and discontinuation 
criteria can be found in Section 8.1.1.2 . Criteria to resume treatment can be fo und in 
Section 8.1.2.2 .
Doses of pemetrexed and/or cisplatin may be interrupted, delaye d, or disconti nued depending on 
how well the participant tolerates the treatment. Dose modifica tions for toxicity will be performed 
according to Section 7.4.1 . Dose delay criteria can be found in Section 7.4.2.2 , and discontinuation 
criteria can be found in Section 8.1.1.2 . Caution should be used when administering NSAIDs 
concurrently with pemetrexed t o patients with mild to moderate renal insufficiency (creatinine 
Protocol Amendment No.: 07
Date: 18-Aug-2021 75
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
clearance from 45 t o 79 m L/min). Pemetrexed  should not be a dministered if the calculated CrCl 
is < 45 mL/min. 
Doses of paclitaxel and/or car boplatin may be modified, delayed, or discontinued depending on  
how well the participant tolerates the treatment. Dose modifica tions for toxicity will be performed 
according to Section 7.4.1 . Dose delay criteria can be found in Section 7.4.2.2 , and discontinuation 
criteria can be found in Section 8.1.1.2 . Criteria to resume treatment can be fo und in 
Section 8.1.2.2 .
Dosing of all drugs shoul d be delayed if any criteria in Section 7.4.2.1 (nivolumab), 
Section 7.4.2.2 , or Section 7.4.2.3 (platinum doublet chemotherapy) are met. That is, nivolumab 
should be delayed if criteria for d elay of platinum doublet chemotherapy are met, and platinum 
doublet chemotherapy should be delayed if criteria for delay of  nivolumab are met. 
Participants may resume dosing only when criteria for BOTH resu mption of nivolumab 
(Section 8.1.2.1 ) AND platinum doublet chemotherapy (Section 8.1.2.2 and Section 8.1.2.3 ) are 
met. That is, nivolumab and platinum doublet chemotherapy must be administered together until 
treatment discontinuation criteria ( Sections 8.1.1.1 , 8.1.1.2 , and 8.1.1.3 ) or up to 3 cycles of study 
treatment have been completed.If a participant who is receiving nivolumab and platinum double t chemotherapy experiences an 
adverse event and the investigator can attribute it to either nivolumab or chemotherapy, then either 
nivolumab or the chemotherapy agents can be discontinued, and t he other agent(s) can be 
continued.
Platinum Doublet Chemotherapy (Arm B)
Vinorelbine/Cisplatin
Vinorelbine will be administered at a dose of 25 mg/m2or 30 mg/m2 (per local prescribing 
information) over 10 minutes or per institutional standard as a n IV infusion on Days 1 and 8 
followed by cisplatin at a dose of 75 mg/m¬≤ as a 120-minute or p er institutional standard IV 
infusio n on Day 1 only, of a 3-week treatment cycle for up to 3  cycles. 
Dosing calculations for vinorelbine should be based on the body surface area calculation assessed 
as per standard of care. The dose should remain the same if the participant‚Äôs weight is within 10% of the baseline weight or prior dose weight. Doses of vinorelbi ne and/or cisplatin may be 
interrupted, delayed, reduced, or discontinued depending on how  well the participant tolerates the 
treatment. Dose modif ications for toxicity will b e performed according to Section 7.4.1 . Dose 
delay criteria can be found in Section 7.4.2.2 , and discontinuation criteria can be found in 
Section 8.1.1.2 . Criteria to resume treatment can be found in Section 8.1.2.2 .
See below for the details regarding administration of cisplatin . 
Docetaxel/Cisplatin
Docetaxel will be administered at a dose of 60 mg/m2or 75 mg/m2(per local prescribing 
information) as a 60 minute or per institutional standard IV infusion on Day 1 followed by cisplatin 
Protocol Amendment No.: 07
Date: 18-Aug-2021 76
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
at a dose of 75 mg/m2as a 120 minute or per institutional standard IV infusion on Da y 1 of a 
3-week treatment cycle for up to 3 cycles. 
Dosing calculations for docetaxel should be based on the body surface area calculation assessed 
as per standard of care. The dose should remain the same if the participant‚Äôs weight is within 10% 
of the baseline weight or prior dose weight. Dose modifications  for toxicity will be performed 
according to Section 7.4.1 . Dose delay criteria can be found in Section 7.4.2.3 , and dose 
discontinuation criteria can be found in  Section 8.1.1.3 . Criteria to resume treatment can be found 
in Section 8.1.2.3.
See below for the details regarding administration of cisplatin . 
Premedications for use with docetaxel: Premedication with corti costeroids will be given to 
participants receiving docetaxel. The recommended premedication  per the USPI and SmPC is 
dexamethasone 8 mg PO twice daily given one day before, on the day of, and one day after 
administration of chemotherapy. For institutions that have esta blished an equivalent premedication 
regimen consistent with local docetaxel labeling, such premedic ation regimens will be permitted.
Gemcitabine/Cisplatin (Squamous histology only)
Participants will r eceive gemcitabine at a dose of 1000 mg/m2 or 1250 mg/m2(per local prescribing 
information) as a  30 minute or per local institutional standard  IV infusion on Days  1 and 8 followed 
by cisplatin at a dose of 75 mg/m2as a 120-minute or per institut ional standard IV infusion on 
Day 1 of a 3-week treatment cycle for up to 3 cycles. Prolonged gemcitabine infusions > 60 
minutes and/or administration more frequent than weekly has bee n associated with increased 
toxicity. Dosing calculations for gemcitabine should be based on the body  surface area calculation 
and may 
be capped per local standards . The dose may remain the same if the participant‚Äôs weight is w ithin 
10% of the baseline weight or prior dose weight.Doses of gemcitabine and/or cisplatin may be modified, delayed,  or discontinued depending on 
how well the participant tolerates the treatment. Dose modifica tions for toxicity will be performed 
according to Section 7.4.1 . Dose delay criteria can be found in  Section 7.4.2.2 , and discontinuation 
criteria can be found in Section 8.1.1.2 . Criteria to resume treatment can be fo und in 
Section 8.1.2.2 .
See below for the details regarding administration of cisplatin . 
Pemetrexed/Cisplatin (non-Squamous histology only)
Pemetrexed will be administered at a dose of 500 mg/m2as a 10 minute or per institutional standard 
IV infusion and cisplatin will be administered at a dose of 75 m g/m¬≤ as a 120-minute or per 
institutional standard IV infusion on Day  1 of a 3-wee k treatment cycle for up to 3 cycles. 
Dosing calculation for pemetrexed should be based on the body s urface area calculation and may 
be capped per local standards. The dose may remain the same if the participant‚Äôs weight is within 
10% of the baseline weight or prior dose weight. All doses should be rounded up or to the nearest 
milligram per institutional standard. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 77
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Doses of pemetrexed and/or cisplatin may be interrupted, delaye d, or disconti nued depending on 
how well the participant tolerates the treatment. Dose modifica tions for toxicity will be performed 
according to Section 7.4.1 . Dose delay criteria can be found in Section 7.4.2.2 , and discontinuation 
criteria can be found in Section 8.1.1.2 . Caution should be used when administering NSAIDs 
concurrently with pemetrexed t o patients with mild to moderate renal insufficiency (creatinine 
clearance from 45 t o 79 m L/min). Pemetrexed s hould not be ad ministered if the calculated  CrCl 
is < 45 mL/min. 
Premedications for use with pemetrexed: Oral corticosteroid should be given according to local 
standards at a dose equivalent to dexamethasone 4 mg twice dail y on the day pri or to, the day of, 
and the day after the administrati on of p emetrexed. Oral folic acid 350 to 1,000 mcg daily should  
be given starting approximately 1 week prior to the first dose of pemetrexed, with at least 5 doses 
of folic acid administered in the 7 days prior to the first dos e. Oral folic acid should be continued 
daily throughout the treatment with pemetrexed and for 21 days after the last dose of pemetrexed. 
Intramuscular (IM) injection of vitamin B12 1000 mcg should be giv en approximately 1 week 
prior to the first dose of pemetrexed. 
See below for the details regarding administration of cisplatin . 
Paclitaxel/Carboplatin
Paclitaxel will be administered at a dose of 175 or 200 mg/m2as a 180 minute or per institutional 
standard IV infusion and carboplatin will be administered at a dose of AUC 5 or 6 as a 30-minute 
or per institutional standard IV infusion on Day  1 of a 3-wee k treatment cycle for up to 3 cycles. 
Dosing calculations for paclitaxel s hould be based on the body surf ace area calculation and may 
be capped per local standards . The dose may remain the same if the participant‚Äôs weight is w ithin 
10% of the baseline weight or prior dose weight.Doses of paclitaxel and/or car boplatin may be modified, delayed, or discontinued depending on  
how well the participant tolerates the treatment. Dose modifica tions for toxicity will be performed 
according to Section 7.4.1 . Dose delay criteria can be found in Section 7.4.2.2 , and discontinuation 
criteria can be found in S ection 8.1.1.2 . Criteria to resume treatment can be fo und in 
Section 8.1.2.2 .
Premedications for use with paclitaxel: Oral or IV corticostero id should be given prior to p aclitaxel 
according to local standard. Such premedication may consist of oral dexamethasone 20 mg 
12 hours and 6 hours prior to paclitaxel administration. Oral or  IV diphenydramine  50 m g (or its 
equivalent) and an H2-blocker (per local standard of care) shou ld be administered 30 to 60 minutes 
prior to paclitaxel infusion. Antiemetic pr emedication will be administered according to local 
standards. Recommended antiemetic treatments are dex amethasone (dosing according to local 
standards; an equivalent dose of another corticosteroid may be substituted) and a 5-HT3 receptor 
antagonist (type per investigator discretion and local standard s of care). Additional use of 
antiemetic premedications may be e mployed at the discretion of the investigator per local standards 
of care.
Protocol Amendment No.: 07
Date: 18-Aug-2021 78
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
All participants should be carefully monitored for i nfusion r eactions during the paclitaxel 
administration. Participants should be treated in a facility wi th the necessary medical-resuscitation 
equipment and medications on hand to manage serious acute infus ion reactions.
See below for the details regarding administration of carboplat in. 
Cisplatin
Cisplatin 75 mg/m2as a 120 minute or per institutional standard IV infusion will be administered 
to participants as the second infusion. Dosing calculations for  cisplatin should be based on the 
body s urface area calculation and may be capped per local standards . The dose may remain the same 
if the participant‚Äôs weight is within 10% of the baseline weigh t or prior dose weight.
Pretreatment hydration for cisplatin can follow local standard of care or use 1 to 2 liters of fluid 
infused IV for 8 to 12 hours prior to cisplatin infusion is rec ommended. Adequate hydration and 
urinary output must be maintain ed for at least 24 hours followi ng cisplatin administration. 
Administration and monitoring should be performed according to local standards. Use of mannitol 
following the cis platin infusion s hould also follow local standards of care. 
All participants who will be r eceiving cisplatin  should have audiometric testing performed pr ior 
to initiation of therapy and prior to subsequent doses of cispl a ti n ,  a s  p e r  l o c a l  o r  i n s ti t u t i o n al  
standards of care. Participants considered to be at higher risk  for ototoxicity with cisplatin have 
the option to receive carboplatin-based chemotherapy reg imen after discussion with the Medical 
Monitor. 
For participants who are unable to tolerate cisplatin, the reas ons for intolerability should be 
documented. If the investigator would like to use a carboplatin -based regimen, the investigator 
should discuss this with and obtain approval from the Medical M onitor prior to utilization, except 
for opting for carboplatin plus paclitaxel. Carboplatin
Carboplatin will be administered at a dose of AUC 5 or 6 as a 3 0-minute or as per institutional 
standard IV in fusion, on Day 1 of each 3-week cycle.
Carboplatin s hould be given following gemcitabine, docetaxel, vinorelbine or pemetrexed on Day 
1 of each cycle, and the carboplatin dose will be calculated us ing the Calvert formula as follows:
‚Ä¢Carboplatin dose (mg) will be calculated using the Calvert form ula as follows = Target AUC 
x [(CrCl (mL/min) + 25]
‚Ä¢Creatinine clearance (CrCl) calcu lation is based on the Cockrof t-Gault formula and should 
include the most recent serum creatinine and most recent weight . NOTE: If calcu lation of the 
CrCl by the Cockroft-Gault formula yields a result of > 125 mL/ min, then a CrCl should be 
calculated by an alternative formula per institutional standard s or capped at 125 mL/min.
‚Ä¢The dose of carboplatin may be capped per local standards.
Protocol Amendment No.: 07
Date: 18-Aug-2021 79
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
For All Arms Containing Chemotherapy:  
Participants should begin study treatment within 7 calendar day s of randomization. Doses of 
chemotherapy may be interrupted, delayed, or discontinued depen ding on how well the 
participants tolerates the treatment. If a dose is d elayed for any reason, participants s hould be  dosed 
no later than 7 days following a planned dose on any arm. 
If more than 7 days delay is needed for any reason, the intende d dose should be skipped. If a 
participant receiving chemotherapy on a Day 1 a nd Day 8 schedule (ie, cisplatin/g emcitabine) is 
unable to receive Day 1 of chemotherapy but recovers in time to  receive the Day 8 dose, the Day 8 
dose of chemotherapy may be administered.Premedications: Antiemetic premedication will be administered a ccording to local standards. 
Recommended antiemetic treatments are dexamethasone (dosing acc ording to local standards; an 
equivalent dose of another corticosteroid may be substituted) a nd a 5-HT3 receptor antagonist 
(type per investigator discretion and local standards-of-care).  Additional use of antiemetic 
premedications may be employed at the discretion of the Investi gator.
7.2 Method of Treatment Assignment
CA209816 is an open-label, randomized trial. Participants with Stage IB ( ‚â•4 cm), II and IIIA (N2) 
considered resectable will be eligible to participate. After th e participant‚Äôs initial eligibility is 
established and informed consent has been obtained, the partici pant must be enrolled into the study 
by calling the IRT to obtain a participant number. Every participant that signs the informed consent 
form must be assigned a participant number in IRT. Specific ins tructions for using IRT will be 
provided to the investigational site in a separate document. Th e investigator or designee will 
register the participant for enrollment by followi ng the enrollment procedures established by BMS.
The following information is required for enrollment:
‚Ä¢Date that informed consent was obtained
‚Ä¢Date of birth, where applicable by local regulations
‚Ä¢Gender at birth
Once enrolled in IRT, enrolled participants who have met all el igibility criteria will be ready to be 
randomized through IRT. PD-L1 expression data will be transferr ed directl y from analyzi ng lab to 
IRT. The following information is required for part icipant rand omization:
‚Ä¢Participant number
‚Ä¢Date of birth, where applicable per local regulations
‚Ä¢Stage of disease (IB, IIA, IIB or IIIA)
‚Ä¢PD-L1 status
‚Ä¢Gender
Protocol Amendment No.: 07
Date: 18-Aug-2021 80
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Participants meeting all eligibility criteria w ill be stratif ied according to PD-L1 status into 
2 categories ( ‚â•1% and < 1% or not evaluable/indeterminate). Enrollment of part icipants with not 
evaluable or indeterminate PD-L1 status will be capped at 10%. Participants will also be stratified 
based disease stage (IB/II vs IIIA) and gender.
The exact procedures for using the IRT will be detailed in the IRT manual.
7.3 Blinding
This is an open-label study; blinding procedures between partic ipants and investigators are not 
applicable. The BIPR and BICR will be blinded.  
7.4 Dosage Modification
7.4.1 Dose Reductions for Platinum Doublet Chemotherapy 
Dose reductions of platinum doublet chemotherapy may be require d and will be performed 
according to Table 7.4.1-1 . Chemotherapy dose reductions a re permanent; once the dose of any 
chemotherapy agent is reduced, it may not be re-escalated in su bsequent cycles. The dose 
reductions for each agent in the platinum doublet chemotherapy regimen are not linked and may 
be adjusted independently as summarized below.
Protocol Amendment No.: 07
Date: 18-Aug-2021 81
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 7.4.1-1: Dose Modifications of Chemotherapeutic Agentsa
Dose Level Vinorelbine Docetaxel Gemcitabine Pemetrexed Cisplatin Car boplatin Paclitaxel
Starting dose25mg/m2or 
30 mg/m260 mg/mg2or 
75 mg/m21000 mg/m¬≤  or 
1250 mg/m¬≤ 500 mg/m¬≤ 75 mg/m¬≤ AUC 5 or 6 175 or 200 mg/m¬≤
First dose reduction75% of 
starting dose75% of starting 
dose75% of starting 
dose75% of starting 
dose75% of 
starting doseAUC 4 or 5 150 mg/m¬≤
Second dose reduction50% of the 
starting dose50% of starting 
dose50% of the 
starting dose50% of the 
starting dose50% of the 
starting doseAUC 3 or 4 100 mg/m¬≤
Third dose reduction Discontinue Discontinue Discontinue Discontinu e Discontinue Discontinue Discontinue
aFollow local regulations if they are different than what appears in this table. 
Any participants with 2 prior dose reductions for 1 agent who ex periences a toxicity that would cause a third dose reduction mu st be 
discontinued from that agent.
Protocol Amendment No.: 07
Date: 18-Aug-2021 82
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
7.4.1.1 Platinum Doublet Chemotherapy - Dose Reductions for Hematologic 
Toxicity
Dose modifications for hematologic toxicities (according to CTC AE version 4) are summarized in 
Table 7.4.1.1-1 . Dose adjustments are based on nadir blood counts (assessed as  per local standards) 
since the preceding drug administration. Dose level adjustments  for platinum doublet 
chemotherapy are relative to that of the preceding administrati on. Generally, both chemotherapy 
agents in the platinum doublet chemotherapy regimen should be d ose reduced together for 
hematologic toxicity. After the  first cycle, growth factors may  be used to assist hematologic 
recovery. Use local standards of care in the use of these suppo rtive measures. Additionally, 
prophylactic antibiotics may be used according to local standar ds of care. Please report any 
antibiotic or growth factor use on the eCRF.
Protocol Amendment No.: 07
Date: 18-Aug-2021 83
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 7.4.1.1-1: Dose Modifications for Hematologic Toxicity (ba sed on Nadir Counts)a
Toxicity Vinorelbine Gemcitabine Pemetrexed Cisplatin Carboplatin Pac lixatel
Neutrophil Count Decreased
Grade 4
(< 500/mm3or
< 0.5 x 109/L)Reduce one dose 
level and consider 
prophylactic 
G-CSF in 
subsequent cyclesReduce one dose 
level and consider 
prophylactic 
G-CSF in 
subsequent cyclesReduce one dose 
level and 
consider 
prophylactic 
G-CSF in 
subsequent 
cyclesReduce one dose 
level and 
consider 
prophylactic 
G-CSF in 
subsequent 
cyclesReduce one dose 
level and consider 
prophylactic 
G-CSF in 
subsequent cyclesReduce one dose 
level and consider 
prophylactic G-CSF 
in subsequent cycles
Platelet Count Decreased
Grade 3
(25,000 to < 50,000/mm3; 
25.0 to < 50.0 x 109/L)Reduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
level
Grade 4
(< 25,000/mm3;
< 25.0 x 109/L)Reduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
level
Hemoglobin
Grade 2
(< 10.0 to 8.0 g/dL; 
< 6.2 to 4.9 mmol/L;
< 100 - 80 g/L)Reduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
level
Grade 3 (< 8.0 g/dL;
< 4.9 mmol/L, < 80 g/L)Reduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
level
Grade 4
(Life threatening 
consequences)Hold drug Hold drug Hold drug Hold Drug Hold Drug Hold Drug
aIf local standard for dose adjustments differ from those outlined, please discuss with the Medical Monitor. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 84
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Dose Modifications for Hematologic Toxicity for Docetaxel: Doses of docetaxel will be 
modified for participants who experience docetaxel-related even ts of febrile neutropenia, 
neutrophils < 500 cell/mm ¬≥ for > 7 days during docetaxel treatment. Participants should ha ve 
treatment delayed according to  Section 7.4.2.3 and then resumed at 1 dose level reduction (75% 
of starting dose). Should these AEs occur after the first dose reduction, then a second dose 
reduction to (50% of starting dose) is permitted. If a third do se reduction is required, then the 
participants should discontinue docetaxel treatment. 
7.4.1.2 Platinum Doublet Chemotherapy - Dose Reductions for Non-
Hematologic Toxicities
Dose adjustments for platinum doublet chemotherapy for non-hema tologic toxicities during 
treatment are described in Table 7.4.1.2-1 . All dose reductions should be made based on the worst 
grade toxicity. Participants experiencing any of the toxicities  detailed in Table 7.4.1.2-1 during the 
previous cycle should have their chemotherapy delayed until ret reatment criteria are met (per 
Section 8.1.2.2 ) and then reduced for all subsequent cy cles by 1 dose level or discontinued as 
appropriate. Dose levels for the 2 drugs in the platinum-double t chemotherapy regimen are not 
linked and may be reduced independently, as summarized in Table 7.4.1.2-1 .
Protocol Amendment No.: 07
Date: 18-Aug-2021 85
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 7.4.1.2-1: Dose Modifications for Non-hematologic Toxicitya,b
Toxicity Vinorelbine Gemcitabine Pemetrexed Cisplatin Carboplatin Pac litaxel
Febrile Neutropenia
Grade ‚â•3Reduce one 
dose levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
levelReduce one dose 
level
Diarrhea Grade ‚â•3Reduce one 
dose levelReduce one dose 
levelReduce one dose 
levelNo change No changeReduce one dose 
level
Allergic reactionc
Grade ‚â•3Reduce one 
dose levelDiscontinue Discontinue Discontinue Discontinue Discontinue
Neuropathy
Grade 2No Change No change No changeReduce one dose 
leveld No changeReduce one dose 
level
Neuropathy
Grade ‚â•3Discontinue Discontinue Discontinue Discontinue Discontinue Discontinue
Calculated creatinine 
clearance
< 50 mL/minNo change No changeDiscontinue if 
creatinine 
clearance < 45 
mL/minDiscontinueDiscontinue if 
creatinine 
clearance 
< 20 mL/minNo change
Other Grade ‚â•‚â•3toxicity 
(except for fatigue and transient 
arthralgia and myalgia)Adjust as 
medically 
indicatedAdjust as 
medically 
indicatedAdjust as 
medically 
indicatedAdjust as 
medically 
indicatedAdjust as
medically 
indicatedAdjust as 
medically indicated
aIf local standard for dose adjustments differ from those outlined, please discuss with the Medical Monitor.
bPlease see local drug label for additional adjustments. 
cOnly the drug(s) causing the hypersensitivity reaction or acute infusion reaction ( ‚â•Grade 3) require(s) discontinuation. All other drugs may be continued.
dWhen given with pemetrexed, cisplatin should be reduced 2 dose levels (ie, by 50% for Grade 2 neuropathy. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 86
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Participants receiving docetaxel who develop Grade ‚â•3 peripheral neuropathy, or who otherwise 
meet criteria specified in Section 8.1.1.3 , should discontinue docetaxel treatment.
Dose Modifications for Non-hematologic Toxicity for Docetaxel: Doses of docetaxel w ill be 
modified for participants who experience docetaxel-related even ts of severe or cumulative 
cutaneous reactions or other Grade 3/4 non-hematological toxici ties during docetaxel treatment. 
Participants shoul d have tr eatment delayed according to Section 7.4.2.3 and then resumed at 1 dose 
level reduction (75% of starting dose). Should these AEs occur after the first dose reduction, then 
a second dose reduction to (50% of star ting dose) is permitted.  If a third dose redu ction is required, 
then the participants should discontinue docetaxel treatment. 
7.4.2 Dose Delay
If any agent is delayed > 7 days, the dose should be skipped, a nd the participant should resume 
treatment at the next scheduled dose if criteria to resume trea tment ( Secti on 8.1.2 ) for the 
appropriate arm are met. If the last dose of study drug is dela yed >7 but < 11 days, while it is 
recommended that this dose be skipped, if the investigator feel s that it is appropriate to administer 
the last dose, discuss with the Medical Monitor before administ ering the last dose of study drug.
7.4.2.1 Nivolumab Dose Delay CriteriaNivolumab administration should be delayed for the following:
‚Ä¢Grade 2 non-skin, drug-related adverse event, with the exceptio n of fatigue
‚Ä¢Grade 2 drug-related creatinine, AST, ALT and/or Total Bilirubi n abnormalities
‚Ä¢Grade 3 skin, drug-related adverse event
‚Ä¢Grade 3 drug-related laboratory abnormality, with the following  exceptions: 
‚àíGrade 3 lymphopenia or asymptomatic amylase or lipase does not require dose delay
‚àíGrade ‚â•3 AST, ALT, Total Bilirubin will require dose discontinuation ( see 
Section 8.1.1.1 )
‚Ä¢Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying the dose of study medicatio n.
Participants who require delay of nivolumab should be re-evalua ted weekly or more frequently if 
clinically indicated and resume nivolumab dosing when re-treatm ent criteria are met.
7.4.2.2 Dose Delay Criteria for Platinum Doublet Chemotherapy
Dosing of both drugs in the platinum doublet chemotherapy regim en selected should be delayed 
for any of the following on the Day  1 of eac h cycle: 
‚Ä¢Absolute neutrophil count (ANC) ‚â§1500/ŒºL 
‚Ä¢Platelets  < 100,000/mm
3 
‚Ä¢Any Grade ‚â•2 non-skin, non-hematologic, drug-related adverse event (exclud ing Grade 2 
alopecia, Grade 2 fatigue, and Gra de 2 laboratory abnormalities ) 
‚Ä¢Any Grade ‚â•3 skin, drug-related adverse event 
Protocol Amendment No.: 07
Date: 18-Aug-2021 87
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢Any Grade ‚â•3 drug-related laboratory abnormality, with the following excep tions for 
lymphopenia, AST, ALT, or total bilirubin: 
‚àíGrade 3 lymphopenia does not require dose delay. 
‚àíIf a participant has a bas eline AST, ALT or total bilirubin that is within normal limits,  delay 
dosing for drug-related Grade ‚â•2 toxicity. 
‚àíIf a participant has baseline AST, ALT, or total bilirubin with in the Grade 1 toxicity range, 
delay dosing for drug-related Grade ‚â•3 toxicity. 
Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of the 
investigator, warrants delaying the dose of study medication. I nvestigators should consult local 
labeling for the chemotherapy drugs being administered to any g iven participant for additional 
guidance on dose delays. Participants receiving gemcitabine wit h cisplatin or carboplatin should 
omit the Day 8 gemcitabine dose for any of the following on Day  8 of any cy cle:
‚Ä¢ANC < 1,000/mm3
‚Ä¢Platelets <  75,000/mm3
If any non-hematologic adverse event meeting the dose delay cri teria above is felt to be related to 
only 1 particular agent in the platinum doublet chemotherapy re gimen, then that agent alone may 
be omitted for that cycle while the other agent is given. In or der to maintain synchronized dosing 
of the regimen, the omitted agent should be resumed with the ne xt scheduled cycle once the AE 
has improved and retreatment criteria are met. Please refer to  Section 7.4.1 to determine if dose 
reduction of the resumed agent is required. 
If both drugs in the platinum doublet chemotherapy regimen are d elayed, then the participant 
should be re-evaluated weekly  or more frequently if clinically indicated until re-treatment criteria 
are met (as per Section 8.1.2.2 or Section 8.1.2.3 ).
7.4.2.3 Docetaxel Dose Delay Criteria
Docetaxel administration should be delayed for the following:
‚Ä¢Any Grade ‚â•2 non-skin, drug-related adverse event, with the following exce ptions:
‚àíGrade 2 drug-related fatigue or l aboratory abnormalities do not require a treatment delay
‚Ä¢Any Grade 3 skin, drug-related adverse event
‚Ä¢Any Grade 3 drug-related laboratory abnormality, with the follo wing exceptions for 
lymphopenia, neutrophil count, AST, ALT, or total bilirubin:
‚àíGrade 3 lymphopenia does not require dose delay
‚àíShould not be given if neutroph il counts are < 1500 cells/mm3
‚àíShoul d not be given if total bilirubin > upper limit of normal (ULN) , or if AST and/or ALT 
> 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN
Protocol Amendment No.: 07
Date: 18-Aug-2021 88
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢Any AE, laboratory abnormality or inter-current illness which, in the judgment of the 
investigator, warrants delaying the dose of study medication
Subsequent dose reductions may be required as per  Section 7.4.1 .
Participants receiving docetaxel may receive growth factors (in cluding G-CSF and erythropoietin) 
at the discretion of the investigator.
7.4.3 Treatment of Nivolumab- and Ipilimumab-related Infusion Reactions
Since nivolumab and ipilimumab contain only human immunoglobuli n protein sequences, they are 
unlikely to be immunogenic and induce infusion or hypersensitiv ity reactions. However, if such a 
reaction were to occur, it might manifest with fever, chills, r igors, headache, rash, pruritus, 
arthralgias, hypotension, hypertension, bronchospasm, or other allergic-like reactions. All Grade 3 
or 4 infusion r eactions should be reported wit hin 24 hours to the study Medica l Monitor and 
reported as an SAE if it meets t he criteria. Infus ion reactions  should be graded according to NCI 
CTCAE (Version 4) guidelines.
Treatment recommendations are provided below and may be modifie d based on local treatment 
standards and guidelines, as appropriate:For Grade 1 symptoms: (mild reaction; i nfusion interruption not indicated; intervention not 
indicated):
‚Ä¢Remain at bedside and monitor participant until recovery from s ymptoms. The following 
prophylactic prem edications are recomme nded for future i nfusions: diphe nhydramine 50 mg 
(or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg  at least 30 minutes before 
additional nivolumab administrations.
For Grade 2 symptoms: (moderate reaction required therapy or in fusion interruption but responds 
promptly to symptomatic treatment (eg, antihis tamines, non-steroidal anti-inflammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids); prophylactic medications indicated for 
‚â§24 hours):
‚Ä¢Stop the nivolumab/ipilimumab infusio n, begin an IV infusion of normal saline, and treat the 
participant with diphenhydramine 50 mg IV (or equivalent) and/o r 
acetaminophen/paracetamol 325 to 1000 mg; remain at bedside and monitor participant until 
resolution of symptoms. Corticosteroid and/or bronchodilator th erapy may also be 
administered as appropriate. If the infusion is inte rrupted, then restart the i nfusion at 50% of 
the original infusion rate when symptoms resolve; if no further  complications ensue after 
30 minutes, the rate may be increased to 100% of the original in fusion rate. Monitor participant 
closely. If symptoms recur, the n no further nivolumab will be administered at that visit.
‚Ä¢For future infusions, the following prophylactic premedications are recommended: 
diphenhydramine 50 mg (or equi valent) and/or acetaminophen/para cetamol 325 to  1000 mg 
should be administered at least 30 minutes before nivolumab inf usions. If necessary, 
corticosteroids (up to 25 m g of hydrocortisone or equiv alent) may be used.
Protocol Amendment No.: 07
Date: 18-Aug-2021 89
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
For Grade 3 or 4 symptoms: (sev ere reaction, Grade 3: prolonged  [ie, not rapidly responsive to 
symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms following 
initial improv ement; hospi talization ind icated for other clinical sequelae (eg, renal impairment, 
pulmonary infiltrates). Grade 4: Life-threatening; pressor or v entilatory support indicated):
‚Ä¢Immediately discontinue infusion of nivolumab/ipilimumab. Begin  an IV infusion of normal 
saline and treat the participant as follows: Recommend bronchodilators, epinephrine 0.2 to 
1 mg of a 1:1000 solution for subcutaneous administration or 0.1  to 0.25 mg of a 
1:10,000 solution injected slowly for IV administration, and/or diphenhydramine 50 mg IV 
with methylprednisolone 100 mg I V (or equivalent), as needed. P articipant should be 
monitored until the Investigator is  comfortable that the symptoms will not recur. Nivolumab 
will be permanently discontinued. Investigators should follow t heir institutional guidelines for 
the treatment of anaphylaxis. Rema in at bedside and monitor par ticipant until recovery of the 
symptoms.
In case of late-occurring hypersen sitivity symptoms (eg, appear ance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral 
antihistamine or corticosteroids).
7.5 Preparation/Handling/Storage/Accountability
The investigational product should be stored in a secure area a ccording to local regulations. It is 
the responsibility of the investigator to ensure that investiga tional product is only dispensed to 
study participants. The investigational product must be dispens ed only from official study sites by 
authorized personnel according to local regulations.
The product storage manager should ensure that the study treatm ent is stored in accordance with 
the environmental conditions (temperature, light, and humidity)  as determined by BMS. If 
concerns regarding the quality or appearance of the study treat ment arise, the study tr eatment 
should not be dispensed and contact BMS immediately.Study treatment not supplied by BMS will be stored in accordanc e with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained that 
includes all processes required to ensure drug is accurately ad ministered. This includes 
documentation of drug storage, administration a nd, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).Handling of chemotherapy should be according to local prescribi ng information.  
Please refer to the current ve rsion of the Investigator Brochur es (IBs) and/or the Pharmacy Manual 
for complete storage, handling, and preparation information. Fu rther guidance and information for 
final disposition of unused study treatment are provided in Appendix 7 and the Pharmacy Manual. 
7.5.1 Retained Samples for Bioavailability / Bioequivalence
At the time of receipt of the investigational product by the in vestigator or designee‚Äôs, BMS will 
specify the appropriate number of containers or units to select for retention, the conditions of 
sample storage, required duration of sample retention, and prov isions for returning or disposing of 
Protocol Amendment No.: 07
Date: 18-Aug-2021 90
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
the investigational product. When samples are selected, contain ers or units should be placed in 
packaging with a tamper evide nt seal provided by B MS. Package l abeling should clearly identify 
the contents as bioavailability/bioequivalence (BA/BE) samples and state that the investigational 
product should be stored in the restricted area with limited ac cess.
7.6 Treatment Compliance
Treatment compliance will be monitored by drug accountability a s well as the participant‚Äôs 
medical record and eCRF.
7.7 Concomitant Therapy
7.7.1 Prohibited and/or Restricted Treatments
The following medications are prohibited during the study (unle ss utilized to treat a drug related 
adverse event):
‚Ä¢Immunosuppressive agents
‚Ä¢Immunosuppressive doses of systemic corticosteroids (except as stated in Section 7.7.3 )
‚Ä¢Any concurrent anti-neoplastic therapy (ie, chemotherapy, hormo nal therapy, immunotherapy, 
extensive, non-p alliative rad iation therapy , or standa rd or investigational agents for treatment 
of NSCLC)
‚Ä¢Investigators should refer to the local product labeling for th e chemotherapy drugs selected for 
use in Arm B and Arm C and for additional prohibited and restricted concomitant medications.
‚Ä¢Caution should be used regarding the use of herbal medication, as there may be as yet unknown 
interactions with nivolumab and ipilimumab. Discontinuation of the use of herbal medications 
prior to the study enrollment is encouraged.  
‚Ä¢Live vaccines (eg, yellow fever, MMR, nasal flu vaccine, chicke n pox [varicella]) should be 
avoided while receiving neoadjuvant or adjuvant study drug
‚Ä¢Avoid using concomitant strong CYP3A4 inhibitors or inducers wi th docetaxel, vinorelbine, 
or paclitaxel. Avoid using concomitant strong CYP2C8 inhibitors  or inducers with paclitaxel.  
Consult the local prescribing information for further guidance.  
‚Ä¢Avoid the concomitant administration of substances that are also  tubularly secreted (eg, 
probenecid) which could potentially result in delayed clearance of pemetrexed.
7.7.2 Other Restrictions and Precautions
Participants with a c ondition requiri ng systemic tr eatment with either corticosteroids (> 10 mg 
daily prednisone equivalent) or other immunosuppressive medicat ions within 14 days of 
randomization are excluded. Inhaled or topical steroids, and ad renal replacement steroid doses 
> 10 mg daily prednisone equivalent, are permitted in the absenc e of active autoimmune disease.
It is the local imaging facility‚Äôs responsibility to determine, based on particip ants attributes 
(eg, allergy history, diabetic history and renal s tatus), the appropr iate imaging mod ality and 
contrast regimen for each participant. Imaging contraindication s and contrast risks should be 
considered in this assessment. Participants with renal insufficiency should be assessed as to 
whether or not t hey shoul d receive contrast and if so, what type and dose of contrast is appropriate. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 91
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Specific to MRI, participants with severe renal insufficiency ( ie, estimated glomerular filtration 
rate [eGFR] < 3 0 mL/min/1.73 m2) are at increased risk of nephrogenic systemic fibrosis. MRI 
contrast should not be given to this population. In addition, pa rticipants are excluded from MRI if 
they have tattoos, metallic implants, pacemakers, etc. The ulti mate decision to perform MRI in an 
individual participant in this study rests with the site radiol ogist, the investigator, and the standard 
set by the local Ethics Committee.
7.7.3 Permitted Therapy
Participants are permitted the use of topical, ocular, intra-ar ticular, intranasal, and inhalational 
corticosteroids (with minimal systemic abs orption). Adrenal replacement steroid doses > 10 mg 
daily prednisone are permitted. A brief (less than 3 weeks) cou rse of corticosteroids for 
prophylaxis (eg, contrast dye allergy) or for treatment of non- autoimmune conditions 
(eg, delayed-type hypersensitivity r eaction cause d by a contact allergen) is permitted.
7.8 Treatment After the End of the StudyAt the end of the study period, BMS w ill not continue t o provide BMS supplied study treatment 
to participants/investigators unless BMS chooses to extend the study. The investigator should 
ensure that the participant receives appropriate standard of ca re lung cancer treatment.
8 DISCONTINUATION CRITERIA8.1 Discontinuation from Study Treatment
Participants MUST discontinue  investigational product (and non- investigational product at the 
discretion of the investigator) for a ny of the following reasons:
‚Ä¢Participant‚Äôs request to stop study tr eatment. Par ticipants who request to discontinue study 
treatment w ill remain in the study and must continue to be followed for pr otocol specified 
follow-up procedures. The only exception to this is when a part icipant specifically withdraws 
consent for any further contact with him/her or persons previously authorized by participant to 
provide this i nformation. Participant should notify the investigator of the d ecision to withdraw 
from future follow-up in writing, whenever possible, and this s hould be documented in the 
medical records.
‚Ä¢Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the opinion of the investigator, indicates that continued participat ion in the study is not in the best 
interest of the participant
‚Ä¢Termination of the study by Bristol-Myers Squibb Company (BMS)
‚Ä¢Loss of ability to fr eely provide consent through imprisonment or involuntarily inca rceration 
for treatment of either a psychiatric or physical (eg, infectious disease) illness
Refer to the Schedule of Activities for data to be collected at  the time of neoad juvant treatment 
discontinuation and subsequent study procedures and for any fur ther evaluations that can be 
completed.
In the case of pregnancy, the investigator must immediately not ify the BMS Medical 
Monitor/designee of this event. In the event a normal healthy f emale participant becomes pregnant 
Protocol Amendment No.: 07
Date: 18-Aug-2021 92
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
during a clinical trial, the study treatment must be discontinu ed immediately. In most cases, the 
study treatment w ill be permanently discontinued in an appropri ate manner (eg, dose tapering if 
necessary for participant safety). Please call the BMS Medical Monitor within 24 hours of 
awareness of the pregnancy. If the investigator d etermines a possible favorable benefit/risk ratio 
that warrants continuation of study treatment, a discussion bet ween the investigator and the BMS 
Medical Monitor/designee must occur.
All participants who discontinue study treatment should comply w ith protocol specified 
procedures as outlined in Section 2 . The only exception to this requirement is when a participant 
withdraws consent for all study procedures including post-treatm ent study follow-up or loses the 
ability to consent fr eely (ie, is imprisoned or involuntarily i ncarcerated for the treatment of either 
a psychiatric or physical illness).
If study treatment is disconti nued prior to the participant‚Äôs c ompletion of the study, the reason for 
the discontinuation must be documented in the participant‚Äôs med ical records and en tered on the 
appropriate case report form (CRF) page.8.1.1 Study Treatment Discontinuation Criteria
Doses that are missed or delayed by > 7 days will not be replace d, and participants should proceed 
to surgery within the indicated timelines. Participants who dis continue their assigned study 
treatment pr ematurely will not be allowed to receive subsequent n eoadjuvant therapy, and 
participants should proceed to surgery within the indicated tim elines.
In Arm C, nivolumab and platinum doublet chemotherapy can be di scontinued independently 
based on their discontinuation criteria.  
8.1.1.1 Nivolumab Discontinuation Criteria
Nivolumab treatment should be permanently discontinued for the following:
‚Ä¢Any Grade 2 drug-related uveitis, eye pain or blurred vision th at does not respond to topical 
therapy and does not improve to Grade 1 severity within the re- treatment period OR requires 
systemic treatment
‚Ä¢Any Grade 3 non-ski n, drug-related adve rse event lasting > 7 days, or recurs with the following 
exceptions for laboratory abnormalities, diarrhea, colitis, neu rologic toxicity, drug-related 
uveitis, pneumonitis, bronchospasm, hypersensitivity reactions,  infusion reactions, and 
endocrinopathies:
‚àíGrade 3 drug-related diarrhea, colitis, neurologic toxicity, uv eitis, pneumonitis, 
bronchospasm, hypersensitivity reaction, or infusion r eaction of any duration requires 
discontinuation
‚àíGrade 3 drug-related endocrinopathies, adequately controlled wit h only physiologic 
hormone replacement do not require d iscontinuation. Adrenal ins ufficiency requires 
discontinuation regardless of  control with hormone replacement.  
Protocol Amendment No.: 07
Date: 18-Aug-2021 93
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚àíGrade 3 drug-related laboratory a bnormalities do not require treatment discontinuation 
except:
‚ô¶Grade 3 drug-related thrombocytopenia > 7 days or associated wi th bleeding requires 
discontinuation
‚ô¶Any drug-related liver function test (LFT) abnormality that mee ts the following criteria 
require discontinuation:
oGrade ‚â•3 drug-related AST, ALT or Total B ilirubin requires discontinua tion*
‚Ä¢* In most cases of Grade 3 AST or ALT elevation, study drug(s) will be permanently 
discontinued. If the investigator determines a possible favorab le benefit/risk ratio that warrants 
continuation of study drug(s), a discussion between the investi gator and the BMS Medical 
Monitor/designee must occur.
oConcurrent AST or ALT > 3 x ULN and total bilirubin > 2x ULN
‚Ä¢Any Grade 4 drug-related adverse event or laboratory abnormalit y (including but not limited 
to creatinine, AST, ALT, or Total Bilirubin), except for the fo llowing events which do not 
require discontinuation:‚àíGrade 4 neutropenia ‚â§7 days
‚àíGrade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase
‚àíIsolated Grade 4 electroly te imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 hours 
of their onset
‚àíGrade 4 drug-related endocrinopathy adverse events, such as, hy per- or hypothyroidism, 
or glucose intolerance, which resolve or are adequately control led with physiologic 
hormone rep lacement (corticosteroids, thyroid hormones) or gluc ose-controlling agents, 
respectively, may not require discontinuation afte r discussion with an d approval from the 
BMS Medical Monitor.
‚Ä¢Any event that leads to delay in dosing of any study drug for > 6 weeks from the previous dose 
requires discontinuation of that drug(s) with the following exception:
‚àíDosing delays lasting > 6 weeks from the previous dose that occur for non-drug-related 
reasons may be allowed if approved by the BMS med ical monit or. Prior to re-initiating 
treatment in a par ticipant with a dosing delay lasting > 6 weeks, the BMS Medical  Monitor 
must be consulted. Periodic study visits to assess safety and laboratory studies should also 
continue every 6 weeks or more frequently if clinically indicat ed during such dosing 
delays.
‚Ä¢Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the p articipant with continued nivolumab 
dosing.
8.1.1.2 Platinum Doublet Chemotherapy Dose Discontinuation
Except where specified below, both chemotherapy drugs in the pl atinum doublet chemotherapy 
regimen should be discontinued for any of the following:
‚Ä¢Any Grade ‚â•3 peripheral neuropathy
Protocol Amendment No.: 07
Date: 18-Aug-2021 94
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢Grade ‚â•3 drug-related thrombocytopenia a ssociated with clinically significant bleeding
‚Ä¢Any drug-related liver function test (LFT) abnormality that mee ts the following criteria 
requires discontinuation:
‚àíAST or ALT > 5-10x ULN for > 2 weeks
‚àíAST or ALT > 10x ULN
‚àíTotal bilirubin > 5 x ULN
‚àíConcurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN
‚Ä¢Any cisplatin-related decrease in creatinine clearance to < 50 mL/min (using the Cockroft 
Gault formula) requires discontinuation of cisplatin. The other  chemotherapeutic agent may be 
continued, and the platinum agent may be switched to carboplati n, the investigator should 
discuss this with and obtain approval from the Medical Monitor prior to switch.
‚Ä¢Pemetrexed s hould be disc ontinued when creatinine clearance to < 45 mL/min (using the 
Cockroft Gault formula)
‚Ä¢Any drug-related adverse event which recurs after 2 prior dose reductions for the same 
drug-related adverse event (as specified in Section 7.4.1.1 and Section 7.4.1.2 ) requires 
discontinuation of the drug(s) which was/were previously dose r educed.
‚Ä¢Any Grade ‚â•3 drug-related hypersensi tivity reaction or i nfusion r eaction requires 
discontinuation of the drug(s) felt to be causing the reaction.  The drug not felt to be related to 
the hypersensitivity r eaction or infusion reaction may be continued.
‚Ä¢Any Grade 4 drug-related adverse event which the investigator d eems is inappropriate to be 
managed by dose reduction(s) requires discontinuation of the dr ug(s) felt to be causing the 
event. The drug not felt to be related to the event may be cont inued.
‚Ä¢Any event that leads to delay in dosing of any study drug(s) for > 6 weeks from the previous 
dose requires discontinuation of that drug(s) with the followin g exception:
‚àíDosing delays lasting > 6 weeks from the previous dose that occ ur for non-drug-related 
reasons may be allowed if approved by the BMS med ical monit or. Prior to re-initiating 
treatment i n a participant with a  dosing delay lasting > 6 weeks, the BMS Medical Monitor 
must be consulted. Periodic study visits to assess safety and l aboratory studies should also 
continue every 6 weeks or more frequently if clinically indicat ed during such dosing 
delays.
‚Ä¢Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the participant with continued platinum 
doublet chemoth erapy dosing. Investigators should consult local  labeling for the chemotherapy 
drugs being administered to any given participant for additiona l guidance on dose 
discontinuation.
For participants in Arms C, if the investigator is unable to determine whether an adverse event is 
due to nivolumab or to platinum doublet chemotherapy, then all drugs must be discontinued.
Protocol Amendment No.: 07
Date: 18-Aug-2021 95
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
8.1.1.3 Docetaxel Dose Discontinuation
Docetaxel treatment should be permanently discontinued for the following:
‚Ä¢Any ‚â•Grade 3 peripheral neuropathy
‚Ä¢Any Grade 3 non-skin, drug-related adverse event lasting > 7 da ys, with the following 
exceptions for laboratory abnormalities:
‚àíGrade 3 drug-related laboratory a bnormalities do not require treatment discontinuation 
except‚ô¶Grade 3 drug-related thrombocytopenia associated with bleeding requires 
discontinuation.
‚ô¶Any drug-related liver function test (LFT) abnormalities that m eets the following 
criteria require discontinuation: 
oAST or ALT > 5 - 10x ULN for > 2 weeks
oAST or ALT > 10x ULN
oTotal bilirubin > 5x ULN
oConcurrent AST or ALT > 3x ULN and total bilirubin > 2x ULN
‚Ä¢Any Grade 4 drug-related adverse event including laboratory abn ormalities except for the 
following events which do not require discontinuation:
‚àíGrade 4 neutropenia >7 days despite 2 prior docetaxel reductions requires discontinuation
‚àíGrade 4 lymphopenia or leukopenia does not require discontinuat ion
‚àíIsolated Grade 4 electroly te imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 hours 
of their onset does not require discontinuation.
‚Ä¢Any dosing interruption lasting > 6 weeks with the following ex ceptions:
‚àíDosing interruptions > 6 weeks that occur for non -drug-related reasons may be allowed if 
approved by the BMS Medical Monitor/Study Dir ector. Prior to re-initiating treatment in 
a participant with a dosing interruption lasting > 6 weeks, the  BMS Medical Monitor/Study 
Director must be consulted. Tumor assessments should continue a s per protocol even if 
dosing is interrupted. 
8.1.2 Criteria to Resume Treatment
8.1.2.1 Criteria to Resume Nivolumab Treatment
Participants may resume treatment with study drug when the drug -related AE(s) resolve to 
Grade‚â§1 or baseline value, with the following exceptions:
‚Ä¢Participants may resume treatm ent in the presence of Grade 2 fa tigue
‚Ä¢Participants who have not experienced a Grade 3 drug-related sk in AE may resume treatment 
in the presence of Grade 2 skin toxicity
‚Ä¢For participants with Grade 2 AST, ALT and/or Total Bilirubin A bnormalities, dosing may 
resume when laboratory values return to baseline and management  with corticosteroids, if 
needed, is complete.
Protocol Amendment No.: 07
Date: 18-Aug-2021 96
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢Participants with combined G rade 2 AST/ALT AND total bilirubin values meeting 
discontinuation parameters ( Section 8.1.1.1) should have treatment permanently discontinued. 
‚Ä¢Drug-related pulmonary tox icity, dia rrhea or colitis must have resolved to baseline before 
treatment is resumed. Participants with persistent Grade 1 pneu monitis after completion of a 
steroid taper over at least 1 month may be eligible for retreat ment if discussed with and 
approved by BMS Medical Monitor.
Participants with drug-related endocrinopathies adequately cont rolled with only  physiologic 
hormone replacement may resume treatment after consultation wit h the BMS Medical Monitor. 
Please refer to the Management Algorithms in Appendix 4. 
8.1.2.2 Criteria to Resume Platinum Doublet Chemotherapy Dosing
‚Ä¢Participants may resume treatment with platinum doublet chemoth erapy when the ANC returns 
to ‚â•1500/ŒºL, the platelet count returns to ‚â•100,000/mm3, and all other drug-related toxicities 
have returned to baseline or Grade ‚â§1 (or Grade ‚â§2 for alopecia and fatigue)
‚Ä¢If a participant f ails to meet criteria for reinitiating tr eatment, then treatment shoul d be delayed, 
and the participant should be re-evaluated weekly or more frequ ently as clinically indicated
‚Ä¢When resuming platinum doublet chemoth erapy treatment, p lease follow the dose reduction 
recommendations in Section 7.4.1
8.1.2.3 Criteria to Resume Treatment with Docetaxel
Participants may resume treatment with docetaxel when the drug- related AE(s) resolve(s) to 
Grade‚â§1 or baseline, with the following exceptions:
‚Ä¢Participants may resume treatm ent in the presence of Grade 2 fa tigue 
‚Ä¢Participants who have not experienced a Grade 3 drug-related sk in AE may resume treatment 
in the presence of Grade 2 skin toxicity 
‚Ä¢Participants with decreased neutrophil counts, or with elevatio ns in total bilirubin, AST or ALT 
must meet criteria for resuming treatment according to the boxe d warning contained within the 
docetaxel Prescribing Information
‚Ä¢Participants with combined Grade 2 AST/ALT AND total bilirubin v alues meeting 
discontinuation parameters ( Section 8.1.1.3 ) should have treatment permanently discontinued
When resuming docetaxel treatment, please follow the dose reduc tion recommendations noted in 
Section 7.4.1 .
8.1.3 Post Study Follow-upIn this study, EFS and pCR are multiple primary endpoints. Post  study follow-up is of critical 
importance and is essential to preserving participant safety an d the integrity of the study. 
Participants who discontinue study treatment must continue to b e followed for collection of 
Protocol Amendment No.: 07
Date: 18-Aug-2021 97
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
outcome and/or survival follow-up data as required and in line with Section 2 until death or the 
conclusion of the study.
BMS may request that survival data be collected on all treated/ randomized participants outside of 
the protocol defined window ( Table 2-3 and Table 2-4 ). At the time of this request, each participant 
will be con tacted to d etermine their survival status unless the participant has withdrawn consent 
for all contacts or is lost to follow-up.8.2 Discontinuation from the Study
Participants who request to discontinue study participation wil l remain in the study and must 
continue to be followed for protocol specified follow-up proced ures. The only exception to this is 
when a participant specifically withdraws consent for any furth er contact with him/her or persons 
previously authorized by particip ant to provide t his informatio n. 
‚Ä¢Participants should notify the investigator of the decision to withdraw consent from future 
follow-up in writing, whenever possible.
‚Ä¢The withdrawal of consent should be explained in detail in the medical rec ords by the 
investigator, as to whether the withdrawal is from further trea tment with study treatment only 
or also from study proce dures and/or post treatment study follow-up, and entered on the  
appropriate CRF page.
‚Ä¢In the event that vital status (whether the participant is alive  or dead) is being measured, 
publicly available information s hould be used to determine vital status only as appropriately 
directed in accordance with local law.
‚Ä¢If the participant withdraws consent for disclosure of future i nformation, the sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.
8.3 Lost to Follow-Up
‚Ä¢All reasonable efforts must be made to locate participants to d etermine and report their ongoing 
status. This include s follow-up with persons authorized by the participant.
‚Ä¢Lost to follow-up is defined by the inability to reach the part icipant after a minimum of three
documented phone calls, faxe s, or emails as well as lack of response by participant to one 
registered mail letter. All attempts should be documented in th e participant‚Äôs medical records.
‚Ä¢If it is determined that the participant has died, the site wil l use permissible local methods to 
obtain date and cause of death.
‚Ä¢If investigator‚Äôs use of third-party representative to assist i n the follow- up portion of the study 
has been included in the participant‚Äôs informed consent, then t he investigator may use a 
Sponsor retained third-party representative to assist site staf f with obtaining participant‚Äôs 
contact information or other public vital s tatus d ata necessary to complete the follow-up 
portion of the study. 
‚Ä¢The site staff and representative will consult publicly availab le sources, such as public h ealth 
registries and databases, in order to obtain updated contact information.
Protocol Amendment No.: 07
Date: 18-Aug-2021 98
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢If after all attempts, the participant remains lost to follow-u p, then the last known alive date as 
determined by the investigator should be reported and documente d in the participant‚Äôs medical 
records.
9 STUDY ASSESSMENTS AND PROCEDURES
‚Ä¢Study procedures and timing are summarized in the Schedule of A ctivities. 
‚Ä¢Protocol waivers or exemptions are not allowed.
‚Ä¢All immediate safety concerns must be discussed with the Sponso r immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatment.
‚Ä¢Adherence to the study design requirements, including those spe cified in the Schedule of 
Activities, is essential and required for study conduct.
‚Ä¢All screening evaluations must be completed and reviewed to con firm that potential 
participants meet all eligibility criteria before randomization . The investigator will maintain a 
screening log to record details of all participants screened an d to confirm eligibility or record 
reasons for screening failure, as applicable.
‚Ä¢Procedures conducted as part of the participant‚Äôs routine clini cal management (eg, blood count) 
and obtained before signing of  informed consent may be utilized  for screening or baseline 
purposes provided the procedure meets the protocol-defined criteria and has been performed 
within the timeframe defined in the Schedule of Activities.
Additional measures, including non-study required laboratory te sts, should be performed as 
clinically ind icated or to comply with local regu lations. Laboratory toxicities (eg, suspected drug 
induced liver enzyme evaluat ions) will be monitored during the follow-up phase via on si te/local 
labs until all study drug related toxicities resolve, return to  baseline, or are deemed irreversible.
If a participant shows pulmona ry-related signs (hypoxia, fever)  or symptoms (eg, dyspnea, cough, 
fever) consistent with possible pulmonary adverse events, the participant should be immediately 
evaluated to rule out pulmonary toxicity, according to the susp ected pulmonary toxicity 
management algorithm in the BMS-936558 (nivolumab) Investigator  Brochure.
Some of the assessments referred to in this section may not be captured as data in the eCRF. They 
are intended to be used as safety monitoring by the treating ph ysician. Additional testing or 
assessments may b e performed as clin ically necessary  or where required by institutional or lo cal 
regulations.
9.1 Efficacy Assessments
The primary efficacy assessments w ill be EFS and pCR, and a key secondary endpoint is MPR 
rate (defined as number of randomized participants with ‚â§ 10% residual tumor in lung and lymph 
nodes as evaluated by BIPR, divided by the number of randomized  participants for each treatment 
group), which w ill be assessed by BIPR at the time of definitive surgery. Surg ery should be 
Protocol Amendment No.: 07
Date: 18-Aug-2021 99
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
performed within 6 weeks after c ompleting up to 3 cycles (last d ose) of neoadjuvant treatment. 
The following lymph node levels should be sampled at the time of  definitive surgery:
‚Ä¢For right-sided tumor: Levels 4, 7, 9R, 10R and 11 R
‚Ä¢For left-sided tumor: Levels 5 and/or 6; 7, 9L, 10L, and 11L 
Tumor and lymph node collection from definitive surgical resect ion and sampling of fresh tumor 
sample in RNAlater for biomarker studies (as applicable dependent on the size of residual tumor) 
is mandatory on the day of surgery. Processing of the remainder  of the specimens for 
histopathologic analysis should be performed within 72 hours of  the procedure. Sections will be 
used for central pathology review assessing pCR and MPR. Any tumor, tumor bed, or lymph 
node specimens that are reviewed locally must be submitted for central pathology review.
Gross examination on the entire specimen should be performed wh ich includes all tumor, 
associated lymph node tissue, and uninvolved parenchyma. The sp ecimen should be sectioned at 
0.5 cm intervals, and blocks shoul d be submitted for the full c ross section for every other 0.5 cm 
interval. When estimating viable tumors, in situ carcinoma shou ld not be included. For very large 
tumors with no gross evidence of response, a minimum of 1 slide /cm is required for assessment of 
major pathologic res ponse. Sites are st rongly enc ouraged to submit the diagnostic H &E stained 
slides assessed by the local pathologist for central pathology r eview. The final diagnostic 
pathology report must be submitted with the slides and blocks f or review. Tumor sample 
acquisition guidelines and submission process will be outlined in the study Laboratory Manual to 
be provided by the central lab.
Radiographic assessments will be performed with the Schedule Ac tivities in Table 2-2.
Disease recurrence, change in tumor measurements , and tumor res ponse w ill be assessed by the 
BICR using the RECIST 1.1 criteria. 
9.1.1 Imaging Assessment for the Study
Study evaluations will take place i n accordance with the Schedu le of Activities. 
Screening (baseline) assessments are to be performed within 28 days prior to randomization. 
PET/CT with contrast s hould be assessed at baseline. A separate  CT with contrast of the chest, 
abdomen, and other suspected areas (as well as the PET/CT) is required if the CT component of a 
PET/CT is not of sufficient d iagnostic quality for RECIST 1.1 measur ements. Participants with 
suspected brain metastases and all those with stage II disease or higher s hould be evaluated with 
MRI/CT of the brain pre- and post-contrast. Tumor assessments sh ould be performed following 
RECIST 1.1 criteria.  
A preoperative PET/CT with contrast should be acquired within 1 4 days of surgery. A separate 
CT with contrast of the chest, abdomen, and other suspected are as (as well as the PET/CT) is 
required if the CT component of a PET/CT is not sufficient diag nostic quality for RECIST 1.1 
measurements. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 100
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Postoperative assessments with CT with contrast of the chest in cluding the adrenal glands and CT 
or MRI of other additional suspected/known sites of disease. Th e first tumor assessment should 
occur 12 weeks ( ¬±7 days) after definitive surgery per RECIST 1.1 and then s hould occur every 
12 weeks ( ¬±7 days) for 2 years (104 weeks), then every 6 months (24 weeks ¬±7 days) for 3 years, 
and then every year (52 weeks ¬±7 days) for 5 years or until disease recurrence or progression 
confirmed by BICR. The same imaging method should be used as the  screening/baseline. For 
participants who did not receive definitive surgery AND without  tumor progression confirmed by 
BICR, the first tumor assessments should be done 12 weeks ( ¬±7 days) following the tumor 
restaging, subsequent tumor assessments will be performed with the same frequency and methods 
as described for those having received definitive surgery; in c ase the planned initiation of 
subsequent anti-cancer therapy is within 12 weeks of restaging,  every effort should be made to 
repeat tumor assessment prior to subsequent anti-cancer therapy .
Images will be submitted to the third-party radiology vendor fo r central review as they are 
performed on an ongoing basis. Sites w ill be trained pri or to scanning the first study participant. 
Image acquisition guidelines and submission process will be out lined in the study Imaging Manual 
to be provided by the radiology vendor. Any incidental findings  of potential clinical relevance that 
are not directly associated with the objectives of the protocol  should be evaluated and handled by 
the Study Investigator as per standard medical/clinical judgeme nt. 
9.1.2 Patient-reported Outcomes
The evaluation of health-related qu ality of life (QoL) is an increasingly important aspect of a 
clinical efficacy in oncology trials. Such data provides an und erstanding of the impact of treatment 
from the participants‚Äô perspective and offers insights into the  patient experience that may not be 
captured through physician reporting. Generic health-related Qo L scales additionally provide d ata 
necessary in calculating ut ility values for h ealth economic models. 
Participants will be asked to comp lete the 3-level version of the EQ-5D before any clinical 
activities are performe d during on-treatment clinic visits, at Post-neoadjuvant Visits  1 and 2, and 
at designated visits or during phone calls during the Survival Follow-up Phase. The questionnaire 
will be provided in the participants pre ferred language and may be admi nistered by telephone 
during the Survival Follow-up Phase. A standardized script will  be used to facilitate tel ephone 
administration of the EQ-5D-3L. Table 2-2 , Table 2-3 , and Table 2-4 provide information 
regarding the timing of participant-reported outcomes assessmen ts.
The EQ-5D-3L is a standardized instrument used to measure self- reports of health status and 
functioning. The instrument‚Äôs descriptive system consists of 5 dimensions: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression. Each  dimension has 3 levels, reflecting 
"no health problems," "moderate health problems," and "extreme health problems." A dimension 
for which there are no problems is said to be at level 1, wh ile a dimension for which there are 
extreme problems is said to be at level 3. Thus, the vectors 11 111 and 33333 represent the best 
health state and the worst health s tate, resp ectively, described by the EQ-5D-3L. Altogether, the 
instrument describes 35= 243 health states. Empirically derived weights can be applied  t o  a n  
individual‚Äôs responses to the EQ-5D-3L descriptive system to ge nerate an index measuring the 
Protocol Amendment No.: 07
Date: 18-Aug-2021 101
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
value to society of his or her current health. Such preference- weighting systems have been 
developed for Japan, UK, US, Spain, Germany, and numerous other  populations. In addition, the 
EQ-5D-3L includes a visual analog scale that allows respondents  to rate their own current health 
on a 101-point scale ranging from ‚Äúbest imaginable‚Äù to ‚Äúworst i maginable‚Äù health. The EQ-5D is 
available for use in over 150 languages.
9.2 Adverse Events
The definitions of an AE or serious adverse event (SAE) can be found in Appendix 8.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally authorized repre sentative). 
The investigator and any designees are responsible for detectin g, documenting, and reporting 
events that meet the definition of an AE or SAE and remain responsible for following up AEs that 
are serious, considered related to the study treatment or the s tudy, or that caused the participant to 
discontinue before completing the study. 
Contacts for SAE reporting specified in Appendix 8.
Immune-mediated adverse events (IMAEs) are AEs consistent with an immune-mediated 
mechanism or immune-mediated component for which non-inflammato ry etiologies (eg, infection 
or tumor progressi on) have been ruled out. IMAEs can include ev ents with an alternate etiology 
which were exacerbated by the induction of autoimmunity. Inform ation supporting the assessment 
will be collected on the participant‚Äôs case report form.
9.2.1 Time Period and Frequency for Collecting AE and SAE Information
The collection of nonserious AE information s hould begin at initiatio n of study treatment un til 
100 days after the last dose of  neoadjuvant therapy or 90 days a fter surgery, whichever is longer, 
and 30 days after the last dose of adjuvant therapy, at the tim e points specified in the Schedule of 
Activities ( Section 2 ). Nonserious AE information s hould also be collected from the start of a 
placebo lead-in period or other observational period intended t o establish a baseline status for the 
participants.
The Investigator Brochure (IB) represents the Reference Safety I nformation to determine 
expectedness of serious adverse events for expedited reporting.  Following the participant‚Äôs written 
consent to participate in the study, all SAEs, whether related or not related to study drug, must be 
collected, including those thought to be associated with protoc ol-specified procedures.
All SAEs must be collected that occur during the screening peri od and 100 days after the last dose 
of neoadjuvant therapy or 90 days after surgery, whichever is l onger, and 30 days after the last 
dose of adjuvant therapy. If applicable, SAEs must be collected  that relate to any later 
protocol-specified procedure (eg, a follow-up skin biopsy).The investigator must report any SAE that occurs after these ti me periods and that is believed to 
be related to study drug or protocol-specified procedure.
‚Ä¢Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate section of the eCRF  section.
Protocol Amendment No.: 07
Date: 18-Aug-2021 102
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢All SAEs will be rec orded and reported to Sponsor or designee within 24 hours, as i ndicated 
in Appendix 8. 
‚Ä¢The investigator will submit any updated SAE data to the sponso r within 24 hours of this being 
available.
Investigators are not obligated to actively seek AEs or SAEs in  former study participants. 
However, if the investigator learns of any SAE, including a dea th, at any time after a participant 
has been discharged from the study, and he/she considers the event reasonably related to the study 
treatment or study participation, t he investigator must promptl y notify the sponsor.
The method of evaluating, and assessing caus ality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in Appendix 8.
9.2.2 Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported  or elicited  during open-ended questioning, 
examination, or evaluation of a participant. (In order to preve nt reporting bias, participants should 
not be questioned regarding the specific occurrence of one or m ore AEs.)
9.2.3 Follow-up of AEs and SAEs
‚Ä¢Nonserious AEs should be follo wed to resolution  or stabilizatio n, or reported as SAEs if they 
become serious (see Appendix 8)
‚Ä¢Follow-up is also required for nonserious AEs that cause interr uption or discontinuation of 
study treatment and for those present at the end of study treatment as appropriate
‚Ä¢ All identified nonserious AEs must be recorded and described on  the nonserious AE page of 
the CRF (paper or electronic). Completion of supplemental CRFs may be requested for AEs 
and/or laboratory abnormalities t hat are reported/identified du ring the course of the study
After the initial AE/SAE report, the investigator is required t o proactively follow each participant 
at subsequent visits/contacts. All SAEs, and non-serious AEs of  special interest (as defined in 
Section 9.2 will be followed until resolution, until the c ondition stabilizes, un til the event is 
otherwise explained, or until the participant is lost to follow -up (as defined in Section 8.3).
Further informatio n on follow- up procedures is given in Appendi x 8.
9.2.4 Regulatory Reporting Requirements for SAEs
‚Ä¢Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
product under clinical investigation are met.
‚Ä¢An investigator who receives an i nvestigator safety report desc ribing SAEs or other specific 
safety information (eg, summary  or listing of SAEs) from the S ponsor w ill file it along with 
the Investigator‚Äôs Brochure and w ill notify the IRB/IEC, if appropri ate acc ording to local 
requirements.
Protocol Amendment No.: 07
Date: 18-Aug-2021 103
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Sponsor or designee w ill be reporting adverse events to regu latory authorities and ethics 
committees according to local applicable laws including Europea n Directive 2001/20/EC and FDA 
Code of Federal Regulations 21 CFR Parts 312 and 320. A SUSAR ( Suspected, Unexpected 
Serious Adverse Reaction) is a subset of SAEs and will be report ed to the appropriate regulatory 
authorities and investigators following local and global  guidelines  and requirements.
All SAEs must be collected that occur during the screening peri od and 100 days after the last dose
of last dose of neoadjuvant therapy or 90 days after surgery, w hichever is longer, and 30 days after 
the last dose of adjuvant therapy. For participants randomized/assigned to treatment and never 
treated with study drug, SAEs should be collected for 30 days f rom the date of randomization. 
9.2.5 Pregnancy
If, following initiation of the study treatment, it is subseque ntly discovered that a participant is 
pregnant or may have been pregnant at the time of study exposur e, including during at least 
5 half-lives after product adminis tration, the investigator must  immediately notify the BMS 
Medical Monitor/designee of this event and complete and forward a Pregnancy Surveillance Form 
to BMS Designee within 24 hours of awareness of the event and i n accordance with SAE reporting 
procedures described in Appendix 8.
In most cases, the study treatment w ill be permanently discontinued in an appropri ate manner 
(eg, dose tapering if necessary for participant safety). Please call the BMS Medical Monitor within 
24 hours of awareness of the pregnancy.
Protocol-required procedures fo r study disconti nuation and foll ow-up must be performed on the 
participant.Follow-up information regarding the course of the pregnancy, in cluding perinatal and neonatal 
outcome and, where applicable, offspring information must be re ported on the Pregnancy 
Surveillance Form.Any pregnancy that occurs in a female partner of a male study participant should be reported to 
Sponsor or designee. In order for Sponsor or designee to collect any pregnancy surveillance 
information from the female partne r, the fe male pa rtner must si gn an informed consent form for 
disclosure of this information. Information on this pregnancy w ill be collected on the Pregnancy 
Surveillance Form.
9.2.6 Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be ca ptured on the nonserious AE CRF 
page or SAE Report Form electronic, as appropriate. Paper forms  are only intended as a back-up 
option when the electronic system is not functioning.
‚Ä¢Any laboratory test result that is clinically significant or me ets the definition of an SAE 
‚Ä¢Any laboratory test result abnormality that required the partic ipant to have study treatment 
discontinued or interrupted
‚Ä¢Any laboratory test result abnormality that required the partic ipant to r eceive sp ecific 
corrective therapy
Protocol Amendment No.: 07
Date: 18-Aug-2021 104
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, anemia versus low hemoglobin value) .
9.2.7 Potential Drug Induced Liver Injury (DILI)
Wherever possible, t imely confirmation of initial liver-related  laboratory abnormalities s hould 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 9.2 and Appendix 8 for reporting 
details).
Potential drug induced liver injury is defined as: 
1) AT (ALT or AST) elevation >  3 times upper limit  of normal (ULN)
AND
2) Total bilirubin > 2 times ULN, without init ial findings of cholestasis ( elevated serum alkaline 
phosphatase),
AND
3) No other immediately apparent possible causes of AT elevation  and hyperbilirubinemia, 
including, but not limi ted to, viral hepatitis, pre-existing ch ronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
9.2.8 Other Safety Considerations
Any significant worsening noted during interim or final physica l examinations, electrocardiogram, 
x-ray filming, any other potential safety assessment required o r not required by protocol should 
also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.
Definition of immune-mediated adverse events (IMAEs) 
Immune-mediated AEs are specific events (that include pneumonit is, diarrhea/colitis, hepatitis, 
nephritis/renal dys function, rash, and endocrine [adrenal insufficiency, 
hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus,  and hypophysitis]) for which 
participants received immunosuppressive medication for treatmen t of the event, with the exception 
of endocrine events (hypothyroidism/thyroiditis, hyperthyroidis m, hypophysitis, diabetes mellitus, 
adrenal insufficiency), which are included regardless of treatm ent since these events are often 
managed without immunosuppression. Immune-mediated AEs are specific events (or groups of PTs descr ibing specific events) that 
include pneumonitis, diarrhea/coli tis, hepatitis, nephritis/ren al dysfunction, rash, endocrine 
(adrenal insufficiency, hypothyroidism/thyroiditis, hyperthyroi dism, diabetes mellitus, and 
hypophysitis), and other specific events, considered as potenti al immune-mediated events by 
investigator, that meet the definition summarized below: 
‚Ä¢those occurring within 100 days of the last dose 
‚Ä¢regardless of causality
Protocol Amendment No.: 07
Date: 18-Aug-2021 105
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢with no clear alternate etiology based on investigator assessme nt, or with an immune-mediated 
component 
‚Ä¢treated with imm une-modulating medication (Of note, adrenal ins ufficiency, 
hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus,  and hypophysitis are 
considered IMAEs regardless of immune-modulating medication use , since e ndocrine drug 
reactions are often managed without immune-modulating medicatio n). 
‚Ä¢Table 9.2.8-1 below provides a summary of the IMAEs category and their respec tive preferred 
terms.
Table 9.2.8-1: Preferred Terms Included in Analysis of IMAEs to S upport 
Warnings and Precautions
IMAE Category Preferred terms included under IMAE Category
Pneumonitis Pneumonitis , interstitial lung disease
Diarrhea/Colitis Diarrhea, colitis, enterocolitis
HepatitisHepatotoxicity, hepatitis, hepatitis acute, autoimmune hepatiti s, AST 
increased, ALT increased, bilirubin increased, ALP increased
Adrenal insufficiency Adrenal insufficiency
Hypothyroidism/ThyroiditisHypothyroidism, thyroiditis
Thyroiditis acute (collapsed with thyroiditis for frequency), A utoimmune 
thyroiditis (collapsed with thyroiditis for frequency)
Hyperthyroidism Hyperthyroidism
Hypophysitis Hypophysitis
Diabetes mellitus Diabetes mellitus, diabetic ketoacidosis
Nephritis and renal dysfunctionNephritis, nephritis allergic, tubulointerstitial nephritis, ac ute renal failure, 
renal failure, increased creatinine
Rash Rash, rash maculopapular
9.2.9 Management Algorithms
Immuno-oncology (I-O) agents are associated with AEs that can d iffer in severity and duration 
than AEs caused by other therapeutic classes. Nivolumab and ipi limumab are considered an 
immuno-oncology agent in this protocol. Early recognition and m anagement of AEs associated 
with immuno-oncology agents may mitigate severe toxicity. Manag ement Al gorithms have been 
developed to assist investigators in assessing and managing the  following groups of AEs:
‚Ä¢Gastrointestinal
‚Ä¢Renal
‚Ä¢Pulmonary
‚Ä¢Hepatic
‚Ä¢Endocrinopathy
Protocol Amendment No.: 07
Date: 18-Aug-2021 106
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚Ä¢Skin
‚Ä¢Neurological
‚Ä¢Myocardial
The above algorithms are found in the Nivolumab Investigator Br ochure and Appendix 4. 
9.3 Overdose
All occurrences of overdose must be reported as SAEs (see Section 9.2).
An overdose is defined as the accidental or intentional adminis tration of any dose of a product that 
is considered both excessive and medically important. All occur rences of overdose must be 
reported as an SAE (see Section 9.2).
9.4 Safety
Planned time points for all safety assessments are listed in th e Schedule of Activities.
At screening, a medical history w ill be ob tained to capture r elevant underlying conditions. The 
screening examinations should include weight, height, ECOG Performance Status, blood pressure 
(BP), heart rate (HR), temperature, and oxygen saturation by pu lse oximetry (at rest). Screening 
assessments and screening laboratory assessments should be performed in accordance with Table
2-1.
Pregnancy tests for WOCBP must be performed within 24 hours prior to the initial administration 
of study drug. 
Participants will be evaluated for safety if they have received any study drug. Toxicity assessments 
will be continuous during the tr eatment phase as w ell as during the first 2 safety (neo-adjuvant) 
follow-up visits, for 90 days after surgery, a nd for 30 days after adjuvant therapy. Once participants 
reach the Survival Follow-up Phase, either in-person visits or documented telephone calls/email 
correspondence to assess the participant‚Äôs status are acceptable.
Adverse events and laboratory values will be graded according t o the NCI-CTCAE version 4.
The start and stop time of the study therapy infusions and any interruptions or i nfusion r ate 
reductions should be documented. Physical examinations are to be performed as clinically indicat ed. If there are any new or 
worsening clinically significant changes since the last exam, r eport changes on the appropriate 
non-serious or serious adverse event page.On treatment local laboratory a ssessments are to be completed w ithin 3 calendar days prior to 
dosing in accordance with Table 2-2 .
On treatment pregnancy tests should be performed as per the schedule in the Schedule of Activity 
Table.
Additional measures, including non-study required laboratory te sts, should be performed as 
clinically ind icated or to comply with local regu lations. Laboratory toxicities (eg, suspected drug 
Protocol Amendment No.: 07
Date: 18-Aug-2021 107
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
induced liver enzyme evaluations) will be monitored during the Neoadjuvant and Adjuvant 
Follow-up Phases via on site/local labs un til all study drug-related toxicities resolve, return to 
baseline, or are deemed irreversible.
If a participant shows pulmona ry-related signs (hypoxia, fever)  or symptoms (eg, dyspnea, cough, 
fever) consistent with possible pulmonary adverse events, the participant should be immediately 
evaluated to rule out pulmonary toxicity, according to the suspe cted pulmonary toxicity 
management algorithm in the nivolumab Investigator Brochure.
Some of the assessments referred to in this section may not be captured as data in the eCRF. They 
are intended to be used as safety monitoring by the treating phy sician. Additional testing or 
assessments may be performed as clinically necessary  or where required by institutional or lo cal 
regulations.
9.4.1 Clinical Safety Laboratory Assessments
Investigators must document their review of each laboratory saf ety report.
Please refer to the Schedule of Activities in Section 2 for details related to the required laboratory 
assessment. 
9.4.2 Imaging Safety Assessment
Any incidental findings of potential clinical relevance that ar e not directly associated with the 
objectives of the protocol should be evaluated and handled by t he Study Investigator as per 
standard medical/clinical judgment. 
9.5 Pharmacokinetics
Samples for ipilimumab PK assessmen t will be collected from par ticipants in Arm A only. Samples 
for nivolumab PK assessments will be collected from participant s in Arm A and Arm C described 
in Table 9.5-1 .Treatment assignments will be r eleased to the bi oanalytical lab oratory in order to 
minimize unnecessary analysis of samples. All time points are r elative to the start of study drug 
administration. All on-treatment time points are intended to al ign with days on which study drug 
is administered, if dosing occurs on a different day, the PK sampling should be adjusted 
accordingly. Further details o f sample collect ion, processing, and shipment will be provided in the 
laboratory procedures manual. PK samples will be analyzed for n ivolumab and ipilimumab by a 
validated ligand binding assay. 
Table 9.5-1: Pharmacokinetic (PK) Sample Collections for Nivolum ab and 
Ipilimumab - Arm A and Arm C
Study Day 
1 Cycle = 2 weeks
for Arm A
and
1 Cycle = 3 weeks
for Arm CEvent
(Relative to Dosing)
HourTime
(Relative to Dosing)
Hour: MinPharmacokinetic 
Blood Sample for 
NivolumabPharmacokinetic 
Blood Sample for 
Ipilimumaba
C1D1 0.5 (EOI)b00:30 X X
Protocol Amendment No.: 07
Date: 18-Aug-2021 108
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 9.5-1: Pharmacokinetic (PK) Sample Collections for Nivolum ab and 
Ipilimumab - Arm A and Arm C
Study Day 
1 Cycle = 2 weeks
for Arm A
and
1 Cycle = 3 weeks
for Arm CEvent
(Relative to Dosing)
HourTime
(Relative to Dosing)
Hour: MinPharmacokinetic 
Blood Sample for 
NivolumabPharmacokinetic 
Blood Sample for 
Ipilimumaba
C2D1 Predosec00:00 X X
C3D1 Predosec00:00 X X
aPK blood samples for ipilimumab were be collected from Arm A participants only.
bEOI: End of Infusion. This sample should be taken immediately ( ie, within 5 minutes) prior to stopping ipilimumab 
infusion in Arm A or nivolumab infusion in Arm C. If the end of  infusion is delayed to be yond the nominal infusion 
duration, the collection of this sample should also be delayed accordingly. EOI samples may not be collected from 
the same IV access as drug was administered.
cPredose sample should be collected just before the administration of nivolumab (preferably within 30 minutes). If 
it is known that a dose is going to be delayed, then the predos e sample should be collected just prior to the delayed 
dose. However, if a predose sample is collected, but the dose is subsequently delayed, an additional predose sample 
should not be collected.
9.6 Pharmacodynamics
Pharmacodynamic parameters are not evaluated in this study.
9.7 Pharmacogenomics
Not applicable.
9.8 Biomarkers
9.8.1 Additional Research Collection
Additional research retention are mandatory for all study participants, except where prohibited by 
local laws or regulations, ethics committees, institutional req uirements, or where a waiver is 
provided by BMS or their designee. Where one or more of these e xceptions occurs, participation 
in the additional research  should be encouraged, but w ill not be a condition of overall st udy 
participation. Study participants may opt out of the additional  research. 
This protocol will include residual sample storage for addition al research (AR).
This retention for additional research is intended to expand th e translational R&D capability at 
Bristol-Myers Squibb Company and will support as yet undefined research aims that will advance our understanding of disease and opt ions for treatment. It may also be used to support health 
authority requests for analysis, and advancement of pharmacodia gnostic development to better 
target drugs to the right participants. This may also include g enetic/genomic e xploration aimed at 
exploring disease pathways, progression and response to treatment etc. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 109
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
All requests for access to samples or data for additional resea rch will be vetted through a diverse 
committee of the study sponsor‚Äôs senior leaders in Research and Development to ensure the 
research supports appropriate and well-defined scientific resea rch activities.
Samples kept for future research will be stored at the BMS Bior epository  
or an independent, BMS-approved storage vendor. The manager of these samples will ensure they 
are properly used t hroughout their usable life and w ill destroy the samples at the end of the 
scheduled storage period, no longer than fifteen (15) years aft e r  t h e  e n d  o f  t h e  s t u d y  o r  t h e  
maximum allowed by applicable law. Transfers of samples by rese arch sponsor to third parties 
will be subject to the recipient‚Äôs agreement to establish simil ar storage procedures.
Samples will be stored in a coded fashion; no researcher will h ave access to the key, which is 
securely held by the Investigator at the clinical site, so that there is no direct ability for a researcher 
to connect a sample to a specific individual.
Further details of sample collection and processing w ill be provided to the site in the procedure 
manual.
Protocol Amendment No.: 07
Date: 18-Aug-2021 110
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
9.8.1.1 Tumor Tissue Specimens
Archival (slides [blocks/slides] ‚â§3 months) FFPE tumor tissue collected at init ial diagnosis is 
required for study entry. Samples  will be sent to a third party  t o  s t a i n  a n d  s c o r e  f o r  P D - L 1  
expression using the PD-L1 IHC 28-8 pharmDx kit (Da ko). Stained tissue samp les will be assessed 
by a pathologist at a central lab identified by the Sponsor and scored as PD-L1 expressing if 
membrane staining is observed in ‚â•1% tumor cells among a minimum of 100 evaluable tumor 
cells. If an archived specimen is not available, a fresh tumor biopsy will be collected. Additional 
tumor will be collected during surgical resection, which will b e after 3 cycles of treatment in each 
arm. A third (optional) biopsy will be collected at the time of  disease progression. The third biopsy 
will not be collected in China.
Collected tumors may be further analyzed by additional modaliti es
Protocol Amendment No.: 07
Date: 18-Aug-2021 111
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 112
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
9.8.2 S
afety Analyses
Endpoint Statistical Analysis Methods
ExploratoryProportion of delayed o r canceled surgery, duration of surgery,  length of hospital stay, surgical 
approach, incidence of AE/SAE a ssociated with surgery, including pneumonitis, ARDS, re-
admission to the Intensive Care Unity, atrial fibrillation or other supraventricular tachycardia up to 
90 days after surgery will be summarized by treatment group using descriptive statistics.
The safety and tolerability objective will be measured by the i ncidence of adverse events, serious 
adverse events, deaths, and laboratory abnormalities.The safety analysis will be performed in all treated participan ts. The rate of treatment-related 
selected AEs and SAEs in each treatment arm will be summarized.  Descriptive statistics of safety 
will be presented using National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.0 by tr eatment arm. All treatment-emergent AEs, drug-related AEs, 
SAEs and drug-related SAEs will be tabulated using worst grade per NCI CTCAE v 4.0 criteria by 
system organ class and preferred term. On-st udy la b parameters including hematology, chemistry, 
liver function, thyroi d function and renal f unction will be sum marized using worst grade per NCI 
CTCAE v 4.0 criteria.
Protocol Amendment No.: 07
Date: 18-Aug-2021 113
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
9.9 Health Economics OR Medical Resource Utilization and Health 
Economics
Health Economics/Medical Resource Utilization and Health Econom ics parameters w ill not be 
evaluated in this study.
9.10 Other Assessments
9.10.1 Diagnostic/Pre-surgical Evaluation and Surgical Guidelines:
A participant is considered functionally operable if the follow ing criteria are met: 
‚Ä¢ECOG Performance Status ‚â§1
‚Ä¢Absence of major associated pathologies that increase the surge ry risk to an unacceptable level
‚Ä¢Pulmonary function capacity (eg, FVC, FEV1, TLC, FRC, and DLco)  capable of tolerating the 
proposed lung resection according to the surgeon
‚Ä¢Absence of locally advanced, unresectable, or metastatic diseas e (stage IV) in the pre-treatment 
assessment 
All participants enrolled on this study must be surgical candidates with clinical stage IB ( ‚â•4 cm), 
II or resectable IIIA (N2) NSCLC. Participants will have underg one radiographic evaluation 
(PET/CT) indicating no evidence of distant disease and no evide nce of unresectable loco-regional 
tumor extension (EBUS, mediastinoscopy , or thoracoscopy) prior to ra ndomization. A ny further 
preoperative testing that is recommended by the surgeon or anes thesiologist will be performed as 
part of standard of care. Surgery for participants enrolled on this protocol w ill be according to 
generally accepted standards of care. Operative approach (VATS vs open) will be determined by 
the surgeon.
Accepted types of resection (with negative margins) will consis t of lobectomy, sleeve lobectomy, 
bi-lobectomy, or pneumonectomy. Resections by segmentectomy  or wedge resecti on will not be 
accepted. If mediastinoscopy was not performed preoperatively, it is expected that, at a minimum, 
mediastinal lymph node systematic sampling and evaluation will have occurred, though complete 
mediastinal lymph node dissection (MLND) is preferred. It is re commended that participants have 
at least 3 mediastinal and hilar lymph node st ations sampled and evaluated during s urgery. 
Systematic sampling is defined as removal of at least 1 represe ntative lymph node at specified 
levels. MLND entails resection of all lymph nodes at those same levels. 
The following sampling or MLND locations are required:
‚Ä¢For right-sided tumor: Levels 4, 7, 9R, 10R and 11 R
‚Ä¢For left-sided tumor: Levels 5 and/or 6; 7, 9L, 10L, and 11L 
If there is clear documentation in  the operative report or in a  separately submitted addendum by 
the surgeon of exploration of the required lymph node areas, th e participant will be considered 
eligible if no lymph nodes are found in those areas. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 114
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Participants should have a PET/CT scan with contrast of the bas e of the skull through the upper 
thigh performed within the 14 days prior to planned surgery to a ssess for clinical response. A 
separate CT with contrast of the chest, abdomen, and other suspe cted areas (as well as the PET/CT) 
is required if the CT component of a PET/CT is not of sufficien t diagnostic quality of RECIST 1.1 
measurements. Surgery should be performed within 6 weeks of comp leting up to 3 cycles (last 
dose) of neoadjuvant treatment.
9.10.2 Post-surgical Evaluation:
The first tumor assessment should occur 12 weeks ( ¬±7 days) after definitive surgery per RECIST 
1.1. Afterwards, radiographic assessment will be performed every 12 weeks ( ¬±7 days) for 2 years) 
following surgery, every 6 months ( ¬±7 days) for 3 years, and then every year ( ¬±7 days) for 5 years 
or until recurrence or progression of disease is documented.
10 STATISTICAL CONSIDERATIONS
10.1 Sample Size Determination
The original study design (before Revised protocol  01) had two arms, with participants randomized 
in a 1:1 ratio to either neoadjuvant nivolumab plus ipilimumab or platinum doublet chemotherapy 
arm. Revised protocol 02 added a new, neoadjuvant nivolumab plus platinum doublet 
chemotherapy arm. When the third arm opens and as each site rec eives IRB/EC approval of revised 
protocol 02, the IRT will switch to a 1:1:1 randomization at th e respective site.  Starting from that 
point on, the site will only enroll under revised protocol 02.
Revised protocol 03 withholds rando mization into the arm of neoadjuvant nivolumab plus 
ipilimumab but continues randomizing eligible participants into  either neoadjuvant nivolumab plus 
platinum doublet chemotherapy arm or platinum doublet chemother apy arm in a 1:1 ratio. 
Approximately 350 participants (175 p articipants per arm) will b e randomized between 2 arms 
neoadjuvant nivolumab plus platinum doublet chemotherapy or pla tinum doublet chemotherapy 
from 1:1:1 randomization in revised protocol 02 and 1:1 randomi zation in revised protocol 03. 
Participants already randomized in the original 2-arm part (neo adjuvant nivolumab plus 
ipilimumab vs neoadjuvant chemotherapy) and in the arm of neoad juvant nivolumab plus 
ipilimumab in 3-arm part defined by revised protocol 02 will re main in trial and continue scheduled 
trial procedures. It is expected to have around 70 participants randomized in the original 2-arm 
part and approximately another 75 participants randomized in the  arm of neoadjuvant nivolumab 
plus ipilimumab in the 3-arm part. It is estimated that there w ill be a total  of approximately 
500 participants on the study.Starting from 1:1:1 randomization, approximately 350 participan ts will be randomized to the 
2 arms neoadjuvant nivolumab plus platinum doublet chemotherapy or platinum doublet 
chemotherapy in a 1:1 ratio. The sample size of the study is ca lculated based on the primary 
endpoint of EFS and accounts for the multiple primary endpoints comparisons: pCR (per BIPR) 
and EFS (per BICR) with an initial alpha allocation of 0.01 and  0.04 respectiv ely. Formal analyses 
of pCR and EFS may be conducted at different timepoints. The fa llback method will be used, ie, 
if the pCR comparison between Arm C and Arm B is s tatist ically significant,  then 0.01 alpha 
allocated to pCR w ill be passed to the EFS comparison for Arm C  vs Arm B and the EFS 
Protocol Amendment No.: 07
Date: 18-Aug-2021 115
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
comparison will be conducted at the alpha = 0.05 level. If the pCR comparison between Arm C 
and Arm B is not statistically significant, then the EFS compar ison for Arm C vs Arm B will be 
conducted at the alpha = 0.04 level. In addition, if EFS is sign ificant, OS will be tested 
hierarchically at the same level as EFS.
10.1.1 Pathologic Complete Response (pCR)
The primary analysis of pCR will be performed after 350 randomize d participants in neoadjuvant 
nivolumab plus platinum doublet chemotherapy and platinum doubl et chemotherapy (from start 
of 1:1:1 randomization) have an opportunity for surgery. 
Assuming an accrual r ate of 10 participants (all comers) a month between Arms B and C  during 
1:1:1 randomization (about 10 mont hs), and 15 participants per month during 1:1 randomization, 
it is anticipated that the 350 participants will be randomized i n approximately 27 months. The pCR 
endpoint is expected to be analyze d after about 30 months from s tart of 1:1:1 randomization.
The sample size of 350 participants is based on the EFS endpoint. With this sample size, assuming 
pCR rate of 10% on Arm B chemotherapy and 30% on Arm C nivolumab  plus chemotherapy, 
respectively, the 350 participants will provide more than 90% powe r to detect an odds ratio of 
3.857 with a 2-sided type I error of 1%.
It is estimated that there will be about 110 subjects randomized  to Arm A neoadjuvant nivolumab 
plus ipilimumab before revised protocol 03 is implemented. Assu ming true pCR rate is 15% on 
this arm, there is 95% probability that the lower bound of 95% exact confidence interval of pCR 
is above 5%.
10.1.2 Event Free Survival (EFS)
For the formal comparison of E FS as assessed by BICR for nivolu mab plus platinum doublet 
chemotherapy (Arm C) vs platinum doublet chemotherapy (Arm B), only participants randomized 
from 1:1:1 randomization in revised protocol 02 and 1:1 randomi zation in revised protocol 03 will 
be counted. 
The power details are provided below using alpha = 0.05 (0.01 alp ha from the pCR endpoint 
fallback to the EFS comparison), considering this protocol amen dment (protamend07) occurs after 
the statistically signi ficant pCR final analysis but before any  analysis of EFS or OS. In addition, 
the accrual reflects 358 particip ants who were actually concurr ently randomized in Arms B and C. 
A total of 185 events ensure that an overall 2-sided 5% signific ance level sequential test procedure 
with 2 interim analyses occ urring after 148 ev ents (80% of events  required for final analysis) and 
167 events (90% of events required for final analysis) in 358 r andomized participa nts will have 
82% power assuming an HR of 0.65 between the 2 arms. Considering  a piecewise exponential 
distribution with control hazard rates of 0.028 before 20 month s, 0.017 between 20 months and 40 
months, 0.014 between 40 and 60 months, and 0.008 after 60 month s, and a dropout rate of 
approximately 20%, it is anticipated t he EFS analyses will take  place at approximately 48, 58, and 
73 months from the start of 1:1:1 randomization. The trigger of the first interim analysis is event 
driven. The second interim analysis will take place when 167 ev ents are observed  
. The final analysis will take pl ace 
Protocol Amendment No.: 07
Date: 18-Aug-2021 116
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
when approximately 185 events are observed  
. The stopping boundaries  at the interim and final EFS 
analyses will be derived based on the exact number of events us ing Lan-DeMets alpha spending 
function with O‚ÄôBrien-Fleming boundaries. If the interim analyses of EFS are performed at exactly 
148 and 167 events, the nominal significance level for EFS super iority will be 0.024 and 0.030,
respectively. The nominal significance level for the final look  of EFS after 185 events would then 
be 0.038. 
Table 10.1.3-1 summarizes the key parameters of the sample size justification in the randomized 
participants.
10.1.3 Power Consideration for Overall Survival (OS)
The secondary endpoint OS will be tested hierarchically after EFS with the same overall alpha as 
for the EFS comparison (two-sided 4% if the pCR comparison is n ot significant or 5% if the pCR 
comparison is significant).
For the formal comparison of OS for nivolumab plus platinum dou blet chemotherapy (Arm C) vs 
platinum doublet chemotherapy (Arm B), only participants concur rently randomized from 1:1:1 
randomization in revised protocol 02 and 1:1 rando mization in revised protocol 03 will be 
included. Three interim analyses for OS are planned to occur at th e time of EFS interim and final 
analyses, only if EFS is significant. 
The power details are provided below using alpha = 0.05 (0.01 alp ha from the pCR endpoint 
fallback to the EFS comparison, then hierarchically on the OS c omparison), considering this 
protocol ame ndment (prot amend 07) occurs after the readout of the statistic ally significant pCR 
final analysis but before any analysis of EFS or OS. In addition , they reflect the 358 participants 
that were actually concurrently randomized in Arms B and C:  
Protocol Amendment No.: 07
Date: 18-Aug-2021 117
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 10.1.3-1:
Power Calculation for EFS and OS
EFS
Arm C vs Arm BOS
Arm C vs Arm B
AccrualActual accrual
25 monthsActual accrual
25 months
Power 82%
Two-sided alpha 0.05 0.05
Hypothesized median control 
vs exp (months)28 vs 52*
Hypothesized h azard ratio 0.65
Sample size for concurrent comparison358 358
First interim analysis for EFS (EFS IA1) and OS (OS IA1)148 events
Alpha boundary: 0.024Triggered by EFS IA1
Second interim analysis for 
EFS (EFS IA2) and OS (OS 
IA2)167 events  
Alpha boundary: 0.030‚Ä¢If EFS IA1 not significant: triggered by 
EFS IA2.
Final EFS (EFS FA) and third OS (OS IA3) interim analysis185 events 
Alpha boundary: 0.038‚Ä¢If EFS IA2 not significant: triggered by 
EFS FA.
Final OS analysis (OS FA) -
*Calculated from piecewise exponential distribution
EFS, event free survival; FA, final analysis; IA, interim analy sis; OS, overall survival
Protocol Amendment No.: 07
Date: 18-Aug-2021 118
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
10.1.4 Analyses Timing Projections
The pCR analysis occurred with a database lock on 16-Sep-2020.
Considering the actual enrollment, it will take:
‚Ä¢Approximately 48 months when 148 events on Arms B and C (after start of 1:1:1
randomizatio n) are observed for the first interim analysis (EFS  IA1, OS IA1). This is about 54
months from first patient first visit (FPFV) of the study. This a nalysis will be triggered by the 
number of EFS events.
‚Ä¢Approximately 58 months when 167 EFS events on Arms B and C (afte r start of 1:1:1
randomization) are observed for th e second interim analysis (EFS IA2, OS IA2). This is 
approximately 64 months from FPFV.  
 
‚Ä¢Approximately 73 months when 185 EFS events on Arms B and C (aft er start of 1:1:1
randomization) are observed for the final EFS analysis (EFS FA, OS IA3). This is about 79
months from FPFV of the study.  
 
 
 
10.2 Populations for Analyses
Population Description
All enrolled 
participantsAll participants who signed an informed consent form and were r egistered into the IRT
All randomized 
participantsAll participants who were randomized to any treatment arm in the study. This is the 
primary dataset for analyses of study conduct, study population  and efficacy.
All concurrently 
randomized participants 
in Arms B and CAll randomized participants on Arms B and C after 1:1:1 randomization. Analysis of 
demography, protocol deviations, baseline characteristics, and primary efficacy 
analyses will be performed for this population.
All treated participantsAll participants who received any dose of study medication in n eoadjuvant setting. 
This is the primary dataset for drug exposure and safety analys is.
PK participantsAll participants with available serum time-concentration data f rom randomized 
participants dosed in Arm A and Arm C
Protocol Amendment No.: 07
Date: 18-Aug-2021 119
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
10.3 Statistical Analyses
10.3.1 Efficacy Analyses
Endpoint Statistical Analysis Methods
PrimaryThe fallback method will be used for the hypothesis testing of the two primary endpoints pCR and 
EFS. Initially, the type 1 erro r of 0.05 will be allocated as f ollows: 0.01 will be allocated to the 
pCR comparison between Arm C and Arm B, and 0.04 w ill be allocated to the EFS comparison 
between Arm C and Arm B. If the pCR comparison between Arm C an d Arm B is statistically 
significant, then 0.01 alpha will be passed to the EFS comparison for Arm C vs Arm B and the test 
comparison will be conducted at the alpha = 0.05 level.
pCR analysis will be based on all concurrently randomized parti cipants in Arms B and C analysis 
population. pCR rate will be computed in each treatment group along with the exact 95% CI using 
Clopper-Pearson method. For pCR rate comp arison between arms C vs  B, the difference will be 
tested via the Cochran Mantel-Haenszel (CMH) test using a 2-side d, 1% alpha level. the odds 
ratios stratified by PD-L1, dis ease stage (IB/II vs IIIA) and g ender (Mantel-Haenszel estimator) 
between Arms C and B will be provided along with the 99% CI. In addition, an estimate of the 
difference in pCR rates and corresponding 99% CI will be calcula ted using CMH methodology 
and adjusted by stratification factors (PD-L1, disease stage (I B/II vs IIIA) and gender). 
pCR rate will also be computed for subjects randomized to Arm A  neoadjuvant nivolumab plus 
ipilimumab along with the exact 95% CI using Clopper-Pearson me thod.
EFS is defined as time from randomization to any of the followi ng events: any documented 
progression of disease precluding surgery, progression or recur rence disease (based on BICR 
assessment per RECIST 1.1) after surgery, or death due to any c ause. Participants who don‚Äôt 
undergo surgery for reason other than progression will be consi dered to have an event at RECIST 
1.1 progre ssion (based on BICR) or death. Particip ants who die without a reported 
progression/disease recurrence will be considered to have experienced an event on the date of their 
death. Participants who did not report progression/recurrence of disease or die will be censored on the date of their last evaluable tumor assessment. Participants  who did not have any on-study tumor 
assessments and did not die will be censored on the date they w ere randomized. Participants who 
started any subsequent anti-cancer therapy outside of the proto col-specified adjuvant therapy 
without a prior reported progression/recurrence will be censore d at the last evaluable tumor 
assessment prior to initiation of the subsequent anti-cancer th erapy.
If the pCR analysis comparing Arms C vs B is statistically sign ificant, a two-sided alpha of 0.05 
will be used for the comparison of EFS in Arms C vs B. If the p CR analysis comparing Arms C 
vs B is not statistically significan t, a two-sided alpha of 0.0 4 will be used for the comparison of 
EFS in Arms C vs B. EFS among the all concurrently randomized p articipants in Arms B and C
analysis population will be tes ted. The distribution of EFS wil l be compared between Arm C vs 
Arm B via a 2-sided, log rank test stratified by the randomizat ion stratification factor (ie, PD-L1, 
disease stage [IB/II vs IIIA ] and gender).The hazard ratio and the corresponding (1-adjusted alpha) 
confidence interval will be estimated for Arm C vs Arm B in a stratified Cox proportional hazards 
model using the randomized arm as a single covariate. The EFS curves for each randomized arm 
will be estimated using the Kaplan-Meier (KM ) produc t-limit met hod using a log-log 
transformation. In addition, EFS rates at 1, 2, 3, and 4 years will be estimated using KM estimates on the EFS curve for each randomized arm provided a minimum fol low-up is longer than the time 
point to generate the rate.  Associated 2-sided 95% CIs w ill be calculated using the Greenwood 
formula (using log-log transformation).
Sensitivity a
nalysis on EFS will also be pe rformed, and details will be included in statistical 
analysis plan.
SecondaryAt the time of pCR analysis, MPR r ate will be computed in each t reatment group along with the 
exact 95% CI using Clopper-Pearson method. An estimate of the di fference in MPR rates between 
Arm C and Arm B and corresponding 95% CI will be calculated usi ng CMH methodology and 
adjusted by stratification factors (PD-L1, disease stage (IB/II vs IIIA) and gender).
Protocol Amendment No.: 07
Date: 18-Aug-2021 120
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Endpoint Statistical Analysis Methods
OS curves, OS medians with 95% CIs, and OS rates at 1, 2, 3, an d 4 years with 95% CIs will be 
estimated using Kaplan-Meier methodology. HR and corresponding 2-sided 95% CI will be 
estimated for Arm C vs Arm B using a Cox proportional hazards model with treatment group as a 
single covariate, stratified by randomization stratification fa ctors. If tested, the distribution of OS 
will be compared between Arm C vs Arm B in the all concurrently  randomized participants in 
Arms B and C population via a 2-sided, log rank test stratified  by the randomization stratification 
factors.
Time to death or distant metastases (TTDM) is defined as the ti me between the date of 
randomization and the first date of distant metastasis or the date of death in the absence of distant 
metastasis. Distant metastasis is defined as any new lesion that is outside of the thorax using BICR 
according to RECIST 1.1. Participants who die without a reporte d distant metastasis will be 
considered to have experienced an event on the date of their de ath. Patients who have not 
developed distant metastasis or died at the time of analysis wi ll be censored on the date of their 
last evaluable tumor assessment. Participants who did not have baseline scan, or participants who 
did not have any on-st udy tum or assessments and did not die, will be censored on the date th ey 
were randomized. 
TTDM curves, TTDM medians with 95% CIs, and TTDM rates at 1, 2,  3, and 4 years with 95% 
CIs will be estimated using Kaplan-Meier methodology. HR and co rresponding 2-s ided 95% CI 
will be estimated for Arm C vs Arm B using a Cox proporti onal hazards model with treatment 
group as a single covariate, stratified by randomization strati fication factors. There will be no 
formal comparison of TTDM.
Exploratory Will be described in the statistical analysis plan finalized before database lock
10.3.2 Other Analyses
Biomarker exploratory analyses will be described in the s tatist ical analysis plan fin alized before 
database lock. The population phar macokinetics analysis will be presented separately from the 
main clinical study report. 
The EQ-5D-3L questionnaire completion rate, defined as the proportion of questionnaires actually 
received out of the expected number, will be calculated and summarized at each assessment point. 
Summary statistics (ie, N, m ean with SD and 95% CI, median, first and third quartiles, minimum, 
maximum) for the EQ-5D-3L utility index and VAS scores, as well  as their corresponding changes 
from baseline, will be tabulated by treatment and planned time point. In the base case, index scores 
will be derived using the UK weighting al gorithm. In addition, the proportion of participants 
reporting no, moderate, or severe  problems in each of the 5 EQ- 5D-3L dimensions will be 
summarized by tr eatment group at each time point. Proportions w ill be based on the number of 
participants assessed at assessment time point. A by-participan t listing of the lev el of probl ems in 
each dimension, corresponding EQ-5D-3L health state (ie, 5-digi t vector), EQ-5D-3L index score, 
and EQ-5D VAS score will be provided.
10.3.3 Interim Analyses
There is no interim analysis for the pCR endpoint.
Protocol Amendment No.: 07
Date: 18-Aug-2021 121
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Two formal interim analyses for EFS are planned after approximately 148 and 167 events have 
been observed on Arms B and C, after the start of 1:1:1 randomization, which is proj ected to occur 
approximately 48 and 58 months after start of 1:1:1 randomi zation.  
 
 The formal comparisons of EFS will allow for early st opping for superiority. An 
independent statistician external to BMS will pe rform the analysis. If the study continues beyond 
the second interim analysis, the final analysis will be conduct ed after 185 EFS events have been 
observed on Arms B and C from the start  of 1:1:1 randomization. The stopping boundaries at the 
interim and final analyses will be based on the actual number o f EFS events at the time of the 
analysis using Lan-DeMets alpha spending function with O‚ÄôBrien- Fleming boundaries.
Protocol Amendment No.: 07
Date: 18-Aug-2021 122
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
11 REFERENCES
1Mountain, CA.  Regional lymph node classification for lung canc er staging. Chest. 1997: 1718-
23.
2Goldstraw P, Crowley J, Chansky K, et al for the International Association for the Study of 
Lung Cancer International Staging Committee. The IASLC Lung Can cer Staging Project: 
proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of 
the TNM Classification of malignant tumours. J Thorac Onco. 200 7; 2(8):706-14.
3Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009; 136: 
260-71.
4NSCLC Meta-analyses Collaborative Group. Adjuvant c hemotherapy,  with or without 
postoperative radiotherapy, in operable non-small-cell lung can cer: two meta-analyses of 
individual patient data. Lancet. 2010 Apr 10;375(9722):1267-77.
5Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. A Cance r J Clin. 2015; 65(1):5-29.
6Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuva nt chemotherapy in patients 
with completely resected non-small-cell lung cancer. N Engl J M ed, 2004, 351-60.
7Douillard JY, R. R.  Adjuvant vinorelbine plus cisplatin versus  observation in patients with 
completely resected stage IB-IIIA  non-small-cell lung cancer (Adjuvant Navelbine 
International Trialist Association [ANITA]): a randomised contr olled trial. Lancet Oncology. 
2006;7: 719-27.
8Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclita xel plus carboplatin 
compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the 
Cancer and Leukemia Group B, Rad iation Therapy Oncology Group and Northern Central 
Cancer Treatment Study Groups. Journal of Clinical Oncology. 20 08;26: 5043-51.
9Winton T, L. R. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung 
cancer. N Engl J Med. 2005;352: 2589-97.
10Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: 
chemotherapy and surgery versus surgery alone in non-s mall c ell lung cancer.  J Thorac Oncol. 
2006 Sep;1(7):611-21. 
11Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous Cell Non-small Cell Lung Cancer. N Engl J Med 2015;373:123-35.
12Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetax el in Advanced 
Nonsquamous Non-small Cell Lung Cancer. N Engl J Med 2015;373:1 627-39.
13Hellmann, MD, Gettinger, SN, Goldman, JW, et al. J Clin Oncol 34, 2016 (suppl; abstr 3001).
Protocol Amendment No.: 07
Date: 18-Aug-2021 123
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
14Goldman JW, Antonia SJ, Gettinger SN, et al. Nivolumab Plus Ipi limumab as First-Line 
Treatment for Advanced NSCLC: 2-Y ear Overall Survival and Long- Term Outcomes From 
CheckMate 012. ASCO, 53rd Annual Meeting, June  2‚Äì6, 2017, Chica go, IL
15Hellmann MD, Ciuleanu TE, Pluzanski A, et al. N Engl J Med. 201 8;378:2093-2104. 
16Antonia SJ, Brahmer JR, Gettinger S et al. Nivolumab (Anti-PD-1 ; BMS-936558, ONO-4538) 
in Combination With Platinum-Based Doublet Chemotherapy (PT-DC)  in Advanced Non-
Small Cell Lung Cancer (NSCLC). Presented at CMSTO 2014 Annual Meeting in Chicago, 
IL
17Borghaei H, Hellmann MD, Paz-Ares L et al. Nivolumab + ipilimum ab, nivolumab + 
chemotherapy, and chemotherapy in chemo-naive patients with adv anced non-small-cell l ung 
cancer and <1% tumor PD-L1 expression: results from CheckMate 2 27. ASCO 2018. Abstr 
9001
18Sorenson S, Glimelius B, Nygren P. A Systematic Overview of Che motherapy effects in non-
small cell lung cancer. Act Oncologica. 2001; 40 (2-3): 327-339 . 
19Pardoll D. Does the immune system see tumors as foreign or self ? Annu Rev Immunol. 
2003;21:807-39.
20Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveil lance: immunoselection 
and immunosubversion. Nat Rev Immunol. 2006;6:715-27.
21Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from i mmunosurveillance to 
tumor escape. Nat Immunol. 2002;3:991-8.
22Greenwald RJ, Freeman GH, Sharpe AH. The B7 family revisited. A nnu Rev Immunol. 
2004;23:515-48.
23Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immu noinhibitory receptor by a 
novel B7 family member l eads to negative regu lation of lymphocyte activation. J Exp Med 
2000; 192(7): 1027-34.
24Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programme d cell d eath 1 and its 
ligands in regulating autoimmunity and infection. Nature Immuno l. 2007;8:237-45.
25Wolchok JD, Hoos A, O‚ÄôDay S, et al. Guidelines for the evaluati on of immune therapy activity 
in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-20.
26Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: Releasing the restraints 
on anti-tumor immunity for patients with m elanoma. Cancer J 2012; 18:153-159.
27van der Most RG, Currie AJ, Mahendran S, et al. Tumor eradicati on after cyclophosphamide 
depends on concurrent depletion of regulatory T cells: A role f or cycling TNFR2-expressing 
effector-suppressor T cells in limiting effective chemotherapy.  Cancer Immunol Immunother. 
2008;58:1219‚Äì28.
28Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of actio n of conventional and 
targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39:74‚Äì88.
Protocol Amendment No.: 07
Date: 18-Aug-2021 124
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
29Harris SJ, Brown J, Lopez J, and Yap TA. Immuno-oncology combin ations: raising the tail of 
the survival curve Cancer Biol Med. 2016 Jun; 13(2): 171‚Äì193.
30First-Line Treatment for Advanced NSCLC: 2-Year Overall S urvival and Long-Term 
Outcomes From CheckMate 012. ASCO, 53rd Annual Meeting, June 2‚Äì 6, 2017, Chicago, IL
31Xu XL, D. L. Neoadjuvant chemoradiotherapy or chemotherapy foll owed by surgery is 
superior to that followed by definitive chemoradiation or radio therapy in stage IIIA (N2) 
nonsmall-cell lu ng cancer: a meta-analysis and system review. Onco Targets Ther .2016:9: 845-
53.
32Gilligan D, Nicolson M, Smith I, et al. Preoperative chemothera py in patients with resectable 
non-small cell lung cancer: results of the results of the MRC 2 2 ? NVALT 2 / EORTC 08012 
multicentre randomised trial and update of systematic review. Lancet. 2007;369:1929.
33Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative che motherapy followed by surgery
compared with primary surgery in resectable stage I (except T1N 0), II, and IIIa non-s mall-cell 
lung cancer. J Clin Oncol. 2002;20:247-253.
34Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized  phase III study of surgery 
alone or surgery plus preoperative cisplatin and gemcitabine in  stages IB to IIIA non-small-
cell lung cancer. J Clin Oncol. 2012:30(2),172-8.
35Pisters K. S9900: A phase III trial of surgery alone or surgery  plus preoperative (preop) 
paclitaxel/carboplatin (PC) chemother apy in early s tage non-smal l cell lung cancer (NSCLC): 
Preliminary results. Proc ASCO 2005;(Abstract 7012), 23.
36Scagliotti G. et al. A phase III randomized study of surgery alo ne or surgery plus preoperative 
gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of 
C.h.E.S.T. Proc ASCO 2009, abstract 7508.
37Felip E, Massuti B, Alonso G, et al. Surgery alone, pre-operati ve paclitaxel/carboplatin 
chemotherapy followed by surgery, or surgery followed by adjuvant PC chemotherapy in early 
stage non-small cell lung cancer. Results of the NATCH multicen ter randomized phase III trial. 
Proc ASCO 2009 (Abstract 7500).
38Forde PM, Chaft JE, S mith KN, et al. Neoadjuvant PD- 1 blockade in resectable lung ca ncer. 
N Engl J Med. 2018; 378:1976-86.
39Provencio M, Nadal E, Cobo-Dols M et al. Neo-adjuvant chemo/imm unotherapy for the 
treatment of stage IIIA  resectable non-small-cell lung cancer ( NSCLC): a phase II multicenter 
exploratory study-NADIM study-SLCG. 2018 ASCO Abstr.8521
40Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combina tion blockade expands 
infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. PNAS 2010; 107: 4275-80.  
41Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimum ab versus ipilimumab in 
untreated melanoma. N Engl J Med 2015; 372:2006-2017. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 125
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
42Larkin J, Chiarion- Sileni V, Gon zalez R, et al. Combined Nivolu mab and Ipilimumab or 
Monotherapy in Untreated Melanoma. New Eng J Med. 2015;373(1):2 3-34.
43Calvo, et al., presented at the 18th ECCO‚Äî40th ESMO European Can cer Congress; 
September 25-29, 2015; Vienna, Austria.
44Rizvi NA, Gettinger S, Goldman J et al.  Safety and Eff icacy of First-line Nivolumab (Anti-
programmed Death-1 [PD -1]) and Ipilimumab in Non-small Cell Lung Cancer (NSCLC).  
Presented at WCLC 2015 Annual Meeting in Denver, CO
45Goldman JW, Antonia SJ, Gettinger SN, et al. Nivolumab Plus Ipi limumab as First-Line 
Treatment for Advanced NSCLC: 2-Y ear Overall Survival and Long- Term Outcomes From 
CheckMate 012. ASCO, 53rd Annu al Meeting, J une 2‚Äì6, 2017, Chica go, IL
46Gettinger S, et al. Oral presentation at the IASLC 17th World C onference on Lung Cancer; 
December 4‚Äì7, 2016; Vienna, Austria. Abstract OA03.01.
47Hellmann MD, Chaft JE,  William Jr WN, for The University of Texas MD Anderson Lung 
Cancer Collaborative Gr oup. Pat hological response after neoadjuvant chemotherapy in 
resectable non-small-cell lung cancers: proposal for the use of  major pathological response as 
a surrogate endpoint. Lancet Oncol 2014; 15: e42‚Äì50.
48Betticher DC, Hsu Schmitz S-F, T otsch M.  Prognostic factors af fecting long-term outcomes 
in patients with resected stag e IIIA pN2 non-small-cell lung can cer: 5-year follow-up of a 
phase II study . British J ournal of Cancer. 2006;94:1099 ‚Äì 1106.
49Pataer A, Kalhor N, Correa AM, et al for the University of Texa s M. D. Anderson Lung Cancer 
Collaborative Research Group. Histopathologic response criteria  predict survival of patients 
with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012; 7(5):825-
32.
50NSCLC Meta-analyses Collaborative Group. Adjuvant c hemotherapy,  with or without 
postoperative radiotherapy, in operable non-small-cell lung can cer: two meta-analyses of 
individual patient data. Lancet. 2010;375:267-77.
51Wakelee H, Chhatwani L. Adjuvant Chemotherapy for Resected Non- Small Cell Lung Cancer.  
Seminars in Thoracic and Ca rdiovascular Surgery.  2008 20:198-2 03.
52Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy  plus surgery versus surgery 
plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J 
Clin Oncol 2010; 28: 3138‚Äì45. 
53Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuva nt chemotherapy in patients 
with completely resected non-small -cell lung cancer: The International Adjuvant Lung Cancer 
Trial Collaborative Group. N Engl J Med. 2004; 350:351-360.  
54Arriagada R, Dunant A, Pignon JP, et al: Long-term results of t he International Adjuvant Lung 
Cancer Trial evaluating adjuvant cisplatin-based chemotherapy i n resected lung cancer. J Clin 
Oncol 2010; 28:35-42. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 126
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
55Winton T, Livingston R, Johnson D, et al: Vi norelbine plus cisplatin vs. observation in resected 
non-small-cell lung cancer. N Engl J Med. 2005; 352:2589-2597. 
56Butts CA, Ding K, Seymour L, et al: Randomized, phase III trial  of vinorelbine plus cisplatin 
compared with observation in completely resected stage IB and I I non-small-cell lung cancer: 
Updated survival analysis of JBR-10. J Clin Oncol. 2010; 28:29- 34.  
57Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus 
observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer 
(Adjuvant Navelbine International Trialist Association [ANITA]) : A randomised controlled 
trial. Lancet Oncol. 2006; 7:719-727.  
58NSCLC Meta-analysis Collaborative Group. Preoperative chemother apy for non-small-cell 
lung cancer: a systematic review and meta-analysis of individua l participant data. Lancet 
2014;383:1561-71.
59Rami-Porta, R. Bol ejack, V . Crowley, J. et al. The IASLC Cancer Staging Project: Proposals 
for the Revisions of the T Descriptors in the Forthcoming Eigth  E d i t i o n  o f  t h e  T N M  
Classification for Lung Cancer. J Thorac Oncol. 2015 Jul;10(7):990 -1003.
60NAVELBINE¬Æ (vinorelbine tartrate). Prescribing Information. 200 2. GlaxoSmithKline. 
Research Triangle Park, NC.
61GEMZAR (gemcitabine for in jection), for intr avenous use. Revised June 2014. Lill y, USA, 
Inc. Indianapolis, IN.
62TAXOTERE¬Æ (docetaxel) Injection Concentrate, Intravenous Infusi on (IV). Prescribing 
Information. Revised December 2015. sanofi-aventis, US, LLC, Br idgewater, NJ. 
63ALIMTA (pemetrexed for injection), for Intravenous Use. Update September  2013. Lilly, 
USA, Inc. Indianapolis, IN.
64Platinol (cisplatin for injection). Prescribing information. Re vised May 2010. Bristol-Myers 
Squibb Company, Princeton, NJ. 
65PARAPLATIN (carboplatin aqueous solution) INJECTION. Updated Ju ly 2010. Bristol-
Myers Squibb Company, Princeton, NJ. 
66Paclitaxel Aurobindo 6 mg/ml Concentrate for solution for i nfusion. Su mmary of Product 
Characteristics. Puren Pharma. 
67Taxol (paclitaxel) Injection. Corden Pharma Latina. January 201 1
Protocol Amendment No.: 07
Date: 18-Aug-2021 127
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
12 APPENDICES
Protocol Amendment No.: 07
Date: 18-Aug-2021 128
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
APPENDIX 1 TNM STAGING SYSTEM FOR LUNG CANCER (7TH EDITION)
Table -1: International Association for the Study of Lung Cancer  Definitions 
for T, N, and M Descriptors
T (Primary Tumor)
T1Tumor ‚â§ 3 cm in greatest dimension, surrounded by lung or visceral pleura, without invasion more 
proximal than the lobar bronchus 
T1a Tumor ‚â§ 2 cm in diameter
T1b Tumor > 2 cm but ‚â§ 3 cm in diameter
T2Tumor > 3 cm but ‚â§ 7 cm or tumor with any of the following features 
Involves main bronchus, ‚â• 2 cm distal to carina
Invades visceral pleura
Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not 
involve the entire lung
T2a Tumor > 3 cm but _5 cm 
T2b Tumor > 5 cm but  ‚â§ 7 cm 
T3 Tumor > 7 cm or any of the following: 
Directly invades any of the following: chest wall, diaphragm, p hrenic nerve, mediastinal pleura, 
parietal pericardium; main bronchus < 2 cm distal to the carina (without involvement of the carina)Atlelectasis or obstructive pneumonitis of the entire lung
Separate tumor nodule in same lobe
T4Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, 
recurrent laryngeal nerve, esophagus, vertebral body, carina; o r without separate tumor nodules in a 
different ipsilateral lobe
N (Regional Lymph Nodes)
N0 No regional lymph node metastasis
N1Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary 
nodes, including involvement by direct extension
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3Metastasis in contralateral mediastinal, contralateral hilar, i psilateral or contralateral scalene, or 
supraclavicular lymph node(s)
M (Distant Metastasis)
M0 No distant metastasis
M1 Distant metastasis
M1aSeparate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural or pericardial effusion
M1b Distant metastasis (in extrathoracic organs)
Stage Groupings
Stage IA T1a-T1b N0 M0
Stage IB T2a N0 M0
Protocol Amendment No.: 07
Date: 18-Aug-2021 129
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table -1: International Association for the Study of Lung Cancer  Definitions 
for T, N, and M Descriptors
Stage IIAT1a, T1b, T2a N1 M0
T2b N0 M0
Stage IIBT2b N1 M0
T3 N0 M0
Stage IIIAT1a, T1b, T2a, T2b N2 M0
T3 N1, N2 M0
T4 N0, N1 M0
Stage IIIBT4 N3 M0
Any T N3 M0
Stage IV Any T Any N M1a or M1b
Adapted from Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the 
revision of the TNM stage groupings in the forthcoming (seventh ) edition of the TNM Classification of malignant 
tumours. J Thorac Oncol. 2007 Aug;2(8):706-14. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 130
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
APPENDIX 2 ABBREVIATIONS AND TRADEMARKS
Term Definition
AE adverse event
ALT alanine aminotransferase
ANC absolute neutrophil count
AR Additional Research
AST aspartate aminotransferase
BICR Blinded independent central review
BID, bid bis in die, twice daily
BIPR Blinded independent pathological review
BMI body mass index
BMS Bristol-Myers Squibb Company
BP blood pressure
BUN blood urea nitrogen
C Celsius
CBC complete blood count
CFR Code of Federal Regulations 
CI confidence interval
C1- chloride
cm centimeter
CONSORT Consolidated Standards of Reporting Trials
CRF Case Report Form, paper or electronic
cRR clinical response rate
dL deciliter
DMC Data Monitoring Committee
EBUS endobronchial ultrasound
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic Case Report Form
EFS event-free survival
Protocol Amendment No.: 07
Date: 18-Aug-2021 131
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Term Definition
eg exempli gratia (for example)
FA final analysis 
FDA Food and Drug Administration
FFPE formalin-fixed paraffin-embedded
FSH follicle stimulating hormone
gg ram
GCP Good Clinical Practice
GFR glomerular filtration rate
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HIV Human Immunodeficiency Virus
HR heart rate
HRT hormone replacement therapy
IA Interim analysis 
IB Investigator‚Äôs brochure 
ICH International Conference on Harmonisation 
ie id est (that is)
IEC Independent Ethics Committee
IHC Immunohistochemical
IMP investigational medicinal products
IRB Institutional Review Board
IRT Interactive Response Technology
IU International Unit
IV intravenous
kg kilogram
L liter
LC liquid chromatography
LDH lactate dehydrogenase
Protocol Amendment No.: 07
Date: 18-Aug-2021 132
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Term Definition
mg milligram
min minute
mL milliliter
mmHg millimeters of mercury
MPR major pathological response
MLND mediastinal lymph node dissection
Œºg microgram
N number of subjects or observations
Na+ sodium
N/A not applicable
NCI CTCAE National Cancer Institute Common Terminology Criteria for 
Adverse Events
NSCLC non-small cell l ung carcinoma
NIMP non-investigational medicinal products 
OS overall survival 
PBMC peripheral blood m ononuclear cells
pCR Pathologic complete response
PFS progression-free survival
PK pharmacokinetics
PPK Populat ion pharmacokinetic 
PO per os (by mouth route of administration)
R&D Research and Development
RCC renal cell carcinoma
RECIST Response Evaluation Criteria in Solid Tumors
SAE serious adverse event
SCCHN squamous cell carcinoma of the head and neck 
SD standard deviation
SNP single nucleotide polymorphisms
SOC Standard of care
SOP Standard Operating Procedures
Protocol Amendment No.: 07
Date: 18-Aug-2021 133
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Term Definition
t temperature
WHO World Health Organization
WOCBP women of childbearing potential
Protocol Amendment No.: 07
Date: 18-Aug-2021 134
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
APPENDIX 3 ECOG PERFORMANCE STATUS 
ECOG PERFORMANCE STATUS a
0 Fully active, able to carry on all pre-disease performance wit hout restriction
1Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work
2Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair mor e than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
aOken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET,  and Carbone PP. Toxicity and Response 
Criteria of the Eastern Cooperative Oncology Group. Am J Clin O ncol 1982; 5: 649-655.
Protocol Amendment No.: 07
Date: 18-Aug-2021 135
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
APPENDIX 4 NIVOLUMAB MANAGEMENT ALGORITHMS
These general guidelines constitu te guidance to the Investigato r and may be supplemented by 
discussions with the Medical Monitor representing the Sponsor. The guidance applies to all 
immuno-oncology agents and regimens.
A general principle is that differential diagnoses should be di ligently evaluated according to 
standard medical practice. N on-inflammatory etiologies s hould be consider ed and appropriately 
treated.Corticosteroids are a primary t herapy for immuno- oncology drug-r elated adverse events. The oral 
equivalent of the recommended IV doses may be considered for am bulatory patients with low-
grade toxicity. The lower bioavailability of oral corticosteroi ds should be taken into account when 
switching to the equivalent dose of oral corticosteroids.Consultation with a medical or surgical specialis t, especially prior to an invasive diagnostic or 
therapeutic procedure, is recommended.The frequency and severity of the related adverse events covere d by these algorithms will depend 
on the immuno-oncology agent or regimen being used.
Protocol Amendment No.: 07
Date: 18-Aug-2021 136
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 137
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 138
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 139
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 140
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 141
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 142
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 143
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 18-Aug-2021 144
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
APPENDIX 5 RESPONSE CRITERIA (RECIST 1.1)
1 EVALUATION OF LESIONS
At baseline, tumor lesions/lymph nodes w ill be categorized measurable or non-measurable as 
follows:
1.1 Measurable
Tumor lesions: Must be accurately measured in at least one dime nsion (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
1) 10 mm by CT scan (CT scan slice thickness no greater than 5 mm )
2) 10 mm caliper measurement by clinical exam (lesions which can not be accurately measured 
with calipers should be recorded as non-measurable)
3) 20 mm by chest x-ray
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymp h node 
must be ‚â•15 mm in short axis when assessed by CT scan (CT scan slice thi ckness recommended 
to be no greater than 5 mm).
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes which are defined as 
measurable and may be identified as target lesions must meet th e criterion of a short axis of 
‚â•15 mm by CT scan. Only the short axis of these nodes will contri bute to the baseline sum. The 
short axis of the node is the diameter normally use d by radiologists to j udge if a node is involved 
by solid tumor. Nodal size is normally reported as two dimensions in the plane in which the image 
is obtained (for CT scan this is almost always the axial plane; for MRI the plane of acquisition  
may be axial, saggital or coronal). The smaller of these measures is the short axis. For e xample, 
an abdominal node which is reported as being 20 mm x 30 mm has a short axis of 20 mm and 
qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node 
measurement. All other pathological nodes (those with short axi s ‚â•10 mm but < 15 mm) should 
be considered non-target lesions. Nodes that have a short axis < 10 mm are considered 
non-pathological and should not be recorded or followed.
1.2 Non-Measurable
All other lesions are considered non-measurable, including smal l lesions (l ongest d iameter 
< 10mm or pathological lymph nodes with ‚â•10 to < 15 mm short axis) as w ell as truly 
non-measurable lesions. Lesions considered truly non-measurable  include: leptomeningeal 
disease, ascites, pleural or pericardial effusion, inflammatory  breast disease, lymphangitic 
involvement of skin or lung, abdominal masses/abdominal organomegaly identified by physical 
exam that is not measurable by reproducible imaging techniques.
Protocol Amendment No.: 07
Date: 18-Aug-2021 145
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
2 BASELINE DOCUMENTATION OF ‚ÄòTARGET‚Äô AND ‚ÄòNON-TARGET‚Äô 
LESIONS
When more than one meas urable lesion is present at baseline all  lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) represen tative of all involved organs should 
be identified as target lesions and will be recorded and measur ed at baseline (this means in 
instances where patients have only one or two organ sites invol ved a maximum of two and four 
lesions respectively will be recorded).
Target lesions should be selecte d on the basis of their size (l esions with the longest diameter), be 
representative of all involved organs, but in addition should b e those that lend themselves to 
reproducible repeated measurements. It may be the case that, on  occasion, the largest lesion does 
not lend itself to reproducible measurement in which circumstan ce the next largest lesion which 
can be measured reproducibly should be selected.A sum of the diameters (longest for non-nodal lesions, short ax is for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted above, only the short axis i s added into the sum. The baseline 
sum diameters will be used as reference to further characterize  any objective tumor regression in 
the measurable dimension of the disease.
All other lesions (or sites of disease) including pathological lymph nodes s hould be identified as 
non-target lesions and should also be recorded at baseline. Mea surements are not required and 
these lesions should be followed as ‚Äòpresent‚Äô, ‚Äòabsent‚Äô, or in rare cases ‚Äòunequivocal progressi on‚Äô 
(more details to follow). In additi on, it is possible to record multiple nontarget lesions involvi ng 
the same organ as a single item on the case record form (eg, ‚Äòmultiple en larged pelvic lymph nodes‚Äô 
or ‚Äòmultiple liver metastases‚Äô).
3 RESPONSE CRITERIA
3.1 Evaluation of Target Lesions
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nod es 
(whether target or non-target) must have reduction in short axi s to < 10 mm.
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesio ns, taking 
as reference the baseline sum diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesio ns, taking 
as reference the smallest sum on study (this includes the basel ine sum if that is the smallest on 
study). In addition to the relative increase of 20%, the sum mu st also demonstrate an absolute 
increase of at least 5 mm. (Note: the appearance of one or more  new lesions is also considered 
progression).Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient i ncrease to 
qualify for PD, taking as reference the smallest sum diameters while on study.
Protocol Amendment No.: 07
Date: 18-Aug-2021 146
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
3.1.1 Special Notes on the Assessment of Target Lesions
3.1.1.1 Lymph nodesLymph nodes identified as target lesions should always have the  actual short axis measurement 
recorded (measured in the same anatomical plane as the baseline  examination), even if the nodes 
regress to below 10 mm on study. This means that when lymph nod es are included as target lesions, 
the ‚Äòsum‚Äô of lesions may not be zero even if complete response criteria are met, since a normal 
lymph node is defined as having a short axis of < 10 mm. Case r eport forms or other data collection 
methods may therefore be designed to have target nodal lesions recorded in a separate s ection 
where, in order to qualify for CR, each node must achieve a sho rt axis < 10 mm. For PR, SD and 
PD, the actual short axis measurement of the nodes is to be included in the sum of target lesions.
3.1.1.2 Target lesions that become ‚Äòtoo small to measure‚Äô
While on study, all lesions (nodal and non-nodal) r ecorded at baseline s hould have their actual 
measurements recorded at each subsequent evaluation, even when very small (eg, 2 mm). 
However, sometimes lesions or lymph nodes which are recorded as  target lesions at baseline 
become so faint on CT scan that the radiologist may not feel co mfortable assigning an exact 
measure and may report them as being ‚Äòtoo small to measure‚Äô. Wh en this occurs it is important 
that a value be recorded on the case report form. If it is the opinion of the radiologist that the lesion 
has likely disappeared, the meas urement should be recorded as 0  mm. If the lesion is believed to 
be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned 
(Note: It is less likely that this rule will be used for lymph nodes since they usually have a definable 
size when normal and are freque ntly surrounded by fat such as i n the retroperitoneum; however, 
if a lymph node is believed to be present and is faintly seen b ut too small to measure, a default 
value of 5 mm should be assigned in this circumstance as well). This default value is derived from 
the 5 mm CT slice thickness (but should not be changed with varying CT slice thickness). The 
measurement of these lesions i s potentially non-reproducible, t herefore providing this default 
value will prevent false responses or progressions based upon m easurement error. To reiterate, 
however, if the radiologist is able to provide an actual measur e, that should be recorded, even if it 
is below 5 mm.
3.1.1.3 Lesions that split or coalesce on treatment
When non-nodal lesions ‚Äòfragment‚Äô, the longest diameters of the  fragmented portions should be 
added together to calculate the target lesion sum. Similarly, a s lesions coalesce, a plane between 
them may be maintained that would aid in obtaining maximal diam eter measurements of each 
individual lesion. If the lesions have truly coalesced such tha t they are no longer separable, the 
vector of the longest diameter in this instance should be the m aximal longest diameter for the 
‚Äòcoalesced lesion‚Äô.
3.2 Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to d etermine the tumor response for the 
group of non-target lesions. While some non-target lesions may actually be measurable, they need 
not be measured and instead should be assessed only qualitative ly at the time points specified in 
the protocol.
Protocol Amendment No.: 07
Date: 18-Aug-2021 147
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Complete Response (CR): Disappearance of all non-target lesions and normalization of tu mor 
marker level. All lymph nodes must be non-pathological in size ( < 10mm short axis). 
Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintena nce of tumor 
marker level above t he normal limits.
Progressive Disease (PD): Unequivocal progression (see commen ts below) of existing non-ta rget 
lesions. (Note: the appearance of one or more new lesions is al so considered progression).
3.2.1 Special Notes on Assessment of Progression of Non-Target Disease
The concept of progression of non-target disease requires addit ional explanation as follows:
3.2.1.1 When the patient also has measurable diseaseIn this setti ng, to achieve ‚Äòunequi vocal progression‚Äô on the basis of the no n-target disease, there 
must be an overall level of substantial worsening in non-target  disease such that, even in presence 
of SD or PR in target disease, the overall tumor burden has inc reased sufficiently to merit 
discontinuation of therapy (see further details below). A modes t ‚Äòincrease‚Äô in the size of one or 
more non-target lesions is usually not sufficient to qualify for  unequivocal progression status. The 
designation of overall progression solely on th e basis of chang e in non-target disease in the face 
of SD or PR of target disease will therefore be extremely rare.
3.2.1.2 When the patient has only non-measurable disease
This circumstance arises in some trials when it is not a criterion of study entry to have measurable 
disease. The same general concepts apply here as noted above, h owever, in this instance there is 
no measurable disease assessment to factor into the inte rpretati on of an increase in non- measurable 
disease burden. Because worsening in non-target disease ca nnot be easil y quantified (by definition: 
if all lesions are truly non-measurable) a useful test that can  be applied when assessing patients for 
unequivocal progressi on is to consider if the increase in overall disease burden bas ed on the change 
in non-measurable disease is comparable in magnitude to the inc rease that would be required to 
declare PD for measurable disease: ie, an increase in tumor bur den representing an additional 73% 
increase in ‚Äòvolume‚Äô (which is equivalent to a 20% increase dia meter in a measura ble lesion). 
Examples include an increase in a pleural effusion from ‚Äòtrace‚Äô  to ‚Äòlarge‚Äô, an increase in 
lymphangitic disease from localized to widespread, or may be described in protocols as ‚Äòsufficient 
to require a change in therapy‚Äô. If ‚Äòunequivocal progression‚Äô i s seen, the patient should be 
considered to have had overall PD at that point. While it would  be ideal t o have objective criteria 
to apply to non-measurable disease, the very nature of that dis ease makes it impossible to do so; 
therefore the increase must be substantial.
3.2.2 New Lesions
The appearance of new malignant lesions denotes disease progres sion; therefore, some comments 
on detection of new lesions are important. There are no specifi c criteria for the identification of 
new radiographic lesions; however, the finding of a new lesion should be unequi vocal: ie, not 
attributable to differences in scanning technique, change in im aging modality or findings thought 
to represent something other than tumor (for example, some ‚Äònew ‚Äô bone lesions may be simply 
healing or flare of pre-existing lesions). This is particularly  important when the patient‚Äôs baseline 
Protocol Amendment No.: 07
Date: 18-Aug-2021 148
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
lesions show partial or complete response. For example, necrosi s of a liver lesion may be reported 
on a CT scan report as a ‚Äònew‚Äô cystic lesion, which it is not.
A lesion identified on a follow-up study in an anatomical locat ion that was not scanned at baseline 
is considered a new lesion and will indicate disease progressio n. An example of this is the patient 
who has visceral disease at baseline and while on study has a CT or MRI brain ordered which 
reveals metastases. The patient‚Äôs brain metastases are consider ed to be evidence of PD even if 
he/she did not have brain imaging at baseline.
If a new lesion is equivocal, for example because of its small size, continued therapy and follow-up 
evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely 
a new lesion, then progression s hould be d eclared using the date  of the initial scan. While FDG-
PET response assessments need additional study, it is sometimes  reasonable to incorporate the use 
of FDG-PET scanning to complement CT scanning in assessment of progression (particularly 
possible ‚Äònew‚Äô disease). New lesions on the basis of FDG-PET im aging can be identified according 
to the following algorithm:
4) Negative FDG-PET at baseline, with a positive FDG-PET at foll ow-up is a sign of PD based 
on a new lesion.
5) No FDG-PET at baseline and a positive FDG-PET at follow-up: I f the positive FDG-PET at 
follow-up corresponds to a new site of disease confirmed by CT,  this is PD. If the positive 
FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up 
CT scans are needed to determine if there is truly progression occurring at that site (if so, the 
date of PD will be the d ate of the initial a bnormal FDG-PET scan). If the positive FDG-PET 
at follow-up corresponds to a pre-existing site of disease on C T that is not progressing on the 
basis of the anatomic images, this is not PD.
3.3 Response Assessment
3.3.1 Evaluation of Best Overall Response
The best overall response is the best response recorded from th e start of the study treatment until 
the end of treatment taking into account any requirement for co nfirmation. The patient‚Äôs best 
overall response assignment will depend on the findings of both  target and non-target disease and 
will also take into consideration the appearance of new lesions . Furthermore, depending on the 
nature of the study and the protocol requirements, it may also require confirmatory measurement.
3.3.2 Time Point Response
It is assumed that at each protocol specified time point, a res ponse assessment occurs. Table 3.3.2-
1provides a summary of the overall response status calculation a t each time point for patients who 
have measurable disease at baseline. When patients have non-mea surable (therefore non-target) 
disease only, Table 3.3.2-2 is to be used. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 149
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 3.3.2-1: Time Point Response -  Patients With Target (+/- N on-Target) 
Disease
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non-PD No PR
CR Not evaluated No PR
PRNon-PD or not all 
evaluatedNo PR
SDNon-PD or not all 
evaluatedNo SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease and NE = inevaluable
Table 3.3.2-2: Time Point Response - Patients with Non-target Dis ease Only
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non-PD No Non-CR/non-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
CR = complete response, PD = progressive disease and NE = ineval uable
aNon-CR/non-PD is preferred over SD for non-target disease since  SD is increasingly used as endpoint for 
assessment of efficacy in some trials so to assign this categor y when no lesions can be measured is not advised.
3.3.3 Best Overall Response 
Best response determinati on of complete or par tial res ponse requires confirmation: Complete or 
partial responses may be claimed only if the criteria for each are met at a subsequent time point of 
‚â•4 weeks later. In this circumstance, the best overall response can be interpreted as in Table 3.3.3-
1.
Special note on response assessment: When nodal disease is included in the sum of target lesions 
and the nodes decrease t o ‚Äònormal‚Äô s ize (< 10 mm), they may st ill have a measurement reported 
on scans. This measurement should be recorded even though the n odes are normal in order not to 
overstate progression should it be based on increase in size of  the nodes. As noted earlier, this 
means that patients with CR may not have a total sum of ‚Äòzero‚Äô on the case report form (CRF).
Protocol Amendment No.: 07
Date: 18-Aug-2021 150
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Table 3.3.3-1: Best Overall Response (Confirmation of CR&PR Requ ired)
Overall Response 
First Time PointOverall Response 
Subsequent Time PointBEST Overall Response
CR CR CR
CR PR SD, PD OR PRa
CR SDSD provided minimum criteria for SD durationbmet, 
otherwise, PD
CR PDSD provided minimum criteria for SD durationbmet, 
otherwise, PD
CR NESD provided minimum criteria for SD durationbmet, 
otherwise, NE
PR CR PR
PR PR PR
PR SD SD
PR PDSD provided minimum criteria for SD durationbmet, 
otherwise, PD
PR NESD provided minimum criteria for SD duration bmet, 
otherwise, NE
NE NE NE
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and 
NE = inevaluable
aIf a CR is truly met at first time point, then any disease seen  at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that poi nt (since disease must have reappeared after CR). Best 
response would depend on whether minimum duration for SD was me t. However, sometimes ‚ÄòCR‚Äô may be claimed 
when subsequent scans suggest small lesions were likely still p resent and in fact the patient had PR, not CR at the 
first time point. Under these circumstances, the original CR sh ould be changed to PR and the best response is PR.
bMinimum criteria for SD duration is 6 weeks.
3.3.4 Confirmation Scans
Verification of Response: To be assigned a status of CR or PR, c hanges in tumor measurements 
must be confirmed by consecutive repeat assessments that should  be performed no less than 
28 days after the criteria for response are first met. For this study, the next scheduled tumor 
assessment can meet this requirement.
Verification of Progression: Progression of disease should be ve rified in cases where progression 
is equivocal. If repeat scans confirm PD, then progression should be declared using the date of the 
initial scan. If repeat scans do not confirm PD, then the subje ct is considered to not have 
progressive disease.
Protocol Amendment No.: 07
Date: 18-Aug-2021 151
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
APPENDIX 6 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until beco ming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hy sterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
‚Ä¢Premenarchal
‚Ä¢Premenopausal female wi th 1 of the following:
‚àíDocumented hysterectomy
‚àíDocumented bilateral salpingectomy
‚àíDocumented bilateral oophorectomy
Note: Documentation can come from the site personnel‚Äôs review of  the participant‚Äôs medical 
records, medical examination, or m edical history interview.
‚Ä¢Postmenopausal female
‚àíA postmenopausal state is defined as 12 months of amenorrhea in  a woman over age 
45 years in the absence of other biological or physiological cau ses. In addition, females 
under the age of 55 years must have a serum follicle stimulatin g hormone, (FSH) level 
> 40 mIU/mL to confirm menopause.
CONTRACEPTION GUIDANCE FOR FEMALE PARTICIPANTS OF CHILD BEARING  
POTENTIAL
One of the highly effective methods of contraception listed bel ow is required during study duration 
and until the end of relevant systemic exposure, defined as 5 mo nths after the end of study 
treatment.
Local laws and regulations may require use of alternative and/o r additional contraception methods.
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctly.a
‚Ä¢Combined (estrogen- and progestogen- containing) hormonal contraception associated with 
inhibition of ovulationb 
‚àíoral 
‚àíintravaginal 
‚àítransdermal
‚Ä¢Progestogen-only hormonal contraception associated with inhibit ion of ovulationb 
Protocol Amendment No.: 07
Date: 18-Aug-2021 152
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
‚àíoral 
‚àíinjectable
Highly Effective Methods That Are User Independent 
‚Ä¢Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulationb
‚Ä¢Hormonal methods of contraception including oral contraceptive pills containing a 
combination of estrogen and progesterone, vaginal ring, injectab les, implants and
intrauterine hormone-releasing system (IUS)c
‚Ä¢Intrauterine device (IUD)c
‚Ä¢Bilateral tubal occlusion
‚Ä¢Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used. 
‚Ä¢Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evalua ted in relation to the duration of the study and 
the preferred and usual lifestyle of the participant.
‚Ä¢It is not necessary to use any other method of contraception whe n complete abstinence is 
elected. 
‚Ä¢WOCBP participants who choose complete abstinence must continue to have pregnancy 
tests, as specified in Section 2. 
‚Ä¢Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participants chooses to forego complete abs tinence 
NOTES: 
aTypical use failure rates may differ from those when used consi stently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive metho ds for participants participating in clinical studies. 
bHormonal contraception may be susceptible to interaction with t he study drug, which may reduce the efficacy 
of the contraceptive method.  Hormonal contraception is permissible only when there is sufficient evidence that 
the IMP and other study med ications will not alter hormonal exposures such that contracept ion would be 
ineffective or result in increased exposures that could be potentially hazardous.  In this case, alternative methods of contraception should be utilized. 
cIntrauterine devices and intrauterine hormone releasing systems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exp osures from intrauterin e devices do not alter 
contraception effectiveness
Protocol Amendment No.: 07
Date: 18-Aug-2021 153
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Unacceptable Methods of Contraception
‚Ä¢Male or female c ondom with or without spermicide.  Male and fem ale condoms cannot be 
used simultaneously
‚Ä¢Diaphragm with spermicide
‚Ä¢Cervical cap with spermicide
‚Ä¢Vaginal Sponge with spermicide
‚Ä¢Periodic abstinence (calendar, symptothermal , post-ovulation me thods)
‚Ä¢Withdrawal(coitus interruptus).
‚Ä¢Spermicide only
‚Ä¢Lactation amenorrhea method (LAM)
CONTRACEPTION GUIDANCE FOR MALE PARTICIPANTS WITH PARTNER(S) OF 
CHILD BEARING POTENTIAL.
Male participants with female partners of childbearing potentia l are eligible to participate if they 
agree to the following during the treatment and until the end o f relevant systemic exposure.
‚Ä¢Inform any and all partner(s) of their participation in a clini cal drug study and the need to 
comply with contraception instructions as directed by the inves tigator.
‚Ä¢Male participants are required to use a condom for study durati on and until the end of relevant 
systemic exposure defined as 7 months after the end of treatment  in the male participant.
‚Ä¢Female partners of males participating in the study to consider  use of effective methods of 
contraception until the end of relevant systemic exposure, defined as 7 months after the end of 
treatment in the male participant.
‚Ä¢Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile vaginal intercourse or use a male condom during each episode of penile penetration 
during the treatment and until 7 months after the end of treatme nt.
‚Ä¢Refrain from donating sperm for the duration of the study treat ment and until 7 months after 
the end of treatment.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnanc y Information and outcome of  pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.2.5 and the Appendix for Adverse Events and Serious 
Adverse Events Definitions and procedures for Evaluating, Follow -up and Reporting
Protocol Amendment No.: 07
Date: 18-Aug-2021 154
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
APPENDIX 7 STUDY GOVERNANCE CONSIDERATIONS
The term ‚ÄòParticipant‚Äô is us ed in the protocol to refer to a person who has consented to participate 
in the clinical research study.  The term ‚ÄòSubject‚Äô used in the  eCRF is intended to refer to a person 
(Participant) who has consented to participate in the clinical research study.
REGULATORY AND ETHICAL CONSIDERATIONS
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:
‚Ä¢Good Clinical Practice (GCP), 
‚Ä¢as defined by the International Council on Harmonisation (ICH)
‚Ä¢in accordance with the ethical principles underlying European U nion Directive 2001/20/EC
‚Ä¢United States Code of Federal Regulations, Title 21, Part 50 (2 1CFR50) 
‚Ä¢applicable local requirements.
The study will be conducted in compliance with the protocol. Th e protocol and any amendments 
and the participant informed consent will r eceive approval/favorable opinion by Institutional 
Review Board/Independent Ethics Committee (IRB/IEC), and regula tory authorities according to 
applicable local regulations prior to initiation of the study.
All potential serious breaches must be reported to Sponsor or designee immediately. A serious
breach is a breach of the conditions and principles of GCP in c onnection with the study or the 
protocol, which is lik ely to affect, to a significant degree, t he safety or physical or mental integrity 
of the subjects of the study or the scientific value of the stu dy.
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where s anctions have been invoked or where 
there has been scientific misconduct or fraud (e.g., loss of me dical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and  dated approval/favorable opinion 
from the IRB/IEC for the protocol , consent form, participant re cruitment materials (e.g., 
advertisements), and any other written information to be provid ed to subjects. The investigator or 
BMS should als o provide the IRB/IEC with a copy of the  Investigator Brochure or product labeling 
information to be provided t o subjects and any updates. 
The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
information (e.g., expe dited safety reports, amendments, and administrative letters)  according to 
regulatory requirements or institution procedures.
Protocol Amendment No.: 07
Date: 18-Aug-2021 155
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not imp lement any deviation or change t o the protocol without prior 
review and documented approval/favorable opinion of an amendmen t from the IRB/IEC (and if 
applicable, also by local health authority) except where necessa ry to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to elimin ate an immediate hazard(s) prior to 
obtaining relevant  approval/favorable opinion(s) the deviation  or change will be submitted, as 
soon as possible to:
‚Ä¢IRB/IEC for 
‚Ä¢Regulatory Authority(ies), if applicable by local regulations ( per national requirements)
Documentation of approval/favorable opinion signed by the chair person or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority  must be sent to BMS.
If an amendment substantially alters the study design or increa ses the potential risk to the 
participant: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review 
and approval/favorable opinion; (2) the revised form must be us ed to obtain consent from subjects 
currently enrolled in the study if they are affected by the ame ndment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment .
If the revision is done via an administrative letter, investiga tors must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and su b-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit comp lete and 
accurate financial certification or disclosure statements to th e appropriate h ealth aut horities. 
Investigators are responsible fo r providing information on financial interests during the course  of 
the study and for 1 year after completion of the study.
INFORMED CONSENT PROCESS
Investigators must ensure that subjects are clearly and fully i nformed about the purpose, potential 
risks, and other critical issues regardi ng clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives (as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the partici pant volunteers to participate. 
Sponsor or designee will provide t he investigator with an appro priate (i.e., Global or Local) sample
informed consent form which will include all elements required by ICH, GCP and app licable
regulatory requirements. The sample informed consent form will adhere to the ethical principles 
that have their origin in the Declaration of Helsinki.
Protocol Amendment No.: 07
Date: 18-Aug-2021 156
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Investigators must:
‚Ä¢Provide a copy of the consent form and written information abou t the study in the language in 
which the participant is most proficient prior to clinical study participation. The language must 
be non-technical and easily understood. 
‚Ä¢Allow time necessary for participant or participant's legally a cceptable representative to 
inquire about the details of the study.
‚Ä¢Obtain an informed consent signed and personally dated by the p articipant or the participant's 
legally acceptable representative and by the person who conduct ed the informed consent 
discussion. 
‚Ä¢Obtain the IRB/IEC‚Äôs written approval/favorable opinion of the written informed consent form 
and any other information to be provided to the subjects, prior  to the beginning of the study, 
and after any revisions are completed for new information.
If informed consent is initially given by a participant‚Äôs legal ly acceptable representative or legal 
guardian, and the participant subsequently becomes capable of m aking and communicating his or 
her informed consent during the study, consent must additionall y be obtained from the participant.
Revise the informed consent whenever important new information becomes available that is 
relevant to the participant's consent. The investigator, or a p erson designated by the investigator, 
should fully inform the participant or the participant's legall y acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
participant's willingness to continue participation in the stud y. This commun ication should be 
documented. 
The confidenti ality of records that could identify subjects must be protected , respecting the privacy 
and confidentiality rules applicable to regulatory requirements , the subjects' signed ICF and, in the 
US, the subjects‚Äô signed HIPAA Authorization.The consent form must also include a statement that BMS and reg ulatory authorities have direct 
access to participant records. 
Subjects unable to give their written consent (e.g., stroke or subjects with or severe dementia) may 
only be enrolled in the study with the consent of a legally acc eptable representative. The participant 
must also be informed about the nature of the study to the exte nt compatible with his or her 
understanding, and should this participant become capable, he or she should personally sign and 
date the consent form as soon as possible. The explicit wish of  a participant who is unable to give 
his or her written consent, but who is capable of forming an op inion and assessing information to 
refuse participation in, or to be withdrawn from, the clinical study at any time should be considered 
by the investigator.
The rights, safety, and well-being of the study subjects are th e most important considerations and 
should prevail over interests of science and society.
Protocol Amendment No.: 07
Date: 18-Aug-2021 157
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
SOURCE DOCUMENTS
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attr ibutable, whether the data are hand-written on paper or entered 
electronically. If source  data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computer ized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such s ystems must be compliant with all 
applicable laws and regulations governing use of electronic rec ords and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments , and/or drug accountability 
records).
When paper records from such systems are used in place of elect ronic format to perform regulated 
activities, such paper records should be certified copies. A ce rtified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes a nd information as the original. 
STUDY TREATMENT RECORDS
Records for study treatments (w hether supplied by BMS, its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for revie w at the request of BMS/designee 
or a Health Authority.
If Then
Supplied by BMS (or its vendors):Records or logs must comply with applicable 
regulations and guidelines and should include:
‚Ä¢amount received and placed in storage area
‚Ä¢amount currently in storage area
‚Ä¢label identification number or batch number
‚Ä¢amount dispensed to and returned by each 
participant, including unique participant identifiers
‚Ä¢amount transferred to another area/site for 
dispensing or storage
‚Ä¢nonstudy disposition (e.g., lost, wasted) 
‚Ä¢amount destroyed at study site, if applicable
‚Ä¢amount returned to BMS
‚Ä¢retain samples for bioavailability/bioequivalence, 
if applicable 
‚Ä¢dates and initials of person responsible for Investigational Product dispensing/accountability, as per the Delegation of Authority Form.
Sourced by site, and not supplied by BMS or its 
vendors (examples include IP sourced from the sites 
stock or commercial supply, or a specialty pharmacy)The investigator or designee accepts responsibility for 
documenting traceability and study drug integrity in 
accordance with requirements applicable under law and the SOPs/standards of the sourcing pharmacy.   
These records should include:
Protocol Amendment No.: 07
Date: 18-Aug-2021 158
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
If Then
‚Ä¢label identification number or batch number 
‚Ä¢amount dispensed to and returned by each 
participant, including unique participant identifiers
‚Ä¢dates and initials of person responsible for Investigational Product dispensing/accountability, as per the Delegation of Authority Form.
BMS or designee will provide  forms to facilitate inventory cont rol if the investigational site does not have an 
established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate an d accurate case histories designed 
to record all observations and other d ata pertinent to the investig ation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source document s or the discrepancies must be 
explained. Additional clinical information may be collected and  analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture tool, electronic CRFs w ill be 
prepared for all data collection fields except for fields speci fic to SAEs and pregnancy, which will 
be reported on the electronic SAE form and Pregnancy Surveillan ce form, respectively.  If 
electronic SAE form is not av ailable, a paper SAE form can be used. Spaces may be left blank  
only in those circumstances permitted by study-specific CRF com pletion guidelin es provi ded by 
Sponsor or designee. 
The confidentiality of records that could identify subjects mus t be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable reg ulatory requirement(s).
The investigator will maintain a signature sheet to document si gnatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. The completed CRF, SAE/pregnancy CRFs, must be promptly reviewe d, signed, and dated by the 
investigator or qualified physician who is a subinvestigator an d who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may not  be delegated the CRF approval 
task For electronic CRFs, review a nd approval/signature is compl eted electroni cally through the 
BMS electronic data capture tool. The investigator must r etain a copy of the CRFs including 
records of the changes and corrections.
Each individual electronically si gning electronic CRFs must mee t Sponsor or designee training
requirements and must only access the BMS electronic data captu re tool using the unique user 
account provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individualsMONITORING
Sponsor or designee representatives will review data centrally to  identify potential issues to 
determine a schedule of on-site visits for targeted review of s tudy records. 
Protocol Amendment No.: 07
Date: 18-Aug-2021 159
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity . On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with th e investigator, and verify that the 
facilities remain acceptable.
In addition, the study may be evaluated by Sponsor or designee in ternal auditors and government 
inspectors who must be allowed access to CRFs, source documents , other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of a ny inspections scheduled by regulatory authori ties, 
and promptly forward copies of inspection reports to Sponsor or  designee.
RECORDS RETENTION
The investigator (or head of the study site in Japan) must reta in all study records and source 
documents for the maximum period required by applicable regulat ions and guidelines, or 
institution procedures, or for the period specified by BMS or d esignee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the st udy site in Japan) when the study 
records are no longer needed.If the investigator withdraws from the study (e.g., relocation,  retirement), the records sh all be 
transferred to a mutually agreed upon designee (e.g., another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS, a vend or or sourced by the investigator) 
such as partially used study treatment containers, vials and sy ringes may be destroyed on site. 
If.. Then
Study treatments supplied by BMS (including its 
vendorsAny unused study treatments supplied by BMS can 
only be destroyed after being inspected and reconciled 
by the responsible Study Monitor unless study 
treatments containers must be immediately destroyed 
as required for safety, or to meet local regulations (e.g., 
cytotoxics or biologics).
If study treatments will be returned, the return will be 
arranged by the responsible Study Monitor.
Study treatments sourced by site, not supplied by BMS 
(or its vendors) (examples include study treatments 
sourced from the sites stock or commercial supply, or a 
specialty pharmacy)It is the investigator‚Äôs or designee‚Äôs responsibility to 
dispose of all containers according to the institutional 
guidelines and procedures.
It is the investigator‚Äôs or designee‚Äôs responsibility to arrang e for disposal, provided that procedures 
for proper disposal have been e stablished according to applicab le federal, state, local, and 
Protocol Amendment No.: 07
Date: 18-Aug-2021 160
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The following minimal standards must be met:
‚Ä¢On-site disposal practices must not expose humans to risks from  the drug.
‚Ä¢On-site disposal practices and procedures are in agr eement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
‚Ä¢Written procedures for on-site disposal are available and follo wed. The procedures must be 
filed with the site‚Äôs SOPs and a copy  provided t o BMS upon request.
‚Ä¢Records are maintain ed that allow for traceability of each cont ainer, including the date 
disposed of, quantity disposed, and identif ication of the person disposing the containers. The 
method of disposal, i.e., incinerator, licensed sanitary landfi ll, or licensed waste disposal 
vendor must be documented.
‚Ä¢Accountability and disposal records are complete, up-to-date, a nd available for the Monitor to 
review throughout the clinical trial period.
It is the investigator‚Äôs or designee‚Äôs responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Stu dy Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors) . Destruction of non- study 
treatments s ourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee.CLINICAL STUDY REPORT AND PUBLICATIONS
A Signatory Investigator must be s elected to sign the clinical study report. 
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
‚Ä¢External Principal Investigator designated at protocol developm ent
‚Ä¢National Coordinating Investigator 
‚Ä¢Study Steering Committee chair or their designee
‚Ä¢Participant recruitment (e.g., among the top quartile of enroll ers)
‚Ä¢Involvement in trial design
‚Ä¢Regional representation (e.g., among top qua rtile of enro llers from a specified region or 
country)
‚Ä¢Other criteria (as determined by the study team)
The data collected during this study are confident ial and proprietary to Spons or or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTA) governing [Study si te or Investigator] par ticipation in 
the study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to s ubmission or presentation and 
otherwise within the time period set forth in the CTA.
Protocol Amendment No.: 07
Date: 18-Aug-2021 161
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
APPENDIX 8 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW UP AND REPORTING ADVERSE 
EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical oc currence or worsening of a 
preexisting medical condition in a clinical investigation parti cipant administered study treatment
and that does not necessarily hav e a causal relati onship with t his treatment. 
An AE can therefore be any unfavorable and unintended sign (suc h as an abnormal laboratory 
finding), symptom, or disease temporally associated with the us e of study treatment, whether or 
not considered related to the study treatment.
Events Meeting the AE Definition
‚Ä¢Any abnormal laboratory test results (hematol ogy, clinical chem istry, or urinalysis) or 
results from other safety assessments (eg, ECG, radiological sc a n s ,  v i t a l  s i g n s  
measurements), including those that worsen from baseline, consi dered clinically significant 
in the medical and scie ntific judgment of the investigator. Note  that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not 
available. Once the final diagnosis is known, the reported term  should be updated to be the 
diagnosis.
‚Ä¢Exacerbation of a chronic or intermittent pre-existing conditio n including either an increase 
in frequency and/or intensity of the condition.
‚Ä¢New conditions detected or diagnosed after study intervention a dministration even though it 
may have been present before the start of the study.
‚Ä¢Signs, symptoms, or the clinical sequelae of a suspected drug-d rug interaction.
‚Ä¢Signs, symptoms, or the clinical sequelae of a s uspected overdo se of either study intervention 
or a concomitant medication. Overdose, as a verbatim term (as r eported by the investigator), 
shoul d not be reported as an AE/SAE unless it is an intentional  overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae and 
should specify "intentional overdose" as the verbatim term
Events NOT Meeting the AE Definition
‚Ä¢Medical or surgical proce dure (eg, endoscopy, appendectomy): th e condition that leads to 
the procedure is the AE.
‚Ä¢Situations in which an untoward medical occ urrence did not occur (so cial and/or 
convenience admission to a hospital).
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot b e an SAE even if serious conditions 
are met.
Protocol Amendment No.: 07
Date: 18-Aug-2021 162
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
SERIOUS ADVERSE EVENTS
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participa nt was at risk of  death at the time 
of the event; it does not refer to an event which hypotheticall y might have caused death if it were 
more severe)
Requires inpatient hospitalization or causes prolongation of ex isting hospitalization (see NOTE 
below)
NOTE: 
The following hospitalizations are not  considered SAEs in BMS clinical studies: 
‚Ä¢a visit to the emergency room or other hospital department < 24 hours, that does not result 
in admission (unless considered an important medical or life-th reatening event)
‚Ä¢elective surgery, planned prior to signing consent
‚Ä¢admissions as per protocol for a planned medical/surgical procedure
‚Ä¢routine health assess ment requiring admission for baseline/tren ding of health status (e.g., 
routine colonoscopy)
‚Ä¢medical/surgical admission other  than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases
‚Ä¢admission encountered for another life circumstance that carrie s no bearing on health status 
and requires no medical/surgical intervention (e.g., lack of ho using, economic inadequacy, 
caregiver respite, family circumstances, administrative reason)
‚Ä¢admission for administr ation of anticancer therapy in the absence of any other SAEs (applies 
to oncology protocols)
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
Is an important medical event (defined as a medical event(s) th at may not be immediately life-
threatening or result in death or hospitalization but, based up on appropriate medical and 
scientific judgment, may jeopardize the participant or may requi re intervention [e.g., medical, 
surgical] to prevent one of the other serious outcomes listed i n the definition above.) Examples 
of such events include, but are not limited to, intensive treat ment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or co nvulsions that do not result in 
hospitalization.) Potential drug indu ced liver injury (DILI) is also considered an important 
medical event. (See Section 9.2.7 for the definition of potential DILI.) 
Pregnancy and potential drug induced liver injury (DILI) must fo llow the same transmission timing 
and processes to BMS as used for SAEs (see section 9.2.5 for reporting pregnancies).
Protocol Amendment No.: 07
Date: 18-Aug-2021 163
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
Any component of a study endpoint that is considered related to  study therapy should be reported 
as SAE (e.g., death is an endpoint, if death occurred due to an aphylaxis, anaphylaxis must be 
reported).
EVALUATING AES AND SAES
Assessment of Causality
‚Ä¢The investigator is obligated to assess the relationship betwee n study intervention and each 
occurrence of each AE/SAE.
‚Ä¢A ‚Äúreasonable possibility‚Äù of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relat ionship cannot be ruled out.
‚Ä¢The investigator will use clinical judgment to determine the re lationship.
‚Ä¢Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention administration 
will be considered and investigated.
‚Ä¢The investigator will also consult the Investigat or‚Äôs Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
‚Ä¢For each AE/SAE, the investigator must document in the medical n otes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality .
‚Ä¢There may be situations in which an SAE has occurred and the in vestigator has minimal 
information to include in the initial report to Sponsor. Howeve r, it is very important that the 
investigator always make an assessment of causality for every e vent before the initial 
transmission of the SAE data to Sponsor.
‚Ä¢The investigator may change his/her opinion of causality in lig ht of follow-up information 
and send a SAE follow-up report with the updated causality asse ssment.
‚Ä¢The causality assessment is one  of the criteria used when deter mining regulatory reporting 
requirements.
Follow-up of AEs and SAEs
If only limited information is i nitially available, follow- up reports are required. (Note: Follow-
up SAE reports must include the same investigator term(s) initi ally reported.) 
If an ongoing SAE changes in its intensity or relationship to s tudy treatment or if new 
information becomes available, the SAE report must be updated and submitted within 24 hours 
to BMS (or designee) using the same procedure used for transmit ting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
Protocol Amendment No.: 07
Date: 18-Aug-2021 164
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
REPORTING OF SAES TO SPONSOR OR DESIGNEE
‚Ä¢SAEs, whether related or not r elated to study treatment, and pregnancies must be reported 
to BMS (or designee) immediately within 24 hours of awareness of the event.
‚Ä¢SAEs must be recorded on the SAE Report Form.
‚àíThe required method for SAE data reporting is through the eCRF.
‚àíThe paper SAE Report Form is only intended as a back-up option when the electronic 
data capture (EDC) system is unavailable/not functioning for tr ansmission of the eCRF 
to BMS (or designee).
‚ô¶In this case, the paper form is transmitted via email or confir med facsimile (fax) 
transmission
‚ô¶When paper forms are used, the original paper forms are to remain on site
‚Ä¢Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via email or 
confirmed facsimile (fax) transmission 
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.SAE Telephone Contact (required for SAE and pregnancy reporti ng): Refer to Contact 
Information list
Protocol Amendment No.: 07
Date: 18-Aug-2021 165
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
APPENDIX 9 REVISED PROTOCOL SUMMARY OF CHANGE HISTORY
OVERALL RATIONALE FOR REVISED PROTOCOL 06, 14-Jul-2020
During recent interactions with health authorities (2020), they  indicated that the early event-free 
survival (EFS) interim analysis (IA) may lack robustness due to immature data. Accordingly, the 
EFS IA plan was changed in protocol revision 06 to remove the f irst planned IA.
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 06
Section Number and Name Description of Change Brief Rationale
Synopsis, Objectives and Endpoints
Table 4-1 Objectives and Endpoints
Table 10.3.1 Efficacy AnalysesClarified that any progression precluding 
surgery is an EFS event and that 
RECIST 1.1 progression/recurrence per blinded independent central review (BICR) applies post surgery or for participants without surgeryClarified EFS definition
Synopsis, Number of Participants
5.2 Number of ParticipantsCorrected the number of participants To align with 10.1 Sample 
Size Determination
5.3 End of Study Definition
10.1.2 Event Fr ee Survival
10.1.3 Power Consideration for 
Overall Survival (OS)
Table 10.1.3-1 Power Calculation for 
EFS and OS
10.1.4 Analyses Timing Projections
Table 10.1.4-1 Scheduled Analyses, 
Criteria, and Projected Timelines
10.3.3 Interim AnalysesRemoved the first of 2 IA of EFS and 
updated alpha spending on the remaining 
single interim and final analyses of EFSHealth authorities suggested 
that the early EFS IA may 
lack robustness at that level of data maturity
10.1.2 Event Free Survival
10.1.4 Analyses Timing ProjectionsTable 10.1.4-1 Scheduled Analyses, 
Criteria, and Projected TimelinesClarified that actual timing of analyses may differ from projected timingClarified potential variation in analyses timing 
10.1.2 Event Free Survival Removed text about descriptive EFS analysisDescriptive analyses for the DMC will be described in the DMC Charter
All Corrected typographical errors Minor, so not specified
Protocol Amendment No.: 07
Date: 18-Aug-2021 166
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
OVERALL RATIONALE FOR REVISED PROTOCOL 05, 18-Sep-2019
The revised protocol updates analyses projections for pCR and EFS and clarif ications of surgery 
exploratory endpoints, instruction for biomarker collection and  pathology review, and rules for 
PD-L1 stratification. Additiona lly, management algorithms were updated for myocarditis.
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 05
Section Number and Name Description of Change Brief Rationale
Synopsis 
Section 4 Objectives and EndpointsUpdated exploratory endpoint to include 
completeness of resection in surgical approachUpdate provides clarity on collection of surgical outcomes
Synopsis 
Section 5.1 Overall DesignUpdated stratification of participants with 
PD-L1 not evaluable/ indeterminate status 
to PD-L1 negative participantsUpdate provides clarity 
for stratification of  participants with PD-L1 
not evaluable/ 
indeterminate status
SynopsisLanguage updated to identify the 
CA209816 Laboratory Manual as a source 
for pathology specimen collection and processing. Additionally, blinded pathology review process will assess for confirmation of endpoints.Updates provide 
instruction for guidelines 
for collection and processing of pathology specimens and confirmation  of 
endpoints
Section 5.3 End of Study Definitions Updated the timing of pCR rateProvides updated projection of analysis for pCR rate. 
Section 9.8.1.1 Tumor Tissue SpecimensClarified tumor biopsy collection will not 
be collected in ChinaSites are unable to collect optional tumor biopsy in China. 
Section 10.1 Sample Size Determination
Section 10.1.1 Pathologic Complete 
Response (pCR)
Sections 10.1.4 Analyses Timing 
Projections
Section 10.2 Populations for Analyses
Section 10.3.1 Efficacy Analyses
Section 10.3.3 Interim AnalysesUpdates anticipated sample size and 
projected timing of analyses for pCR and EFSProvides updated information for analysis for pCR and EFS..
Section 10.3.1 Efficacy AnalysesUpdated statistical analysis methods for TTDM Statistical analysis methods for TTDM were updated.
Appendix 4 Management AlgorithmsUpdated management algorithms to 
include myocarditisAligns management algorithms with updated 
Investigator Brochure
Protocol Amendment No.: 07
Date: 18-Aug-2021 167
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
OVERALL RATIONALE FOR REVISED PROTOCOL 04, 25-Jun-2019
The CA209816 revised protocol 04 adds EFS on next line of therapy as an exploratory objective. 
Statistical analyses, power calculations, proj ected timelines  
. Additional changes were added for clarity.
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 04
Section Number and Name Description of Change Brief Rationale
Synopsis
Table 4-1: Objectives and EndpointsAdded exploratory endpoint of Event Free 
Survival on next line of therapyAdded EFS on next line of therapy, as provides additional follow-up information for efficacy and survival 
Section 7.7.1 Prohibited and/or 
Restricted TreatmentsAdded the concomitant administration of substances that are also tubularly secreted 
(eg, probenecid) could potentially result in delayed clearance of pemetrexed.Added to comply with 
HA request
Section 10.2.1 Populations for Analysis at Pathologic Complete 
Response Analysis TimepointClarified the pCR analysis populationUpdated section for 
clarity
SynopsisSection 5.1 Overall Design
Section 5.1.1 Data Monitoring Committee and Other External Committees‚Ä¢BICR confirmation of progression should not be requested if investigator judges the progression will not preclude surgery.
‚Ä¢Tumor assessments (if clinically feasible) and BICR should continueeven after the initiation of subsequent anti-cancer therapies.Updated parameters for 
BICR confirmation for 
clarity
Section 10.1.3 Power Consideration for Overall Survival (OS)Table 10.1.3-1: Power Calculation for EFS and OSSection 10.3.3 Interim AnalysesAdded power consideration for OS testingIn case of significant EFS, OS will be tested.
Section 10.1.4 Analyses Timing 
Projections
Table 10.1.3-1 Scheduled Analyses, Criteria, and Projected TimelinesUpdated the analysis timing projectionsUpdated the analysis 
timing projections
Appendix 8 Adverse Events and Serious Adverse Events: Definitions 
and Procedures for Recording, Evaluating, Follow Up and Reporting Adverse EventsUpdated AE template languageUpdated appendix to 
align with program 
standards
Protocol Amendment No.: 07
Date: 18-Aug-2021 168
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
OVERALL RATIONALE FOR REVISED PROTOCOL 03, 21-Sep-2018
The CA209816 revised protocol closes enrollment in Arm A (nivol umab plus ipilimumab) and 
expands the sample size in Arm B (chemotherapy) and Arm C (nivo lumab plus chemotherapy). 
Subsequently, the study rati onale and statistic al section was up dated to support the new analyses. 
Additional changes were made to provide clarity in study conduc t.
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 03
Section Number and Name Description of Change Brief Rationale
Synopsis, Objectives, Overall Design, 
Schema, Number of Participants 
Section 4 Objectives and Endpoints
Section 5.1 Overall Design
Section 5.2 Number of ParticipantsEnrollment in Arm A (nivolumab 
plus ipilimumab) was stopped and 
randomization of participants (1:1 
ratio) into Arm B and C will continue 
enrolling for a total of 350 
participantsStudy design was changed 
to support nivolumab plus 
chemotherapy as 
neoadjuvant therapy in 
NSCLC based on emerging 
data.
Synopsis, Objectives
Section 4 Objectives and Endpoints‚Ä¢Updated objectives for 
assessments of Arm B to Arm C
‚Ä¢Added time to death or distant 
metastases (TTDM) as 
secondary objective
‚Ä¢Updated tertiary objectives for Arm A (nivolumab and ipilimumab)Objectives were updated to 
align with change in study 
design
Synopsis Overall DesignParticipants with large-cell 
neuroendocrine carcinoma tumor 
histology are excludedEligibility criteria was 
updated as protocol‚Äôs 
chemotherapy regimens are 
not optimal for treating this specific subtype of NSCLC
Synopsis Treatment Arms and Duration, 
Study Treatment 
Section 5.1 Overall Design
Section 5.4.6 Rationale for Choices of 
Platinum-based Chemotherapy Doublet
Table 7-1 Study Treatments for CA209816
Section 7.1 Treatments Administered
Table 7.1-1 Selection and Timing of Doses
Section 7.4 Dose ModificationsAdditional platinum doublet 
chemotherapy regimen 
(paclitaxel/carboplatin) was addedAdditional platinum 
doublet chemotherapy 
regimens 
(paclitaxel/carboplatin) 
added to reflect knowledge 
gained from emerging data.
Section 7.4.1.1 Platinum Doublet 
Chemotherapy - Dose Reductions for 
Hematologic Toxicity
Section 7.4.1.2 Platinum Doublet 
Chemotherapy - Dose Reductions for Non-
Hematologic ToxicitiesUpdated and moved dose 
modification for docetaxel into 
hematologic t oxicity and non-
hematologic toxicity sections.Updated dose modification 
for docetaxel into correct 
sections of protocol.
Section 7.4.2.2 Dose Delay Criteria for 
Platinum Doublet ChemotherapyProvided updated dose delay criteria 
for chemotherapy Provided updated dose 
delay criteria for safety
Protocol Amendment No.: 07
Date: 18-Aug-2021 169
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 03
Section Number and Name Description of Change Brief Rationale
Table 2-3 Post Neoadjuvant Period for 
Those Participants Not Receiving 
Adjuvant Therapy
Section 9.1.1 Imaging Assessment for the 
Study‚Ä¢Updated time relationship 
between adjuvant radiotherapy and tumor imaging assessments
‚Ä¢Clarified imaging for tumor assessments for participants who 
do not proceed to definitive 
surgery Updated imaging 
assessment requirements 
for clarity
Section 5.3 End of Study Definition
Section 10.1 Sample Size Determination 
Section 10.1.1 Pathologic Complete 
Response (pCR)
Section 10.1.2 Event Free Survival (EFS)
Section 10.1.3 Analyses Timing 
Projections
Section 10.3.1 Efficacy Analyses
Section 10.3.3 Interim AnalysesStatistical analysis plan was updatedStatistical analyses were 
updated to align with 
change in study design.
Section 3.2.1 Indication Background
Section 3.2.4 Nivolumab Combined with 
Ipilimumab Clinical Activity
Section 3.2.5 Immuno-oncology Treatment 
Combined with Chemotherapy Clinical 
Activity
Section 3.3 Benefit/Risk Assessment 
Section 5.4.3 Rationale for Immuno-
oncology Treatment in Neoadjuvant 
NSCLC
Section 5.4.3.1 Rationale for Combination 
of Nivolumab and Ipilimumab (Arm A)
Section 5.4.3.2 Rationale for PD-1 
Inhibitor with Chemotherapy (Arm C)
Section 5.4.4 Rationale for Pathologic 
ResponseRationale, background information, 
and trial schematic were updated Rationale, background 
information, and trial 
schematic were updated to 
align with changes in study 
design and current data. 
Table 2-1 Screening Procedural Outline 
Table 2-2 Neoadjuvant Period Procedural 
OutlineUpdated to include FVC, FEV1, 
TLC, FRC, and DLco.Parameters of pulmonary 
function tests to be 
collected were clarified.
Section 9.5 PharmacokineticsTime window of Cycle 1 Day 1 end-
of-infusion PK sampling for Arm A
and C was clarifiedTime window for certain 
PK sample collection was 
provided.
Appendix 4 Hepatic Adverse Event 
Management AlgorithmFootnote stating I-O therapy may be 
delayed rather than discontinued if 
AST/ALT ‚â§ 8 x ULN or T.bili ‚â§ 5 x 
ULN was removed.Language was modified to 
align protocol with current 
Nivolumab Investigator 
Brochure and nivolumab 
program safety 
management principals.
Protocol Amendment No.: 07
Date: 18-Aug-2021 170
Approved 9.0 v
Approved
1.0
v
Clinical Protocol CA209816
BMS-936558 nivolumab
OVERALL RATIONALE FOR REVISE D PROTOCOL 02 , 06-JUL-2017
The CA209816 study has been revised in response to a health aut hority reque st to add the primary 
objective of event-free survival for the study p opulation. In addition, a new treatment arm was 
added to the study as a new comparison for the current treatmen t landscape.
This revised protocol applies to all current and future partici pants.
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 02
Section Number and Name Description of Change Brief Rationale
Title; Section 1 Synopsis, Ob jective and Endpoints, Study 
Design, Number of Participants, Treatment Arms and Duration; 
Section 2 Schedule of Activities; Section 3.1 Study Rationale, 
Research Hypothesis; Section 4 Objectives and Endpoints; 
Section 5 Study Design; Section 5.2 Number of Participants; 
Section 5.3 End of Study Definition; Section 6 Study 
Population; Section 7 Treatment; Section 9.5 Pharmacokinetics; 
Section 10 Statistical Considerations (Sections 10.1.1, 10.1.2,   
10.1.3, 10.2, 10.3, 10.3.3)A new treatment arm of 
nivolumab plus 
platinum doublet 
chemotherapy (Arm C) 
was added to the study. 
The sample size was 
increased to 642 with 
the addition of the new 
treatment arm.New treatment arm 
was added for 
current treatment 
landscape.
Title, Section 1 Synopsis, Objectiv e and Endpoints, Study 
Design, Number of Participants, Treatment Arms and Duration; 
Section 2 Schedule of Activities‚Äô Section 3.1 Study Rationale; 
Section 3.2; Section 4 Objectives and Endpoints; Section 5 
Study Design (Section 5.1, Schema, Section 5.2, Number of 
participants, Section 5.3 End of Study Definition; Section 9.1 
Efficacy Assessments; Section 10 Statistical Considerations 
(Sections 10.1.1, 10.1.2, 10.1.3, 10.2 Populations for Analyses, 
10.3 Statistical Analyses, 10.3.3)Primary objectives were 
modified to event free 
survival and 
pathological response.New multiple 
primary objective 
was added in 
response to health 
authority request.
Synopsis, Background Section 3.2 (Sections 3.2.4, 3.2.5); 
Section 3.3 Benefit/Risk Assessment, Background, Section 5.4 
Scientific Rationale for Study Design (Sections 5.4.3, 5.4.4, 
5.5.2)With the addition of 
new treatment arm and 
new primary endpoints, 
the background and 
rationale we re updated 
with current safety and 
efficacy data.Study sections 
were updated to 
reflect current 
study design and 
available data on 
safety and efficacy 
of study treatments.
Protocol Amendment No.: 07
Date: 18-Aug-2021 171
Approved 9.0 v
Approved
1.0
v